CA2323111C - New substituted indolinones, the preparation thereof and their use as pharmaceutical compositions - Google Patents
New substituted indolinones, the preparation thereof and their use as pharmaceutical compositions Download PDFInfo
- Publication number
- CA2323111C CA2323111C CA002323111A CA2323111A CA2323111C CA 2323111 C CA2323111 C CA 2323111C CA 002323111 A CA002323111 A CA 002323111A CA 2323111 A CA2323111 A CA 2323111A CA 2323111 C CA2323111 C CA 2323111C
- Authority
- CA
- Canada
- Prior art keywords
- group
- alkyl
- phenyl
- substituted
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
The present invention relates to substituted indolinones of general formula (see formula I) wherein R1 to R5 and X are defined as in claim 1, the isomers thereof and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, particularly an inhibitory effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.
Description
S018-546a.603 Boehringer Ingelheim Pharma KG Case 5/1238-FL
D-55216 INGELHEIM Foreign filing text New substituted indolinones, the preparation thereof and their use as pharmaceutical compositions The present invention relates to new substituted indolinones of general formula \
Ra g Rs <)!N>
I
the isomers thereof, the salts thereof, particularly the physiologically acceptable salts thereof which have valuable properties.
The above compounds of general formula I wherein Rl denotes a hydrogen atom or a prodrug group have valuable pharmacological properties, particularly an inhibiting effect on various kinases, especially complexes of CDKs (CDK1, CDK2, CDK3, CDK4, CDK6, CDK7, CDK8 and CDK9) with their specific cyclines (A, Bl, B2, C, D1, D2, D3, E, F, G1, G2, H, I and K) and on viral cycline (cf. L. Mengtao in J. Virology 71(3), 1984-1991 (1997)), and the other compounds of the above general formula I wherein R1 does not represent a hydrogen atom or a prodrug group are valuable intermediate products for preparing the abovementioned compounds.
D-55216 INGELHEIM Foreign filing text New substituted indolinones, the preparation thereof and their use as pharmaceutical compositions The present invention relates to new substituted indolinones of general formula \
Ra g Rs <)!N>
I
the isomers thereof, the salts thereof, particularly the physiologically acceptable salts thereof which have valuable properties.
The above compounds of general formula I wherein Rl denotes a hydrogen atom or a prodrug group have valuable pharmacological properties, particularly an inhibiting effect on various kinases, especially complexes of CDKs (CDK1, CDK2, CDK3, CDK4, CDK6, CDK7, CDK8 and CDK9) with their specific cyclines (A, Bl, B2, C, D1, D2, D3, E, F, G1, G2, H, I and K) and on viral cycline (cf. L. Mengtao in J. Virology 71(3), 1984-1991 (1997)), and the other compounds of the above general formula I wherein R1 does not represent a hydrogen atom or a prodrug group are valuable intermediate products for preparing the abovementioned compounds.
Thus, the present invention relates to the above compounds of general formula I (the compounds wherein Rl denotes a hydrogen atom or a prodrug group having valuable pharmacological properties), the pharmaceutical compositions containing the pharmacologically active compounds, their use and processes for preparing them.
In the above general formula I
X denotes an oxygen or sulphur atom, R1 denotes a hydrogen atom, a C1-9-alkoxy-carbonyl or C2_q-alkanoyl group, R2 denotes a carboxy-, C1-9-alkoxy-carbonyl or aminocarbonyl group wherein the amino moiety may be substituted by one or two C1_3-alkyl groups and the substitutents may be identical or different, R3 denotes a phenyl or naphthyl group which may be substituted by fluorine, chlorine or bromine atoms, by C1_3-alkyl, C1_3-alkoxy, cyano, trifluoromethyl, nitro, amino, C1_3-alkylamino, di- (C1_3-alkyl) -amino, C2_4-alkanoyl-amino, N- (C1_3-alkyl) -C2_9-alkanoylamino, N- (C1_3-alkyl) -C2_9-alkanoylamino, C1_3-alkylsulphonylamino, amino-C1_3-alkyl, C1_3-alkylamino-C1_3-alkyl, di-(C1-3-alkyl) -amino-C1_3-alkyl, N- (C2-9-alkanoyl) -amino-C1_3-alkyl or N- (C2_9-alkanoyl) -C1_3-alkylamino-C1-3-alkyl groups and the substituents may be identical or different, R4 denotes a hydrogen atom or a C1_3-alkyl group and R5 denotes a hydrogen atom, a C:_5-alkyl group optionally substituted by a phenyl, carboxy or C1_3-alkoxy-carbonyl group, a C3-,-cycloalkyl group optionally substituted by a C1_3-alkyl group, an indanyl group optionally substituted by a C1-3-alkyl group, a 5-membered heteroaryl group which contains an imino group optionally substituted by a C1_3-alkyl group, an oxygen or sulphur atom or an imino group optionally substituted by a C1_3-alkyl group and an oxygen, sulphur or nitrogen atom or two nitrogen atoms or a 6-membered heteroaryl group which contains 1 to 3 nitrogen atoms, whilst additionally a 1,3-butadienylene bridge may be attached via two adjacent carbon atoms or via one carbon atom and an adjacent imino group of the abovementioned 5- and 6-membered heteroaryl groups and the carbon skeleton of the abovementioned mono- and bicyclic rings may be mono or disubstituted by fluorine, chlorine, bromine or iodine atoms, by C1_5-alkyl or cyano groups and the substituents may be identical or different, a pyrrolidinyl or piperidinyl group linked via a carbon atom, which may be substituted at the nitrogen atom by a C1_3-alkyl group, a phenyl group optionally disubstituted by fluorine, chlorine, bromine or iodine atoms, by C1_5-alkyl, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminosulphonyl, nitro or cyano groups, whilst the substituents may be identical or different, a phenyl, pyridyl, pyrimidyl or thienyl group each of which is substituted by a trifluoromethoxy group, by a fluorine, chlorine, bromine or iodine atom, by a C1_3-alkoxy group which may be substituted in the 2- or 3- position by an amino, C1_3-alkylamino, di- (C1-3-alkyl) amino, phenyl-C1_3-alkylamino, N- (C1_3-alkyl) -phenyl-C,_3-alkylamino, pyrrolidino or piperidino group, by a phenyl-C1_3-alkylamino-C1_3-alkyl group which may be mono- or disubstituted in the phenyl nucleus by a trifluoromethyl group, by fluorine, chlorine, bromine or iodine atoms, by C;_5-alkyl or C1_3-alkoxy groups, whilst the substituents may be identical or different, and additionally may be replaced at the amine nitrogen atom by a C1_3-alkyl group wherein the hydrogen atoms from position 2 may be wholly or partially replaced by fluorine atoms, by a C1_5-alkyl, phenyl, imidazolyl, C3_-,-cycloalkyl, C1_3-alkoxy-C1_3-alkoxy, phenyl-C1-3-alkoxy, carboxy-C1_3-alkyl, C1_3-alkoxycarbonyl-C1_3-alkyl, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylamino-carbonyl, di-(C1_3-alkyl)-aminocarbonyl, phenyl-Cl-3-alkylaminocarbonyl, N- (C1-3-alkyl) -phenyl-C1_3-alkylaminocarbonyl, piperazinocarbonyl, N-(C1_3-alkyl)-piperazinocarbonyl, nitro, amino, C1_3-alkylamino, di-(C1_3-alkyl)-amino, pyrrolidino, piperidino, morpholino, C2_4-alkanoyl-amino, N- (Cl_3-alkyl) -CZ_9-alkanoylamino, benzoylamino or N-(C1_3-alkyl)-benzoylamino group, by an N- (C1_3-alkyl) -C2_q-alkanoylamino group which is additionally substituted in the alkyl moiety by a carboxy or C1_3-alkoxycarbonyl group, by a C1-3-alkylaminocarbonyl or di- (C1_3-alkyl) -aminocarbonyl group wherein an alkyl moiety is additionally substituted by a di-(C1-3-alkyl)-amino group, or by an N- (C1-3-alkyl) -C1_3-alkylsulphonylamino or N-(C1_3-alkyl)-phenylsulphonylamino group wherein the alkyl moiety may additionally be substituted by a cyano, carboxy, C1_3-alkoxycarbonyl, C1-3-alkylamino, di-(C1_3-alkyl) -amino group, aminocarbonyl, C1_3-alkylaminocarbonyl, di-(C1_3-alkyl)-aminocarbonyl, piperidinocarbonyl or 2-[di-(C1_3-alkylamino)]-ethylaminocarbonyl group, a phenyl or thienyl group substituted by a C1_3-alkyl group wherein the alkyl moiety is substituted by a hydroxy, C,_3-alkoxy, carboxy, C1_3-alkoxy-carbonyl, amino, C1_5-alkylamino, di- (C1_;-alkyl) -amino, C2_4-alkanoylamino, N- (C1_3-alkyl) -C2_q-alkanoylamino, pyrrolidino, dehydropyrrolidino, piperidino, dehydropiperidino, 3-hydroxypiperidino, 4-hydroxypiperidino, hexamethyleneimino, morpholino, thiomorpholino, piperazino, 4-(C1_3-alkyl)-piperazino, 4-phenyl-piperazino, 4-(C2_9-alkanoyl)-piperazino, 4-benzoyl-piperazino or imidazolyl group, whilst the abovementioned saturated cycloalkyleneimino rings, C1_5-alkylamino or di-(C1_5-alkyl)-amino groups may additionally be substituted by one or two C1-5-alkyl groups, by a C3-,-cycloalkyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C:_3-alkylaminocarbonyl or di- (C1-3-alkyl) -aminocarbonyl group, by a phenyl-C1_3-alkyl or phenyl group optionally mono- or disubstituted in the phenyl nucleus by fluorine, chlorine, bromine or iodine atoms or by C1-3-alkyl or cyano groups, whilst the substituents may be identical or different, or a methylene group adjacent to the nitrogen atom in the abovementioned cycloalkyleneimino rings may be replaced by a carbonyl or sulphonyl group, and the abovementioned monosubstituted phenyl groups may additionally be substituted by a fluorine, chlorine or bromine atom or by a methyl, amino, C1-3-alkylamino or di- (C1_3-alkyl) -amino group, or a phenyl ring optionally substituted by one or two C1-3-alkoxy groups may be fused to one of the abovementioned unsubstituted cycloalkyleneimino rings via two adjacent carbon atoms.
The carboxy groups mentioned in the definition of the groups above may also be replaced by a group which can be converted in vivo into a carboxy group and the amino and imino groups mentioned in the definition of the groups above may also be replaced by a group which can be cleaved in vivo.
Moreover, the saturated alkyl and alkoxy moieties mentioned in the above definition containing more than 2 carbon atoms also include the branched isomers thereof, such as, for example, the isopropyl, tert.butyl, isobutyl group, etc.
Preferred compounds of general formula I are those wherein X denotes an oxygen or sulphur atom, R1 denotes a hydrogen atom, a Cl_9-alkoxy-carbonyl or C2_4-alkanoyl group, R2 denotes a carboxy-, C1-9-alkoxy-carbonyl or aminocarbonyl group wherein the amino moiety may be substituted by one or two C1_3-alkyl groups and the substituents may be identical or different, R3 denotes a phenyl or naphthyl group which may be substituted by fluorine, chlorine or bromine atoms, by C1_3-alkyl, C1_3-alkoxy, cyano, trifluoromethyl, nitro, amino, C1_3-alkylamino, di- (C1_3-alkyl) -amino, C2_4-alkanoyl-amino, N- (C1_3-alkyl) -C2_4-alkanoylamino, N- (C1_3-alkyl) -C2_q-alkanoylamino, C1_3-alkylsulphonylamino, amino-C1-3-alkyl, C1_3-alkylamino-C1_3-alkyl, di-(C1_3-alkyl) -amino-C1_3-alkyl, N- (C2_q-alkanoyl) -amino-C1_3-alkyl or N- (C2_9-alkanoyl) -C1_3-alkylamino-C1_3-alkyl groups and the substituents may be identical or different, R4 denotes a hydrogen atom or a C1_3-alkyl group and R. denotes a hydrogen atom, a C1_5-alkyl group optionally substituted by a phenyl, carboxy or C1_3-alkoxy-carbonyl group, a C3-7-cycloalkyl group optionally substituted by a C1_3-alkyl group, an indanyl group optionally substituted by a C1-3-alkyl group, a 5-membered heteroaryl group which contains an imino group optionally substituted by a C1_3-alkyl group, an oxygen or sulphur atom or an imino group optionally substituted by a C1_3-alkyl group and an oxygen, sulphur or nitrogen atom or two nitrogen atoms or a 6-membered heteroaryl group which contains 1 to 3 nitrogen atoms, whilst additionally a 1,3-butadienylene bridge may be attached via two adjacent carbon atoms or via one carbon atom and an adjacent imino group of the abovementioned 5- and 6-membered heteroaryl groups and the carbon skeleton of the abovementioned mono- and bicyclic rings may be mono or disubstituted by fluorine, chlorine, bromine or iodine atoms, by C1_5-alkyl or cyano groups and the substituents may be identical or different, a pyrrolidinyl or piperidinyl group linked via a carbon atom, which may be substituted at the nitrogen atom by a C1_3-alkyl group, a phenyl group optionally mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms, by C1_5-alkyl or cyano groups, whilst the substituents may be identical or different, a phenyl, pyridyl, pyrimidyl or thienyl group each of which is substituted by a C3_,-cycloalkyl, C1-3-alkoxy, phenyl-C, _3-al koxy, carboxy-C1_3-al kyl, C, _3-al koxy-carbonyl-C1_3-alkyl, carboxy, C,__j-alkoxycarbonyl, aminocarbonyl, C1_;-alkylaminocarbonyl, di- (C,__,-alkyl) -aminocarbonyl, nitro, amino, C,_3-alkylamino, di-(C1_3-alkyl) -amino, C,_4-alkanoyl-amino, N- (C,_3-alkyl) -C2_4-alkanoylamino or N- (C1_3-alkyl ) -Cz_4-alkanoylamino group, by a C1_3-alkylaminocarbonyl group wherein the alkyl moiety additionally substituted by a di-(C1_3-alkyl) -amino group, or by a N- (C1_3-alkyl) -C1_3-al-kylsulphonylamino group wherein the alkyl moiety may additionally be substituted by a cyano, carboxy, C1_3-alkoxycarbonyl, C;_3-alkylamino or di- (C1-3-alkyl) -amino group, a phenyl or thienyl group substituted by a C1_3-alkyl group wherein the alkyl moiety is substituted by a hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxy-carbonyl, amino, C1_5-alkylamino, di- (C,_5-alkyl) -amino, C2_9-alkanoylamino, N- (C1-3-alkyl) -C2_4-alkanoylamino, pyrrolidino, piperidino, hexamethyleneimino, morpholino, piperazino, 4- (C1-3-alkyl) -piperazino, 4- (C2-9-alkanoyl) -piperazino, 4-benzoyl-piperazino or imidazolyl group, whilst the abovementioned cycloalkyleneimino rings, C1_5-alkylamino or di-(C1_5-alkyl)-amino groups may additionally be substituted by a C1_5-alkyl, C3_,-cycloalkyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl or di- (C1_3-alkyl) -aminocarbonyl group, by a phenyl-C1-3-alkyl or phenyl group optionally mono or disubstituted in the phenyl nucleus by fluorine, chlorine, bromine or iodine atoms or by C1_3-alkyl or cyano groups, whilst the substituents may be identical or different, or a methylene group adjacent to the nitrogen atom in the abovementioned cycloalkyleneimino rings may be replaced by a carbonyl or sulphonyl group, and the abovementioned monosubstituted phenyl group may additionally be substituted by a fluorine, chlorine or bromine atom or by a methyl group, particularly those compounds of general formula I
wherein X denotes an oxygen atom, R1 denotes a hydrogen atom or a C1_4-alkoxycarbonyl group, R2 denotes a carboxy, C,_q-alkoxycarbonyl or aminocarbonyl group wherein the amino moiety may be substituted by one or two C1_3-alkyl groups and the substituents may be identical or different, R3 denotes a phenyl group optionally substituted by a fluorine, chlorine or bromine atom, by a methyl, cyano or aminomethyl group, R4 denotes a hydrogen atom or a methyl group and R. denotes a hydrogen atom, a C1_5-alkyl group optionally substituted by a carboxy or C1_3-alkoxycarbonyl group, or a benzyl group, a C3_7-cycloalkyl group optionally substituted by a methyl group, an indanyl, pyridyl, oxazolyl, thiazolyl or imidazolyl group optionally substituted by a methyl group, to which a phenyl ring may additionally be fused via two adjacent carbon atoms, a methylphenyl group optionally substituted by a fluorine, chlorine or bromine atom, or by a methoxy, carboxy, C1_3-alkyloxycarbonyl, nitro or aminosulphonyl group, or a dimethoxyphenyl group, a pyrrolidinyl or piperidinyl group linked via a carbon atom, which may be substituted at the nitrogen atom by a C1_,-alkyl group, a phenyl group which is substituted by a trifluoromethoxy group, by a fluorine, chlorine, bromine or iodine atom, by a Cl-3-alkoxy group which may be substituted in the 2- or 3- position by an amino, C1_3-alkylamino, di-(C1_;-alkyl) amino, phenyl-C1_3-alkylamino, N- (C1-3-alkyl) -phenyl-C1_3-alkylamino, pyrrolidino or piperidino group, by a phenyl-C1_3-alkylamino-C1_3-alkyl group which may be [substituted] in the phenyl nucleus by a fluorine, chlorine, bromine or iodine atom, by a C1_5-alkyl, Cl_3-alkoxy or trifluoromethyl group and additionally at the amine nitrogen atom by a C,-3-alkyl group wherein the hydrogen atoms from position 2 may be wholly or partially replaced by fluorine atoms, by a C1-5-alkyl, phenyl, imidazolyl, C3_,-cycloalkyl, C1_3-alkoxy-C1-3-alkoxy, phenyl-C1_3-alkoxy, carboxy-Cl-3-alkyl, C1-3-alkoxycarbonyl-C1_3-alkyl, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylamino-carbonyl, di-(C1_3-alkyl)-aminocarbonyl, phenyl-C1_3-alkylaminocarbonyl, N- (C1_3-alkyl) -phenyl-C1_3-alkylaminocarbonyl, piperazinocarbonyl, N-(C1-3-alkyl)-piperazinocarbonyl, nitro, amino, C1_3-alkylamino, di-(Cl_3-alkyl)-amino, pyrrolidino, piperidino, morpholino, Cz_q-alkanoyl-amino, N- (C1-3-alkyl) -C2_4-alkanoylamino, benzoylamino or N-(C1_3-alkyl)-benzoylamino group, by an N- (C1-3-alkyl) -C2_4-alkanoylamino group which is additionally substituted in the alkyl moiety by a carboxy or C1-3-alkoxycarbonyl group, by a C1_3-alkylaminocarbonyl or di- (C1_3-alkyl) -aminocarbonyl group wherein an alkyl moiety is additionally substituted by a di-(C1_3-alkyl)-amino group, or by an N- (C1_3-alkyl) -C,_3-alkylsulphonylamino or N-(C,_3-alkyl)-phenylsulphonylamino group wherein the alkyl moiety may additionally be substituted by a cyano, carboxy, C1_3-alkoxycarbonyl, C,_3-alkylamino, di-(C,_3-alkyl) -amino group, aminocarbonyl, C1_3-alkylaminocarbonyl, di-(C,_3-alkyl)-aminocarbonyl, piperidinocarbonyl or 2-[di-(C1_3-alkylamino)]-ethylaminocarbonyl group, a phenyl group optionally substituted by a C1_3-alkyl group wherein the alkyl moiety is substituted by a hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxy-carbonyl, amino, C1_5-alkylamino, di- (C1_5-alkyl) -amino, C2_9-alkanoylamino, N- (C1_3-alkyl) -C2_4-alkanoylamino, pyrrolidino, dehydropyrrolidino, piperidino, dehydropiperidino, 3-hydroxypiperidino, 4-hydroxypiperidino, hexamethyleneimino, morpholino, thiomorpholino, piperazino, 4-(C1_3-alkyl)-piperazino, 4-phenyl-piperazino, 4-(C2-4-alkanoyl)-piperazino, 4-benzoyl-piperazino or imidazolyl group, whilst the abovementioned saturated cycloalkyleneimino rings, C1_5-alkylamino or di-(C1-5-alkyl)-amino groups may additionally be substituted by one or two Cl_5-alkyl groups, by a C3_,-cycloalkyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl or di- (C1_3-alkyl) -aminocarbonyl group, by a phenyl-C1-3-alkyl or phenyl group optionally mono- or disubstituted in the phenyl nucleus by fluorine, chlorine, bromine or iodine atoms or by C1-3-alkyl or cyano groups, whilst the substituents may be identical or different, or a methylene group adjacent to the nitrogen atom in the abovementioned cycloalkyleneimino rings may be replaced by a carbonyl or sulphonyl group, and the abovementioned monosubstituted phenyl groups may additionally be substituted by a fluorine, chlorine or bromine atom or by a methyl, amino, C1_3-alkylamino or di- (C1_3-alkyl) -amino group, or a phenyl ring optionally substituted by one or two C1_3-alkoxy groups may be fused to one of the above-mentioned unsubstituted cycloalkyleneimino rings via two adjacent carbon atoms, the isomers and salts thereof.
Particularly preferred compounds of the above general formula I are those wherein X denotes an oxygen atom, R1 denotes a hydrogen atom, R2 denotes a carboxy, C1_9-alkoxycarbonyl or aminocarbonyl group wherein the amino moiety may be substituted by one or two C1_3-alkyl groups and the substituents may be identical or different, R3 denotes a phenyl group optionally substituted by a methyl group, R4 denotes a hydrogen atom or a methyl group and R. denotes a hydrogen atom, a C1_3-alkyl group, a benzyl group or a methyl or ethyl group substituted by a carboxy or C1_3-alkoxycarbonyl group, a C3_7-cycloalkyl group optionally substituted by a methyl group, an indanyl, pyridyl, oxazolyl, thiazolyl or imidazolyl group optionally substituted by a methyl group, to which a phenyl ring may additionally be fused via two adjacent carbon atoms, a methylphenyl group optionally substituted by a fluorine, chlorine or bromine atom, or by a methoxy, carboxy, C1_3-alkyloxycarbonyl, nitro or aminosulphonyl group, or a dimethoxyphenyl group, a 3-pyrrolidinyl or 4-piperidinyl group which may be substituted at the nitrogen atom by a C1_3-alkyl group, a phenyl group which is substituted by a trifluoromethoxy, benzyloxy, cyano or nitro group, by a fluorine, chlorine or bromine atom, by a C1_3-alkoxy group, whilst the ethoxy and n-propoxy groups may each be terminally substituted by a dimethylamino, diethylamino, N-ethyl-methylamino, N-benzyl-methylamino or piperidino group, by a phenyl-C1_3-alkylamino-C1_3-alkyl group which may be substituted in the phenyl nucleus by a fluorine, chlorine, bromine or iodine atom, by a methyl, methoxy or trifluoromethyl group and additionally at the amine nitrogen atom by a C1_3-alkyl or 2,2,2-trifluoroethyl group, by a C1-4-alkyl, phenyl, imidazolyl, cyclohexyl, methoxymethyl, carboxymethyl, C1_3-alkoxycarbonyl-methyl, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl, di- (C1_3-alkyl ) -aminocarbonyl, phenyl-C1-3-alkylaminocarbonyl, N- (C1-3-alkyl) -phenyl-C1-3-alkylaminocarbonyl, piperazinocarbonyl, N-(C1_3-alkyl)-piperazinocarbonyl, amino, C1_3-alkylamino, di-(C1_3-alkyl)-amino, pyrrolidino, piperidino, morpholino, C2-4 -alkanoyl-amino, N- (C,_3-alkyl) -C2_4-alkanoylamino, benzoylamino or N-(C1-3-alkyl)-benzoylamino group, by an N- (C1_3-alkyl )-CZ-4-alkanoylamino group which is additionally substituted-in the alkyl moiety by a carboxy or C1_3-alkoxycarbonyl group, by a C1_3-alkylaminocarbonyl or di- (C1_3-alkyl) -aminocarbonyl group wherein an alkyl moiety is additionaliy substituted by a di-(C1_3-alkyl)-amino group, or by an N- (C,_3-alkyl) -C,_3-alkylsulphonylamino or N-(C1_3-alkyl)-phenylsulphonylamino group wherein the alkyl moiety may additionally be substituted by a cyano, carboxy, C1_3-alkoxycarbonyl, C7_3-alkylamino, di-(C1_3-alkyl)-amino group, aminocarbonyl, C1_;-alkylaminocarbonyl, di-(C1_3-alkyl)-aminocarbonyl, piperidinocarbonyl or 2-[di-(C1_3-alkylamino)]-ethylaminocarbonyl group, a phenyl group optionally substituted by a C1_3-alkyl group wherein the alkyl moiety is substituted by a hydroxy, C1-3-alkoxy, carboxy, C1_3-alkoxy-carbonyl, amino, C1_5-alkylamino, di- (C1_5-alkyl) -amino, C2_4-alkanoylamino, N- (C1_3-alkyl) -C2_4-alkanoylamino, pyrrolidino, dehydropyrrolidino, piperidino, dehydropiperidino, 4-hydroxypiperidino, hexamethyleneimino, morpholino, thiomorpholino, piperazino, 4-(C1_3-alkyl)-piperazino, 4-phenyl-piperazino, 4-(C2_4-alkanoyl)-piperazino, 4-benzoyl-piperazino or imidazolyl group, whilst the abovementioned saturated cycloalkyleneimino rings may additionally be substituted by a phenyl group or by one or two methyl groups, the abovementioned C1_5-alkylamino and di- (C1_s-alkyl)-amino groups may additionally be substituted by one or two C1_3-alkyl groups, by a cyclohexyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl or di-(C1_3-alkyl)-aminocarbonyl group, by a phenyl-C1_3-alkyl or phenyl group optionally substituted in the phenyl nucleus by a fluorine, chlorine, bromine or iodine atom or by a methyl or cyano group, or a methylene group adjacent to the nitrogen atom in the abovementioned cycloalkyleneimino rings may be replaced by a carbonyl or sulphonyl group, and the abovementioned monosubstituted phenyl groups may additionally be substituted by a fluorine, chlorine or bromine atom or by a methyl, amino, C,_3-alkylamino or di- (C1_3-alkyl) -amino group, or a phenyl ring optionally substituted by one or two C1_3-alkoxy groups may be fused to one of the abovementioned unsubstituted cycloalkyleneimino rings via two adjacent carbon atoms, the isomers and salts thereof.
Most particularly preferred compounds of the above general formula I are those wherein X denotes an oxygen atom, R1 denotes a hydrogen atom, R2 denotes a carboxy or aminocarbonyl group wherein the amino moiety may be substituted by one or two C1_3-alkyl groups and the substituents may be identical or different, R3 denotes a phenyl group optionally substituted by a methyl group, R4 denotes a hydrogen atom and R5 denotes a hydrogen atom, a 3-pyrrolidinyl or 4-piperidinyl group which may be substituted at the nitrogen atom by a C1_3-alkyl group, a phenyl group which is substituted by a C1_3-alkoxy group, whilst the ethoxy and n-propoxy groups may each be terminally substituted by a dimethylamino, diethylamino, N-ethyl-methylamino, N-benzyl-methylamino or piperidino group, by a phenyl-C1_3-alkylamino-C1_3-alkyl group which may be substituted in the phenyl nucleus by a fluorine, chlorine, bromine or iodine atom, by a methyl, methoxy or trifluoromethyl group and additionally at the amine nitrogen atom by a C,_-alkyl or 2,2,2-trifluoroethyl group, a phenyl group optionally substituted by a C1_3-alkyl group wherein the alkyl moiety is substituted by a hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxy-carbonyl, amino, C1_5-alkylamino, di- (C:_5-alkyl) -amino, C1-4-alkanoylamino, N- (C1_3-alkyl) -C2_4-alkanoylamino, pyrrolidino, dehydropyrrolidino, piperidino, dehydropiperidino, 4-hydroxypiperidino, hexamethyleneimino, morpholino, thiomorpholino, piperazino, 4-(C1_3-alkyl)-piperazino, 4-phenyl-piperazino, 4-(C2_4-alkanoyl)-piperazino, 4-benzoyl-piperazino or imidazolyl group, whilst the abovementioned saturated cycloalkyleneimino rings may additionally be substituted by a phenyl group or by one or two methyl groups , the abovementioned C1_;-alkylamino and di- (C1_5-alkyl) -amino groups may additionally be substituted by one or two C1_3-alkyl groups, by a cyclohexyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl or di- (C1_3-alkyl) -aminocarbonyl group, by a phenyl-C1__j-alkyl or phenyl group optionally substituted in the phenyl nucleus by a fluorine, chlorine, bromine or iodine atom or by a methyl or cyano group, or a methylene group adjacent to the nitrogen atom in the abovementioned cycloalkyleneimino rings may be replaced by a carbonyl or sulphonyl group, and the abovementioned monosubstituted phenyl groups may additionally be substituted by a fluorine, chlorine or bromine atom or by a methyl, amino, C1-3-alkylamino or di- (C1_3-alkyl) -amino group, or a phenyl ring optionally substituted by one or two C1_3-alkoxy groups may be fused to one of the abovementioned unsubstituted cycloalkyleneimino rings via two adjacent carbon atoms, the isomers and salts thereof.
Particularly preferred are the abovementioned compounds wherein the group R2 is in the 5-position, particularly the following compounds:
(a) 3-Z-[1-(4-aminomethyl-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinone, (b) 3-Z-(1-phenylamino)-1-phenyl-methylene)-5-amido-2-indolinone, (c) 3-Z-[l-(4-bromophenylamino)-l-phenyl-methylene]-5-amido-2-indolinone, (d) 3-Z-[l-(4-dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone, (e) 3-Z-[1-(4-pyrrolidinomethyl-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinone, (f) 3-Z-[l-(4-piperidinomethyl-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinone, (g) 3-Z-[l-(4-hexamethyleneiminomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone, (h) 3-Z-[l-(4-(4-benzyl-piperidino)-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone, (i) 3-Z-[l-(4-(N-butyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone, (j) 3-Z-[1-(4-(N-(phenyl-methyl)-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone, (k) 3-Z-[1-(4-(N-methyl-N-benzyl-amino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone, (1) 3-Z-[l-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-5-dimethylcarbamoyl-2-indolinone, (m) 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-5-diethylcarbamoyl-2-indolinone, (n) 3-Z-[l-(4-(3-diethylamino-propoxy)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone and the salts thereof.
According to the invention the new compounds are obtained for example using the following methods known in principle from the literature:
a. reacting a compound of general formula I
- zl R X
I
wherein R6 X, R2 and R3 are as hereinbefore defined, R. denotes a hydrogen atom, a protecting group for the nitrogen atom of the lactam group or a bond to a solid phase and Z, denotes a halogen atom, a hydroxy, alkoxy or aralkoxy group, e.g. a chlorine or bromine atom, a methoxy, ethoxy or benzyloxy group, with an amine of general formula N RS
H _ \ (III), Ra wherein Rq and R. are as hereinbefore defined, and if necessary subsequently cleaving any protecting group used for the nitrogen atom of the lactam group, or cleaving from a solid phase.
A suitable protecting group for the nitrogen atom of the lactam group might be for example an acetyl, benzoyl, ethoxycarbonyl, tert.butyloxycarbonyl or benzyloxycarbonyl group and a suitable solid phase might be a Rink or Sieber resin.
The reaction is conveniently carried out in a solvent such as dimethylformamide, toluene, acetonitrile, tetrahydrofuran, dimethylsulphoxide, methylene chloride or mixtures thereof, optionally in the presence of an inert base such as triethylamine, N-ethyl-diisopropylamine or sodium hydrogen carbonate at temperatures between 20 and 175 C, whilst any protecting group used can be cleaved simultaneously by transamidation.
If Z1 in a compound of general formula II denotes a halogen atom, the reaction is preferably carried out in the presence of an inert base at temperatures between 20 and 120 C.
If Z1 in a compound of general formula II denotes a hydroxy, alkoxy or aralkoxy group, the reaction is preferably carried out at temperatures between 20 and 200 C.
If any protecting group used subsequently has to be cleaved, this is conveniently carried out either hydro-lytically in an aqueous or alcoholic solvent, e.g. in methanol/water, ethanol/water, isopropanol/water, tetrahydrofuran/water, dioxane/water, dimethylformamide/water, methanol or ethanol in the presence of an alkali metal base such as lithium hydroxide, sodium hydroxide or potassium hydroxide at temperatures between 0 and 100 C, preferably at temperatures between 10 and 50 C, or advantageously by transamidation with a primary or secondary organic base such as ammonia, methylamine, butylamine, dimethylamine or piperidine in a solvent such as methanol, ethanol, dimethylformamide and mixtures thereof or in an excess of the amine used at temperatures between 0 and 100 C, preferably at temperatures between 10 and 50 C.
Any solid phase used is preferably cleaved using trifluoroacetic acid and water in the presence of a dialkylsulphide such as dimethylsulphide at temperatures between 0 and 35 C, preferably at ambient temperature.
b. In order to prepare a compound of general formula I
which contains an aminomethyl group and X denotes an oxygen atom:
Reduction of a compound of general formula N
Rz p ~IV) , wherein R1 to Rq are as hereinbefore defined and R7 has the meanings given for R5 hereinbefore with the proviso that R5 contains a cyano group.
In the above general formula I
X denotes an oxygen or sulphur atom, R1 denotes a hydrogen atom, a C1-9-alkoxy-carbonyl or C2_q-alkanoyl group, R2 denotes a carboxy-, C1-9-alkoxy-carbonyl or aminocarbonyl group wherein the amino moiety may be substituted by one or two C1_3-alkyl groups and the substitutents may be identical or different, R3 denotes a phenyl or naphthyl group which may be substituted by fluorine, chlorine or bromine atoms, by C1_3-alkyl, C1_3-alkoxy, cyano, trifluoromethyl, nitro, amino, C1_3-alkylamino, di- (C1_3-alkyl) -amino, C2_4-alkanoyl-amino, N- (C1_3-alkyl) -C2_9-alkanoylamino, N- (C1_3-alkyl) -C2_9-alkanoylamino, C1_3-alkylsulphonylamino, amino-C1_3-alkyl, C1_3-alkylamino-C1_3-alkyl, di-(C1-3-alkyl) -amino-C1_3-alkyl, N- (C2-9-alkanoyl) -amino-C1_3-alkyl or N- (C2_9-alkanoyl) -C1_3-alkylamino-C1-3-alkyl groups and the substituents may be identical or different, R4 denotes a hydrogen atom or a C1_3-alkyl group and R5 denotes a hydrogen atom, a C:_5-alkyl group optionally substituted by a phenyl, carboxy or C1_3-alkoxy-carbonyl group, a C3-,-cycloalkyl group optionally substituted by a C1_3-alkyl group, an indanyl group optionally substituted by a C1-3-alkyl group, a 5-membered heteroaryl group which contains an imino group optionally substituted by a C1_3-alkyl group, an oxygen or sulphur atom or an imino group optionally substituted by a C1_3-alkyl group and an oxygen, sulphur or nitrogen atom or two nitrogen atoms or a 6-membered heteroaryl group which contains 1 to 3 nitrogen atoms, whilst additionally a 1,3-butadienylene bridge may be attached via two adjacent carbon atoms or via one carbon atom and an adjacent imino group of the abovementioned 5- and 6-membered heteroaryl groups and the carbon skeleton of the abovementioned mono- and bicyclic rings may be mono or disubstituted by fluorine, chlorine, bromine or iodine atoms, by C1_5-alkyl or cyano groups and the substituents may be identical or different, a pyrrolidinyl or piperidinyl group linked via a carbon atom, which may be substituted at the nitrogen atom by a C1_3-alkyl group, a phenyl group optionally disubstituted by fluorine, chlorine, bromine or iodine atoms, by C1_5-alkyl, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminosulphonyl, nitro or cyano groups, whilst the substituents may be identical or different, a phenyl, pyridyl, pyrimidyl or thienyl group each of which is substituted by a trifluoromethoxy group, by a fluorine, chlorine, bromine or iodine atom, by a C1_3-alkoxy group which may be substituted in the 2- or 3- position by an amino, C1_3-alkylamino, di- (C1-3-alkyl) amino, phenyl-C1_3-alkylamino, N- (C1_3-alkyl) -phenyl-C,_3-alkylamino, pyrrolidino or piperidino group, by a phenyl-C1_3-alkylamino-C1_3-alkyl group which may be mono- or disubstituted in the phenyl nucleus by a trifluoromethyl group, by fluorine, chlorine, bromine or iodine atoms, by C;_5-alkyl or C1_3-alkoxy groups, whilst the substituents may be identical or different, and additionally may be replaced at the amine nitrogen atom by a C1_3-alkyl group wherein the hydrogen atoms from position 2 may be wholly or partially replaced by fluorine atoms, by a C1_5-alkyl, phenyl, imidazolyl, C3_-,-cycloalkyl, C1_3-alkoxy-C1_3-alkoxy, phenyl-C1-3-alkoxy, carboxy-C1_3-alkyl, C1_3-alkoxycarbonyl-C1_3-alkyl, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylamino-carbonyl, di-(C1_3-alkyl)-aminocarbonyl, phenyl-Cl-3-alkylaminocarbonyl, N- (C1-3-alkyl) -phenyl-C1_3-alkylaminocarbonyl, piperazinocarbonyl, N-(C1_3-alkyl)-piperazinocarbonyl, nitro, amino, C1_3-alkylamino, di-(C1_3-alkyl)-amino, pyrrolidino, piperidino, morpholino, C2_4-alkanoyl-amino, N- (Cl_3-alkyl) -CZ_9-alkanoylamino, benzoylamino or N-(C1_3-alkyl)-benzoylamino group, by an N- (C1_3-alkyl) -C2_q-alkanoylamino group which is additionally substituted in the alkyl moiety by a carboxy or C1_3-alkoxycarbonyl group, by a C1-3-alkylaminocarbonyl or di- (C1_3-alkyl) -aminocarbonyl group wherein an alkyl moiety is additionally substituted by a di-(C1-3-alkyl)-amino group, or by an N- (C1-3-alkyl) -C1_3-alkylsulphonylamino or N-(C1_3-alkyl)-phenylsulphonylamino group wherein the alkyl moiety may additionally be substituted by a cyano, carboxy, C1_3-alkoxycarbonyl, C1-3-alkylamino, di-(C1_3-alkyl) -amino group, aminocarbonyl, C1_3-alkylaminocarbonyl, di-(C1_3-alkyl)-aminocarbonyl, piperidinocarbonyl or 2-[di-(C1_3-alkylamino)]-ethylaminocarbonyl group, a phenyl or thienyl group substituted by a C1_3-alkyl group wherein the alkyl moiety is substituted by a hydroxy, C,_3-alkoxy, carboxy, C1_3-alkoxy-carbonyl, amino, C1_5-alkylamino, di- (C1_;-alkyl) -amino, C2_4-alkanoylamino, N- (C1_3-alkyl) -C2_q-alkanoylamino, pyrrolidino, dehydropyrrolidino, piperidino, dehydropiperidino, 3-hydroxypiperidino, 4-hydroxypiperidino, hexamethyleneimino, morpholino, thiomorpholino, piperazino, 4-(C1_3-alkyl)-piperazino, 4-phenyl-piperazino, 4-(C2_9-alkanoyl)-piperazino, 4-benzoyl-piperazino or imidazolyl group, whilst the abovementioned saturated cycloalkyleneimino rings, C1_5-alkylamino or di-(C1_5-alkyl)-amino groups may additionally be substituted by one or two C1-5-alkyl groups, by a C3-,-cycloalkyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C:_3-alkylaminocarbonyl or di- (C1-3-alkyl) -aminocarbonyl group, by a phenyl-C1_3-alkyl or phenyl group optionally mono- or disubstituted in the phenyl nucleus by fluorine, chlorine, bromine or iodine atoms or by C1-3-alkyl or cyano groups, whilst the substituents may be identical or different, or a methylene group adjacent to the nitrogen atom in the abovementioned cycloalkyleneimino rings may be replaced by a carbonyl or sulphonyl group, and the abovementioned monosubstituted phenyl groups may additionally be substituted by a fluorine, chlorine or bromine atom or by a methyl, amino, C1-3-alkylamino or di- (C1_3-alkyl) -amino group, or a phenyl ring optionally substituted by one or two C1-3-alkoxy groups may be fused to one of the abovementioned unsubstituted cycloalkyleneimino rings via two adjacent carbon atoms.
The carboxy groups mentioned in the definition of the groups above may also be replaced by a group which can be converted in vivo into a carboxy group and the amino and imino groups mentioned in the definition of the groups above may also be replaced by a group which can be cleaved in vivo.
Moreover, the saturated alkyl and alkoxy moieties mentioned in the above definition containing more than 2 carbon atoms also include the branched isomers thereof, such as, for example, the isopropyl, tert.butyl, isobutyl group, etc.
Preferred compounds of general formula I are those wherein X denotes an oxygen or sulphur atom, R1 denotes a hydrogen atom, a Cl_9-alkoxy-carbonyl or C2_4-alkanoyl group, R2 denotes a carboxy-, C1-9-alkoxy-carbonyl or aminocarbonyl group wherein the amino moiety may be substituted by one or two C1_3-alkyl groups and the substituents may be identical or different, R3 denotes a phenyl or naphthyl group which may be substituted by fluorine, chlorine or bromine atoms, by C1_3-alkyl, C1_3-alkoxy, cyano, trifluoromethyl, nitro, amino, C1_3-alkylamino, di- (C1_3-alkyl) -amino, C2_4-alkanoyl-amino, N- (C1_3-alkyl) -C2_4-alkanoylamino, N- (C1_3-alkyl) -C2_q-alkanoylamino, C1_3-alkylsulphonylamino, amino-C1-3-alkyl, C1_3-alkylamino-C1_3-alkyl, di-(C1_3-alkyl) -amino-C1_3-alkyl, N- (C2_q-alkanoyl) -amino-C1_3-alkyl or N- (C2_9-alkanoyl) -C1_3-alkylamino-C1_3-alkyl groups and the substituents may be identical or different, R4 denotes a hydrogen atom or a C1_3-alkyl group and R. denotes a hydrogen atom, a C1_5-alkyl group optionally substituted by a phenyl, carboxy or C1_3-alkoxy-carbonyl group, a C3-7-cycloalkyl group optionally substituted by a C1_3-alkyl group, an indanyl group optionally substituted by a C1-3-alkyl group, a 5-membered heteroaryl group which contains an imino group optionally substituted by a C1_3-alkyl group, an oxygen or sulphur atom or an imino group optionally substituted by a C1_3-alkyl group and an oxygen, sulphur or nitrogen atom or two nitrogen atoms or a 6-membered heteroaryl group which contains 1 to 3 nitrogen atoms, whilst additionally a 1,3-butadienylene bridge may be attached via two adjacent carbon atoms or via one carbon atom and an adjacent imino group of the abovementioned 5- and 6-membered heteroaryl groups and the carbon skeleton of the abovementioned mono- and bicyclic rings may be mono or disubstituted by fluorine, chlorine, bromine or iodine atoms, by C1_5-alkyl or cyano groups and the substituents may be identical or different, a pyrrolidinyl or piperidinyl group linked via a carbon atom, which may be substituted at the nitrogen atom by a C1_3-alkyl group, a phenyl group optionally mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms, by C1_5-alkyl or cyano groups, whilst the substituents may be identical or different, a phenyl, pyridyl, pyrimidyl or thienyl group each of which is substituted by a C3_,-cycloalkyl, C1-3-alkoxy, phenyl-C, _3-al koxy, carboxy-C1_3-al kyl, C, _3-al koxy-carbonyl-C1_3-alkyl, carboxy, C,__j-alkoxycarbonyl, aminocarbonyl, C1_;-alkylaminocarbonyl, di- (C,__,-alkyl) -aminocarbonyl, nitro, amino, C,_3-alkylamino, di-(C1_3-alkyl) -amino, C,_4-alkanoyl-amino, N- (C,_3-alkyl) -C2_4-alkanoylamino or N- (C1_3-alkyl ) -Cz_4-alkanoylamino group, by a C1_3-alkylaminocarbonyl group wherein the alkyl moiety additionally substituted by a di-(C1_3-alkyl) -amino group, or by a N- (C1_3-alkyl) -C1_3-al-kylsulphonylamino group wherein the alkyl moiety may additionally be substituted by a cyano, carboxy, C1_3-alkoxycarbonyl, C;_3-alkylamino or di- (C1-3-alkyl) -amino group, a phenyl or thienyl group substituted by a C1_3-alkyl group wherein the alkyl moiety is substituted by a hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxy-carbonyl, amino, C1_5-alkylamino, di- (C,_5-alkyl) -amino, C2_9-alkanoylamino, N- (C1-3-alkyl) -C2_4-alkanoylamino, pyrrolidino, piperidino, hexamethyleneimino, morpholino, piperazino, 4- (C1-3-alkyl) -piperazino, 4- (C2-9-alkanoyl) -piperazino, 4-benzoyl-piperazino or imidazolyl group, whilst the abovementioned cycloalkyleneimino rings, C1_5-alkylamino or di-(C1_5-alkyl)-amino groups may additionally be substituted by a C1_5-alkyl, C3_,-cycloalkyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl or di- (C1_3-alkyl) -aminocarbonyl group, by a phenyl-C1-3-alkyl or phenyl group optionally mono or disubstituted in the phenyl nucleus by fluorine, chlorine, bromine or iodine atoms or by C1_3-alkyl or cyano groups, whilst the substituents may be identical or different, or a methylene group adjacent to the nitrogen atom in the abovementioned cycloalkyleneimino rings may be replaced by a carbonyl or sulphonyl group, and the abovementioned monosubstituted phenyl group may additionally be substituted by a fluorine, chlorine or bromine atom or by a methyl group, particularly those compounds of general formula I
wherein X denotes an oxygen atom, R1 denotes a hydrogen atom or a C1_4-alkoxycarbonyl group, R2 denotes a carboxy, C,_q-alkoxycarbonyl or aminocarbonyl group wherein the amino moiety may be substituted by one or two C1_3-alkyl groups and the substituents may be identical or different, R3 denotes a phenyl group optionally substituted by a fluorine, chlorine or bromine atom, by a methyl, cyano or aminomethyl group, R4 denotes a hydrogen atom or a methyl group and R. denotes a hydrogen atom, a C1_5-alkyl group optionally substituted by a carboxy or C1_3-alkoxycarbonyl group, or a benzyl group, a C3_7-cycloalkyl group optionally substituted by a methyl group, an indanyl, pyridyl, oxazolyl, thiazolyl or imidazolyl group optionally substituted by a methyl group, to which a phenyl ring may additionally be fused via two adjacent carbon atoms, a methylphenyl group optionally substituted by a fluorine, chlorine or bromine atom, or by a methoxy, carboxy, C1_3-alkyloxycarbonyl, nitro or aminosulphonyl group, or a dimethoxyphenyl group, a pyrrolidinyl or piperidinyl group linked via a carbon atom, which may be substituted at the nitrogen atom by a C1_,-alkyl group, a phenyl group which is substituted by a trifluoromethoxy group, by a fluorine, chlorine, bromine or iodine atom, by a Cl-3-alkoxy group which may be substituted in the 2- or 3- position by an amino, C1_3-alkylamino, di-(C1_;-alkyl) amino, phenyl-C1_3-alkylamino, N- (C1-3-alkyl) -phenyl-C1_3-alkylamino, pyrrolidino or piperidino group, by a phenyl-C1_3-alkylamino-C1_3-alkyl group which may be [substituted] in the phenyl nucleus by a fluorine, chlorine, bromine or iodine atom, by a C1_5-alkyl, Cl_3-alkoxy or trifluoromethyl group and additionally at the amine nitrogen atom by a C,-3-alkyl group wherein the hydrogen atoms from position 2 may be wholly or partially replaced by fluorine atoms, by a C1-5-alkyl, phenyl, imidazolyl, C3_,-cycloalkyl, C1_3-alkoxy-C1-3-alkoxy, phenyl-C1_3-alkoxy, carboxy-Cl-3-alkyl, C1-3-alkoxycarbonyl-C1_3-alkyl, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylamino-carbonyl, di-(C1_3-alkyl)-aminocarbonyl, phenyl-C1_3-alkylaminocarbonyl, N- (C1_3-alkyl) -phenyl-C1_3-alkylaminocarbonyl, piperazinocarbonyl, N-(C1-3-alkyl)-piperazinocarbonyl, nitro, amino, C1_3-alkylamino, di-(Cl_3-alkyl)-amino, pyrrolidino, piperidino, morpholino, Cz_q-alkanoyl-amino, N- (C1-3-alkyl) -C2_4-alkanoylamino, benzoylamino or N-(C1_3-alkyl)-benzoylamino group, by an N- (C1-3-alkyl) -C2_4-alkanoylamino group which is additionally substituted in the alkyl moiety by a carboxy or C1-3-alkoxycarbonyl group, by a C1_3-alkylaminocarbonyl or di- (C1_3-alkyl) -aminocarbonyl group wherein an alkyl moiety is additionally substituted by a di-(C1_3-alkyl)-amino group, or by an N- (C1_3-alkyl) -C,_3-alkylsulphonylamino or N-(C,_3-alkyl)-phenylsulphonylamino group wherein the alkyl moiety may additionally be substituted by a cyano, carboxy, C1_3-alkoxycarbonyl, C,_3-alkylamino, di-(C,_3-alkyl) -amino group, aminocarbonyl, C1_3-alkylaminocarbonyl, di-(C,_3-alkyl)-aminocarbonyl, piperidinocarbonyl or 2-[di-(C1_3-alkylamino)]-ethylaminocarbonyl group, a phenyl group optionally substituted by a C1_3-alkyl group wherein the alkyl moiety is substituted by a hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxy-carbonyl, amino, C1_5-alkylamino, di- (C1_5-alkyl) -amino, C2_9-alkanoylamino, N- (C1_3-alkyl) -C2_4-alkanoylamino, pyrrolidino, dehydropyrrolidino, piperidino, dehydropiperidino, 3-hydroxypiperidino, 4-hydroxypiperidino, hexamethyleneimino, morpholino, thiomorpholino, piperazino, 4-(C1_3-alkyl)-piperazino, 4-phenyl-piperazino, 4-(C2-4-alkanoyl)-piperazino, 4-benzoyl-piperazino or imidazolyl group, whilst the abovementioned saturated cycloalkyleneimino rings, C1_5-alkylamino or di-(C1-5-alkyl)-amino groups may additionally be substituted by one or two Cl_5-alkyl groups, by a C3_,-cycloalkyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl or di- (C1_3-alkyl) -aminocarbonyl group, by a phenyl-C1-3-alkyl or phenyl group optionally mono- or disubstituted in the phenyl nucleus by fluorine, chlorine, bromine or iodine atoms or by C1-3-alkyl or cyano groups, whilst the substituents may be identical or different, or a methylene group adjacent to the nitrogen atom in the abovementioned cycloalkyleneimino rings may be replaced by a carbonyl or sulphonyl group, and the abovementioned monosubstituted phenyl groups may additionally be substituted by a fluorine, chlorine or bromine atom or by a methyl, amino, C1_3-alkylamino or di- (C1_3-alkyl) -amino group, or a phenyl ring optionally substituted by one or two C1_3-alkoxy groups may be fused to one of the above-mentioned unsubstituted cycloalkyleneimino rings via two adjacent carbon atoms, the isomers and salts thereof.
Particularly preferred compounds of the above general formula I are those wherein X denotes an oxygen atom, R1 denotes a hydrogen atom, R2 denotes a carboxy, C1_9-alkoxycarbonyl or aminocarbonyl group wherein the amino moiety may be substituted by one or two C1_3-alkyl groups and the substituents may be identical or different, R3 denotes a phenyl group optionally substituted by a methyl group, R4 denotes a hydrogen atom or a methyl group and R. denotes a hydrogen atom, a C1_3-alkyl group, a benzyl group or a methyl or ethyl group substituted by a carboxy or C1_3-alkoxycarbonyl group, a C3_7-cycloalkyl group optionally substituted by a methyl group, an indanyl, pyridyl, oxazolyl, thiazolyl or imidazolyl group optionally substituted by a methyl group, to which a phenyl ring may additionally be fused via two adjacent carbon atoms, a methylphenyl group optionally substituted by a fluorine, chlorine or bromine atom, or by a methoxy, carboxy, C1_3-alkyloxycarbonyl, nitro or aminosulphonyl group, or a dimethoxyphenyl group, a 3-pyrrolidinyl or 4-piperidinyl group which may be substituted at the nitrogen atom by a C1_3-alkyl group, a phenyl group which is substituted by a trifluoromethoxy, benzyloxy, cyano or nitro group, by a fluorine, chlorine or bromine atom, by a C1_3-alkoxy group, whilst the ethoxy and n-propoxy groups may each be terminally substituted by a dimethylamino, diethylamino, N-ethyl-methylamino, N-benzyl-methylamino or piperidino group, by a phenyl-C1_3-alkylamino-C1_3-alkyl group which may be substituted in the phenyl nucleus by a fluorine, chlorine, bromine or iodine atom, by a methyl, methoxy or trifluoromethyl group and additionally at the amine nitrogen atom by a C1_3-alkyl or 2,2,2-trifluoroethyl group, by a C1-4-alkyl, phenyl, imidazolyl, cyclohexyl, methoxymethyl, carboxymethyl, C1_3-alkoxycarbonyl-methyl, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl, di- (C1_3-alkyl ) -aminocarbonyl, phenyl-C1-3-alkylaminocarbonyl, N- (C1-3-alkyl) -phenyl-C1-3-alkylaminocarbonyl, piperazinocarbonyl, N-(C1_3-alkyl)-piperazinocarbonyl, amino, C1_3-alkylamino, di-(C1_3-alkyl)-amino, pyrrolidino, piperidino, morpholino, C2-4 -alkanoyl-amino, N- (C,_3-alkyl) -C2_4-alkanoylamino, benzoylamino or N-(C1-3-alkyl)-benzoylamino group, by an N- (C1_3-alkyl )-CZ-4-alkanoylamino group which is additionally substituted-in the alkyl moiety by a carboxy or C1_3-alkoxycarbonyl group, by a C1_3-alkylaminocarbonyl or di- (C1_3-alkyl) -aminocarbonyl group wherein an alkyl moiety is additionaliy substituted by a di-(C1_3-alkyl)-amino group, or by an N- (C,_3-alkyl) -C,_3-alkylsulphonylamino or N-(C1_3-alkyl)-phenylsulphonylamino group wherein the alkyl moiety may additionally be substituted by a cyano, carboxy, C1_3-alkoxycarbonyl, C7_3-alkylamino, di-(C1_3-alkyl)-amino group, aminocarbonyl, C1_;-alkylaminocarbonyl, di-(C1_3-alkyl)-aminocarbonyl, piperidinocarbonyl or 2-[di-(C1_3-alkylamino)]-ethylaminocarbonyl group, a phenyl group optionally substituted by a C1_3-alkyl group wherein the alkyl moiety is substituted by a hydroxy, C1-3-alkoxy, carboxy, C1_3-alkoxy-carbonyl, amino, C1_5-alkylamino, di- (C1_5-alkyl) -amino, C2_4-alkanoylamino, N- (C1_3-alkyl) -C2_4-alkanoylamino, pyrrolidino, dehydropyrrolidino, piperidino, dehydropiperidino, 4-hydroxypiperidino, hexamethyleneimino, morpholino, thiomorpholino, piperazino, 4-(C1_3-alkyl)-piperazino, 4-phenyl-piperazino, 4-(C2_4-alkanoyl)-piperazino, 4-benzoyl-piperazino or imidazolyl group, whilst the abovementioned saturated cycloalkyleneimino rings may additionally be substituted by a phenyl group or by one or two methyl groups, the abovementioned C1_5-alkylamino and di- (C1_s-alkyl)-amino groups may additionally be substituted by one or two C1_3-alkyl groups, by a cyclohexyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl or di-(C1_3-alkyl)-aminocarbonyl group, by a phenyl-C1_3-alkyl or phenyl group optionally substituted in the phenyl nucleus by a fluorine, chlorine, bromine or iodine atom or by a methyl or cyano group, or a methylene group adjacent to the nitrogen atom in the abovementioned cycloalkyleneimino rings may be replaced by a carbonyl or sulphonyl group, and the abovementioned monosubstituted phenyl groups may additionally be substituted by a fluorine, chlorine or bromine atom or by a methyl, amino, C,_3-alkylamino or di- (C1_3-alkyl) -amino group, or a phenyl ring optionally substituted by one or two C1_3-alkoxy groups may be fused to one of the abovementioned unsubstituted cycloalkyleneimino rings via two adjacent carbon atoms, the isomers and salts thereof.
Most particularly preferred compounds of the above general formula I are those wherein X denotes an oxygen atom, R1 denotes a hydrogen atom, R2 denotes a carboxy or aminocarbonyl group wherein the amino moiety may be substituted by one or two C1_3-alkyl groups and the substituents may be identical or different, R3 denotes a phenyl group optionally substituted by a methyl group, R4 denotes a hydrogen atom and R5 denotes a hydrogen atom, a 3-pyrrolidinyl or 4-piperidinyl group which may be substituted at the nitrogen atom by a C1_3-alkyl group, a phenyl group which is substituted by a C1_3-alkoxy group, whilst the ethoxy and n-propoxy groups may each be terminally substituted by a dimethylamino, diethylamino, N-ethyl-methylamino, N-benzyl-methylamino or piperidino group, by a phenyl-C1_3-alkylamino-C1_3-alkyl group which may be substituted in the phenyl nucleus by a fluorine, chlorine, bromine or iodine atom, by a methyl, methoxy or trifluoromethyl group and additionally at the amine nitrogen atom by a C,_-alkyl or 2,2,2-trifluoroethyl group, a phenyl group optionally substituted by a C1_3-alkyl group wherein the alkyl moiety is substituted by a hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxy-carbonyl, amino, C1_5-alkylamino, di- (C:_5-alkyl) -amino, C1-4-alkanoylamino, N- (C1_3-alkyl) -C2_4-alkanoylamino, pyrrolidino, dehydropyrrolidino, piperidino, dehydropiperidino, 4-hydroxypiperidino, hexamethyleneimino, morpholino, thiomorpholino, piperazino, 4-(C1_3-alkyl)-piperazino, 4-phenyl-piperazino, 4-(C2_4-alkanoyl)-piperazino, 4-benzoyl-piperazino or imidazolyl group, whilst the abovementioned saturated cycloalkyleneimino rings may additionally be substituted by a phenyl group or by one or two methyl groups , the abovementioned C1_;-alkylamino and di- (C1_5-alkyl) -amino groups may additionally be substituted by one or two C1_3-alkyl groups, by a cyclohexyl, hydroxy, C1_3-alkoxy, carboxy, C1_3-alkoxycarbonyl, aminocarbonyl, C1_3-alkylaminocarbonyl or di- (C1_3-alkyl) -aminocarbonyl group, by a phenyl-C1__j-alkyl or phenyl group optionally substituted in the phenyl nucleus by a fluorine, chlorine, bromine or iodine atom or by a methyl or cyano group, or a methylene group adjacent to the nitrogen atom in the abovementioned cycloalkyleneimino rings may be replaced by a carbonyl or sulphonyl group, and the abovementioned monosubstituted phenyl groups may additionally be substituted by a fluorine, chlorine or bromine atom or by a methyl, amino, C1-3-alkylamino or di- (C1_3-alkyl) -amino group, or a phenyl ring optionally substituted by one or two C1_3-alkoxy groups may be fused to one of the abovementioned unsubstituted cycloalkyleneimino rings via two adjacent carbon atoms, the isomers and salts thereof.
Particularly preferred are the abovementioned compounds wherein the group R2 is in the 5-position, particularly the following compounds:
(a) 3-Z-[1-(4-aminomethyl-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinone, (b) 3-Z-(1-phenylamino)-1-phenyl-methylene)-5-amido-2-indolinone, (c) 3-Z-[l-(4-bromophenylamino)-l-phenyl-methylene]-5-amido-2-indolinone, (d) 3-Z-[l-(4-dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone, (e) 3-Z-[1-(4-pyrrolidinomethyl-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinone, (f) 3-Z-[l-(4-piperidinomethyl-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinone, (g) 3-Z-[l-(4-hexamethyleneiminomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone, (h) 3-Z-[l-(4-(4-benzyl-piperidino)-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone, (i) 3-Z-[l-(4-(N-butyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone, (j) 3-Z-[1-(4-(N-(phenyl-methyl)-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone, (k) 3-Z-[1-(4-(N-methyl-N-benzyl-amino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone, (1) 3-Z-[l-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-5-dimethylcarbamoyl-2-indolinone, (m) 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-5-diethylcarbamoyl-2-indolinone, (n) 3-Z-[l-(4-(3-diethylamino-propoxy)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone and the salts thereof.
According to the invention the new compounds are obtained for example using the following methods known in principle from the literature:
a. reacting a compound of general formula I
- zl R X
I
wherein R6 X, R2 and R3 are as hereinbefore defined, R. denotes a hydrogen atom, a protecting group for the nitrogen atom of the lactam group or a bond to a solid phase and Z, denotes a halogen atom, a hydroxy, alkoxy or aralkoxy group, e.g. a chlorine or bromine atom, a methoxy, ethoxy or benzyloxy group, with an amine of general formula N RS
H _ \ (III), Ra wherein Rq and R. are as hereinbefore defined, and if necessary subsequently cleaving any protecting group used for the nitrogen atom of the lactam group, or cleaving from a solid phase.
A suitable protecting group for the nitrogen atom of the lactam group might be for example an acetyl, benzoyl, ethoxycarbonyl, tert.butyloxycarbonyl or benzyloxycarbonyl group and a suitable solid phase might be a Rink or Sieber resin.
The reaction is conveniently carried out in a solvent such as dimethylformamide, toluene, acetonitrile, tetrahydrofuran, dimethylsulphoxide, methylene chloride or mixtures thereof, optionally in the presence of an inert base such as triethylamine, N-ethyl-diisopropylamine or sodium hydrogen carbonate at temperatures between 20 and 175 C, whilst any protecting group used can be cleaved simultaneously by transamidation.
If Z1 in a compound of general formula II denotes a halogen atom, the reaction is preferably carried out in the presence of an inert base at temperatures between 20 and 120 C.
If Z1 in a compound of general formula II denotes a hydroxy, alkoxy or aralkoxy group, the reaction is preferably carried out at temperatures between 20 and 200 C.
If any protecting group used subsequently has to be cleaved, this is conveniently carried out either hydro-lytically in an aqueous or alcoholic solvent, e.g. in methanol/water, ethanol/water, isopropanol/water, tetrahydrofuran/water, dioxane/water, dimethylformamide/water, methanol or ethanol in the presence of an alkali metal base such as lithium hydroxide, sodium hydroxide or potassium hydroxide at temperatures between 0 and 100 C, preferably at temperatures between 10 and 50 C, or advantageously by transamidation with a primary or secondary organic base such as ammonia, methylamine, butylamine, dimethylamine or piperidine in a solvent such as methanol, ethanol, dimethylformamide and mixtures thereof or in an excess of the amine used at temperatures between 0 and 100 C, preferably at temperatures between 10 and 50 C.
Any solid phase used is preferably cleaved using trifluoroacetic acid and water in the presence of a dialkylsulphide such as dimethylsulphide at temperatures between 0 and 35 C, preferably at ambient temperature.
b. In order to prepare a compound of general formula I
which contains an aminomethyl group and X denotes an oxygen atom:
Reduction of a compound of general formula N
Rz p ~IV) , wherein R1 to Rq are as hereinbefore defined and R7 has the meanings given for R5 hereinbefore with the proviso that R5 contains a cyano group.
The reduction is preferably carried out by catalytic hydrogenation with hydrogen in the presence of a catalyst such as palladium/charcoal or platinum in a solvent such as methanol, ethanol, ethyl acetate, dimethylformamide, dimethylformamide/acetone or glacial acetic acid optionally with the addition of an acid such=
as hydrochloric acid at temperatures between 0 and 50 C, but preferably at ambient temperature, and at a hydrogen pressure from 1 to 7 bar, but preferably from 3 to 5 bar.
If according to the invention a compound of general formula I is obtained which contains an alkoxycarbonyl group, this can be converted by hydrolysis into a corresponding carboxy compound, or If a compound of general formula I is obtained which contains an amino or alkylamino group, this may be converted by alkylation or reductive alkylation into a corresponding alkylamino or dialkylamino compound, or If a compound of general formula I is obtained which contains an amino or alkylamino group, this may be converted by acylation into a corresponding acyl compound, or If a compound of general formula I is obtained which contains a carboxy group, this can be converted by esterification or amidation into a corresponding ester or aminocarbonyl compound.
The subsequent hydrolysis is preferably carried out in an aqueous solvent, e.g. in water, isopropanol/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as lithium hydroxide, sodium hydroxide or potassium hydroxide at temperatures between 0 and 100 C, preferably at temperatures between 10 and 50 C.
The subsequent reductive alkylation is preferably carried out in a suitable solvent such as methanol, methanol/water, methanol/water/ammonia, ethanol, ether, tetrahydrofuran, dioxane or dimethylformamide optionally with the addition of an acid such as hydrochloric acid in the presence of catalytically activated hydrogen, e.g. hydrogen in the presence of Raney nickel, platinum or palladium/charcoal, or in the presence of a metal hydride such as sodium borohydride, lithium borohydride or lithium aluminium hydride at temperatures between 0 and 100 C, preferably at temperatures between 20 and 80 C.
The subsequent alkylation is carried out with an alkylating agent such as an alkyl halide or dialkyl sulphate such as methyliodide, dimethylsulphate or propylbromide preferably in a solvent such as methanol, ethanol, methylene chloride, tetrahydrofuran, toluene, dioxane, dimethylsulphoxide or dimethylformamide optionally in the presence of an inorganic or a tertiary organic base such as triethylamine, N-ethyl-diisopropylamine or dimethylaminopyridine, preferably at temperatures between 20 C and the boiling temperature of the solvent used.
The subsequent acylation is preferably carried out in a solvent such as methylene chloride, diethylether, tetrahydrofuran, toluene, dioxane, acetonitrile, dimethylsulphoxide or dimethylformamide, optionally in the presence of an inorganic or a tertiary organic base, preferably at temperatures between 20 C and the boiling temperature of the solvent used. The acylation with a corresponding acid is preferably carried out in the presence of a dehydrating agent, e.g. in the presence of isobutyl chloroformate, tetraethyl orthocarbonate, trimethyl orthoacetate, 2,2-dimethoxypropane, tetramethoxysilane, thionylchloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexylcarbodiimide, N,N'-dicyclohexyl-carbodiimide/N-hydroxysuccinimide, N,N'-dicyclohexylcarbodiimide/1-hydroxy-benztriazole, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate/1-hydroxy-benzotriazole,. N,N'-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride, and optionally with the addition of a base such as pyridine, 4-dimethylamino-pyridine, N-methyl-morpholine or triethylamine, conveniently at temperatures between 0 and 150 C, preferably at temperatures between 0 and 100 C, and the acylation with a corresponding reactive compound such as an anhydride, ester, imidazolide or halide thereof is optionally carried out in the presence of a tertiary organic base such as triethylamine, N-ethyl-diisopropylamine or N-methyl-morpholine at temperatures between 0 and 150 C, preferably at temperatures between 50 and 100 C.
The subsequent esterification or amidation is conveniently carried out by reacting a corresponding reactive carboxylic acid derivative with a corresponding alcohol or amine as described hereinbefore.
In the reactions described hereinbefore, any reactive groups present such as carboxy, amino, alkylamino or imino groups may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.
For example, a protecting group for a carboxyl group may be a trimethylsilyl, methyl, ethyl, tert.butyl, benzyl or tetrahydropyranyl group and protecting groups for an amino, alkylamino or imino group may be an acetyl, trifluoroacetyl, benzoyl, ethoxycarbonyl, tert.butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group and additionally, for the amino group, a phthalyl group.
Any protecting group used is optionally subsequently cleaved for example by hydrolysis in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as lithium hydroxide, sodium hydroxide or potassium hydroxide, at temperatures between 0 and 100 C, preferably at temperatures between 10 and 50 C.
However, a benzyl, methoxybenzyl or benzyloxycarbonyl group is cleaved, for example, hydrogenolytically, e.g.
with hydrogen in the presence of a catalyst such as palladium/charcoal in a solvent such as methanol, ethanol, ethyl acetate, dimethylformamide, dimethylformamide/acetone or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid or glacial acetic acid at temperatures between 0 and 50 C, but preferably at ambient temperature, and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar.
A methoxybenzyl group may also be cleaved in the presence of an oxidising agent such as cerium(IV)ammonium nitrate in a solvent such as methylene chloride, acetonitrile or acetonitrile/water at temperatures of between 0 and 50 C, but preferably at ambient temperature.
as hydrochloric acid at temperatures between 0 and 50 C, but preferably at ambient temperature, and at a hydrogen pressure from 1 to 7 bar, but preferably from 3 to 5 bar.
If according to the invention a compound of general formula I is obtained which contains an alkoxycarbonyl group, this can be converted by hydrolysis into a corresponding carboxy compound, or If a compound of general formula I is obtained which contains an amino or alkylamino group, this may be converted by alkylation or reductive alkylation into a corresponding alkylamino or dialkylamino compound, or If a compound of general formula I is obtained which contains an amino or alkylamino group, this may be converted by acylation into a corresponding acyl compound, or If a compound of general formula I is obtained which contains a carboxy group, this can be converted by esterification or amidation into a corresponding ester or aminocarbonyl compound.
The subsequent hydrolysis is preferably carried out in an aqueous solvent, e.g. in water, isopropanol/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as lithium hydroxide, sodium hydroxide or potassium hydroxide at temperatures between 0 and 100 C, preferably at temperatures between 10 and 50 C.
The subsequent reductive alkylation is preferably carried out in a suitable solvent such as methanol, methanol/water, methanol/water/ammonia, ethanol, ether, tetrahydrofuran, dioxane or dimethylformamide optionally with the addition of an acid such as hydrochloric acid in the presence of catalytically activated hydrogen, e.g. hydrogen in the presence of Raney nickel, platinum or palladium/charcoal, or in the presence of a metal hydride such as sodium borohydride, lithium borohydride or lithium aluminium hydride at temperatures between 0 and 100 C, preferably at temperatures between 20 and 80 C.
The subsequent alkylation is carried out with an alkylating agent such as an alkyl halide or dialkyl sulphate such as methyliodide, dimethylsulphate or propylbromide preferably in a solvent such as methanol, ethanol, methylene chloride, tetrahydrofuran, toluene, dioxane, dimethylsulphoxide or dimethylformamide optionally in the presence of an inorganic or a tertiary organic base such as triethylamine, N-ethyl-diisopropylamine or dimethylaminopyridine, preferably at temperatures between 20 C and the boiling temperature of the solvent used.
The subsequent acylation is preferably carried out in a solvent such as methylene chloride, diethylether, tetrahydrofuran, toluene, dioxane, acetonitrile, dimethylsulphoxide or dimethylformamide, optionally in the presence of an inorganic or a tertiary organic base, preferably at temperatures between 20 C and the boiling temperature of the solvent used. The acylation with a corresponding acid is preferably carried out in the presence of a dehydrating agent, e.g. in the presence of isobutyl chloroformate, tetraethyl orthocarbonate, trimethyl orthoacetate, 2,2-dimethoxypropane, tetramethoxysilane, thionylchloride, trimethylchlorosilane, phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexylcarbodiimide, N,N'-dicyclohexyl-carbodiimide/N-hydroxysuccinimide, N,N'-dicyclohexylcarbodiimide/1-hydroxy-benztriazole, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium-tetrafluoroborate/1-hydroxy-benzotriazole,. N,N'-carbonyldiimidazole or triphenylphosphine/carbon tetrachloride, and optionally with the addition of a base such as pyridine, 4-dimethylamino-pyridine, N-methyl-morpholine or triethylamine, conveniently at temperatures between 0 and 150 C, preferably at temperatures between 0 and 100 C, and the acylation with a corresponding reactive compound such as an anhydride, ester, imidazolide or halide thereof is optionally carried out in the presence of a tertiary organic base such as triethylamine, N-ethyl-diisopropylamine or N-methyl-morpholine at temperatures between 0 and 150 C, preferably at temperatures between 50 and 100 C.
The subsequent esterification or amidation is conveniently carried out by reacting a corresponding reactive carboxylic acid derivative with a corresponding alcohol or amine as described hereinbefore.
In the reactions described hereinbefore, any reactive groups present such as carboxy, amino, alkylamino or imino groups may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.
For example, a protecting group for a carboxyl group may be a trimethylsilyl, methyl, ethyl, tert.butyl, benzyl or tetrahydropyranyl group and protecting groups for an amino, alkylamino or imino group may be an acetyl, trifluoroacetyl, benzoyl, ethoxycarbonyl, tert.butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group and additionally, for the amino group, a phthalyl group.
Any protecting group used is optionally subsequently cleaved for example by hydrolysis in an aqueous solvent, e.g. in water, isopropanol/water, acetic acid/water, tetrahydrofuran/water or dioxane/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as lithium hydroxide, sodium hydroxide or potassium hydroxide, at temperatures between 0 and 100 C, preferably at temperatures between 10 and 50 C.
However, a benzyl, methoxybenzyl or benzyloxycarbonyl group is cleaved, for example, hydrogenolytically, e.g.
with hydrogen in the presence of a catalyst such as palladium/charcoal in a solvent such as methanol, ethanol, ethyl acetate, dimethylformamide, dimethylformamide/acetone or glacial acetic acid, optionally with the addition of an acid such as hydrochloric acid or glacial acetic acid at temperatures between 0 and 50 C, but preferably at ambient temperature, and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar.
A methoxybenzyl group may also be cleaved in the presence of an oxidising agent such as cerium(IV)ammonium nitrate in a solvent such as methylene chloride, acetonitrile or acetonitrile/water at temperatures of between 0 and 50 C, but preferably at ambient temperature.
A 2,4-dimethoxybenzyl group, however, is preferably cleaved in trifluoroacetic acid in the presence of anisol.
A tert.butyl or tert.butyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid or hydrochloric acid, optionally using a solvent such as methylene chloride, dioxan, ethyl acetate or ether.
A phthalyl group is preferably cleaved in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene/water or dioxan at temperatures between 20 and 50 C.
Moreover, chiral compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers.
Thus, for example, the compounds of general formula I
obtained which occur as racemates may be separated by methods known per se (cf. Allinger N. L. and Eliel E. L.
in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their optical antipodes and compounds of general formula I with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known per se, e.g. by chromatography and/or fractional crystallisation, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above.
The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids in common use are e.g. the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, N-acetylglutamic acid, aspartic acid, N-acetylaspartic acid or quinic acid. An optically active alcohol may be for example (+) or (-)-menthol and an optically active acyl group in amides, for example, may be a (+)-or (-)-menthyloxycarbonyl group.
Furthermore, the compounds of formula I obtained may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids. Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, maleic acid or methanesulphonic acid.
Moreover, if the new compounds of formula I thus obtained contain a carboxy group, they may subsequently, if desired, be converted into the salts thereof with inorganic or organic bases, particularly for phar-maceutical use into the physiologically acceptable salts thereof. Suitable bases for this purpose include for example sodium hydroxide, potassium hydroxide, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.
A tert.butyl or tert.butyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid or hydrochloric acid, optionally using a solvent such as methylene chloride, dioxan, ethyl acetate or ether.
A phthalyl group is preferably cleaved in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene/water or dioxan at temperatures between 20 and 50 C.
Moreover, chiral compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers.
Thus, for example, the compounds of general formula I
obtained which occur as racemates may be separated by methods known per se (cf. Allinger N. L. and Eliel E. L.
in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their optical antipodes and compounds of general formula I with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known per se, e.g. by chromatography and/or fractional crystallisation, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above.
The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids in common use are e.g. the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, N-acetylglutamic acid, aspartic acid, N-acetylaspartic acid or quinic acid. An optically active alcohol may be for example (+) or (-)-menthol and an optically active acyl group in amides, for example, may be a (+)-or (-)-menthyloxycarbonyl group.
Furthermore, the compounds of formula I obtained may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids. Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, maleic acid or methanesulphonic acid.
Moreover, if the new compounds of formula I thus obtained contain a carboxy group, they may subsequently, if desired, be converted into the salts thereof with inorganic or organic bases, particularly for phar-maceutical use into the physiologically acceptable salts thereof. Suitable bases for this purpose include for example sodium hydroxide, potassium hydroxide, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.
The compounds of general formulae I to VIII used as starting materials are known from the literature in some cases or may be obtained by methods known from the literature or are described in the Examples.
As already mentioned, the new compounds of general formula I wherein Rl represents a hydrogen atom or a prodrug group have valuable pharmacological properties, particularly inhibitory effects on various kinases and cycline/CDK-complexes, on the proliferation of cultivated human tumour cells and, when administered orally, on the growth of tumours in nude mice infected with human tumour cells.
For example, the compounds listed in Table 1 were tested for their biological properties as follows:
Test 1 Inhibition of cycline/CDK enzyme, in vitro activity High FiveTM insect cells (BTI-TN-5B1_4) which had been infected with a high titre of recombinant baculovirus were used to produce active human cycline/CDK
holoenzymes. By using a baculovirus vector which contained two promoters (polyhedrin enhancer promoter, P10 enhancer promoter), GST-tagged cyclines (e.g.
cycline Dl or cycline D3) with the corresponding His6-tagged CDK subunit (e.g. for CDK4 or CDK6) were expressed in the same cell. The active holoenzyme was isolated by affinity chromatography on glutathione sepharose. Recombinant GST-tagged pRB (aa 379-928) was produced in E. coli and purified by affinity chromatography on glutathione sepharose.
The substrates used for the kinase assays depended on the specific kinases. Histone H1 (Sigma) was used as the substrate for cycline E/CDK2, cycline A/CDK2, cycline B/CDK1 and for v-cycline/CDK6. GST-tagged pRB
(aa 379-928) was used as substrate for cycline D1/CDK4, cycline D3/CDK4, cycline D1/CDK6 and for cycline D3/CDK6.
Lysates of the insect cells infected with recombinant baculovirus or recombinant kinases (obtained from the lysates by purification) were incubated together with radiolabelled ATP in the presence of a suitable substrate with various concentrations of the inhibitor in a 1% DMSO solution (dimethyl sulphoxide) for 45 minutes at 30 C. The substrate proteins with associated radioactivity were precipitated with 5% TCA
(trichloroacetic acid) in water-repellent PVDF multi-well microtitre plates (Millipore) or with 0.5%
phosphoric acid solution on WhatmanTMP81 filters. After the addition of scintillation liquid the radioactivity was measured in a Wallace 1450 Microbeta Liquid Scintillation Counter. For each concentration of the substance double measurements were carried out; IC50 values were calculated for the enzyme inhibition.
Test 2 Inhibition of the proliferation of cultivation human tumour cells Cells of the Leimyosarcoma tumour cell line SK-UT-1B
(obtained from the American Type Culture Collection (ATCC)) were cultivated in Minimum Essential Medium with non-essential amino acids (Gibco), supplemented with sodium pyruvate (1 mmol), glutamine (2 mmol) and 10%
foetal calf serum (Gibco) and harvested during the log-growth phase. Then the SK-UT-1B cells were added to Cytostar multi-well plates (Amersham) at a density of 4000 cells per well and incubated overnight in an incubator. Various concentrations of the compounds (dissolved in DMSO; final concentration: <1%) were added to the cells. After 48 hours' incubation 14C-thymidine (Amersham) was added to each well and incubation was continued for a further 24 hours. The quantity of 14C-thymidine incorporated into the tumour cells in the presence of the inhibitor and representing the number of cells in the S phase was measured in a Wallace 1450 Microbeta Liquid Scintillation Counter. IC50 values for the inhibition of proliferation (= inhibition of incorporated 14C-thymidine) were calculated, correcting for the background radiation. All the measurements were done twice.
Test 3 In vivo effects on tumour-bearina nude mice 106 cells [SK-UT-lB, or non-small cell lung tumour NCI-H460 (obtained from ATCC)] in a volume of 0.1 ml were injected subcutaneously into male and/or female nude mice (NMRI nu/nu; 25-35g; N = 10-20); alternatively, small fragments of SK-UT-1B or NCI-H460 cell clumps were implanted subcutaneously. One to three weeks after the injection or implantation a kinase inhibitor was administered daily by oral route for a period of 2 to 4 weeks (by oesophageal tube). The size of the tumour was measured three times a week using a digital sliding gauge. The effect of a kinase inhibitor on the tumour growth was determined as a percentage inhibition compared with a control group treated with placebo.
Table 2 which follows contains the results obtained in in vitro test 2:
As already mentioned, the new compounds of general formula I wherein Rl represents a hydrogen atom or a prodrug group have valuable pharmacological properties, particularly inhibitory effects on various kinases and cycline/CDK-complexes, on the proliferation of cultivated human tumour cells and, when administered orally, on the growth of tumours in nude mice infected with human tumour cells.
For example, the compounds listed in Table 1 were tested for their biological properties as follows:
Test 1 Inhibition of cycline/CDK enzyme, in vitro activity High FiveTM insect cells (BTI-TN-5B1_4) which had been infected with a high titre of recombinant baculovirus were used to produce active human cycline/CDK
holoenzymes. By using a baculovirus vector which contained two promoters (polyhedrin enhancer promoter, P10 enhancer promoter), GST-tagged cyclines (e.g.
cycline Dl or cycline D3) with the corresponding His6-tagged CDK subunit (e.g. for CDK4 or CDK6) were expressed in the same cell. The active holoenzyme was isolated by affinity chromatography on glutathione sepharose. Recombinant GST-tagged pRB (aa 379-928) was produced in E. coli and purified by affinity chromatography on glutathione sepharose.
The substrates used for the kinase assays depended on the specific kinases. Histone H1 (Sigma) was used as the substrate for cycline E/CDK2, cycline A/CDK2, cycline B/CDK1 and for v-cycline/CDK6. GST-tagged pRB
(aa 379-928) was used as substrate for cycline D1/CDK4, cycline D3/CDK4, cycline D1/CDK6 and for cycline D3/CDK6.
Lysates of the insect cells infected with recombinant baculovirus or recombinant kinases (obtained from the lysates by purification) were incubated together with radiolabelled ATP in the presence of a suitable substrate with various concentrations of the inhibitor in a 1% DMSO solution (dimethyl sulphoxide) for 45 minutes at 30 C. The substrate proteins with associated radioactivity were precipitated with 5% TCA
(trichloroacetic acid) in water-repellent PVDF multi-well microtitre plates (Millipore) or with 0.5%
phosphoric acid solution on WhatmanTMP81 filters. After the addition of scintillation liquid the radioactivity was measured in a Wallace 1450 Microbeta Liquid Scintillation Counter. For each concentration of the substance double measurements were carried out; IC50 values were calculated for the enzyme inhibition.
Test 2 Inhibition of the proliferation of cultivation human tumour cells Cells of the Leimyosarcoma tumour cell line SK-UT-1B
(obtained from the American Type Culture Collection (ATCC)) were cultivated in Minimum Essential Medium with non-essential amino acids (Gibco), supplemented with sodium pyruvate (1 mmol), glutamine (2 mmol) and 10%
foetal calf serum (Gibco) and harvested during the log-growth phase. Then the SK-UT-1B cells were added to Cytostar multi-well plates (Amersham) at a density of 4000 cells per well and incubated overnight in an incubator. Various concentrations of the compounds (dissolved in DMSO; final concentration: <1%) were added to the cells. After 48 hours' incubation 14C-thymidine (Amersham) was added to each well and incubation was continued for a further 24 hours. The quantity of 14C-thymidine incorporated into the tumour cells in the presence of the inhibitor and representing the number of cells in the S phase was measured in a Wallace 1450 Microbeta Liquid Scintillation Counter. IC50 values for the inhibition of proliferation (= inhibition of incorporated 14C-thymidine) were calculated, correcting for the background radiation. All the measurements were done twice.
Test 3 In vivo effects on tumour-bearina nude mice 106 cells [SK-UT-lB, or non-small cell lung tumour NCI-H460 (obtained from ATCC)] in a volume of 0.1 ml were injected subcutaneously into male and/or female nude mice (NMRI nu/nu; 25-35g; N = 10-20); alternatively, small fragments of SK-UT-1B or NCI-H460 cell clumps were implanted subcutaneously. One to three weeks after the injection or implantation a kinase inhibitor was administered daily by oral route for a period of 2 to 4 weeks (by oesophageal tube). The size of the tumour was measured three times a week using a digital sliding gauge. The effect of a kinase inhibitor on the tumour growth was determined as a percentage inhibition compared with a control group treated with placebo.
Table 2 which follows contains the results obtained in in vitro test 2:
Compound Inhibition of (Example no.) SKUT-1B-proliferation IC50 [um]
4( 2) 0.17 4( 14) 0.18 4( 62) 0.05 4 ( 53) 0.01 4( 54) 0.03 4( 60) 0.03 4(120) 0.04 4(122) 0.04 4( 94) 0.03 3( 3) 0.01 3( 7) 0.01 4(129) 0.04 In view of their biological properties, the new compounds of general formula I, their isomers and physiologically acceptable salts are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation.
Such diseases include (with no claim to completeness):
viral infections (e.g. HIV and Kaposi's sarcoma);
inflammation and autoimmune diseases (e.g. colitis, arthritis, Alzheimer's disease, glomerulonephritis and wound healing); bacterial, fungal and/or parasitic infections; leukaemias, lymphoma and solid tumours; skin diseases (e.g. psoriasis); bone diseases; cardiovascular diseases (e.g. restenosis and hypertrophy). They are also useful for protecting proliferating cells (e.g.
hair, intestinal, blood and progenitor cells) against DNA
damage caused by radiation, UV treatment and/or cytostatic treatment.
The new compounds may be used for the short-term or long-term treatment of the abovementioned diseases, optionally in conjunction with other state-of-the-art compounds such as other cytostatics.
The dosage required to achieve such an effect is appropriately 0.1 to 30 mg/kg, preferably 0.3 to 10 mg/kg by intravenous route, and 0.1 to 100 mg/kg, preferably 0.3 to 30 mg/kg by oral route, in each case administered 1 to 4 times a day. For this purpose, the compounds of formula I prepared according to the invention may be formulated, optionally together with other active substances, with one or more inert conventional carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof, to produce conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories.
The Examples which follow are intended to illustrate the invention:
4( 2) 0.17 4( 14) 0.18 4( 62) 0.05 4 ( 53) 0.01 4( 54) 0.03 4( 60) 0.03 4(120) 0.04 4(122) 0.04 4( 94) 0.03 3( 3) 0.01 3( 7) 0.01 4(129) 0.04 In view of their biological properties, the new compounds of general formula I, their isomers and physiologically acceptable salts are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation.
Such diseases include (with no claim to completeness):
viral infections (e.g. HIV and Kaposi's sarcoma);
inflammation and autoimmune diseases (e.g. colitis, arthritis, Alzheimer's disease, glomerulonephritis and wound healing); bacterial, fungal and/or parasitic infections; leukaemias, lymphoma and solid tumours; skin diseases (e.g. psoriasis); bone diseases; cardiovascular diseases (e.g. restenosis and hypertrophy). They are also useful for protecting proliferating cells (e.g.
hair, intestinal, blood and progenitor cells) against DNA
damage caused by radiation, UV treatment and/or cytostatic treatment.
The new compounds may be used for the short-term or long-term treatment of the abovementioned diseases, optionally in conjunction with other state-of-the-art compounds such as other cytostatics.
The dosage required to achieve such an effect is appropriately 0.1 to 30 mg/kg, preferably 0.3 to 10 mg/kg by intravenous route, and 0.1 to 100 mg/kg, preferably 0.3 to 30 mg/kg by oral route, in each case administered 1 to 4 times a day. For this purpose, the compounds of formula I prepared according to the invention may be formulated, optionally together with other active substances, with one or more inert conventional carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof, to produce conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories.
The Examples which follow are intended to illustrate the invention:
Example I
Methyl 1-acetyl-2-indolinone-5-carboxylate 10.5 g of methyl 2-indolinone-5-carboxylate (prepared analogously to Ogawa et al. Chem.Pharm.Bull 36, 2253-2258 (1988)) are stirred in 30 ml of acetic anhydride for 4 hours at 140 C. Then it is allowed to cool, poured onto ice water and the precipitate is suction filtered. The product is again washed with water, then taken up in methylene chloride, dried over sodium sulphate and concentrated by evaporation.
Yield: 11 g (86 % of theory), Rf value: 0.63 (silica gel; methylene chloride/methanol =
50:1) Example II
Methyl 1-acetyl-3-(1-ethoxy-l-phenyl-methylene)-2-indolinone-5-carboxylate 11 g of methyl 1-acetyl-2-indolinone-5-carboxylate are stirred into 110 ml of acetic anhydride and 30 ml of triethyl orthobenzoate for 2 hours at 100 C. Then the mixture is concentrated by rotary evaporation, the residue is washed with ether and suction filtered.
Yield: 11.5 g (67 % of theory), Rf value: 0.55 (silica gel, methylene chloride/petroleum ether/ethyl acetate = 4:5:1) Example III
28.0 g of Rink resin (MBHA resin, Messrs Novobiochem) are allowed to swell in 330 ml of dimethylformamide. Then 330 ml of 30 % piperidine in dimethylformamide are added and the mixture is shaken for 7 minutes in order to cleave the FMOC protecting group. The resin is then washed several times with dimethylformamide. Finally, 7.3 g of 2-indolinone-5-carboxylic acid, 5.6 g of hydroxybenzotriazole, 13.3 g of 0-(benzotriazol-1-yl)-N,N,N',N'-tetramethyl-uronium-tetrafluoroborate and 5.7 ml of N-ethyl-diisopropylamine in 300 ml of dimethylformamide are added and the mixture is shaken for 1 hour. The solution is then suction filtered and the resin is washed five times with 300 ml of dimethylformamide and three times with 300 ml of methylene chloride. To dry the resin, nitrogen is blown through it.
Yield: 28 g of charged resin Example IV
5 g of the charged resin prepared according to Example III are stirred with 15 ml of acetic anhydride at 80 C
for 1 hour. Then 15 ml of triethyl orthobenzoate are added and the resulting mixture is shaken for a further 3 hours at 110 C. The resin is then suction filtered and washed with dimethylformamide, methanol and finally with methylene chloride.
Yield: 7 g of moist resin Exam lp e V
4-(Ethylamino-methyl)-nitrobenzene 6 g of 4-nitrobenzylbromide are dissolved in 25 ml of ethanol, mixed with 25 ml of 10% ethanolic ethylamine solution and refluxed for 2 hours. Then the solution is evaporated down, the residue is taken up in methylene chloride and washed with dilute sodium hydroxide solution. Finally, the organic phase is evaporated down.
Yield: 2.3 g (46 % of theory), Rf value: 0.2 (silica gel; methylene chloride/methanol =
Methyl 1-acetyl-2-indolinone-5-carboxylate 10.5 g of methyl 2-indolinone-5-carboxylate (prepared analogously to Ogawa et al. Chem.Pharm.Bull 36, 2253-2258 (1988)) are stirred in 30 ml of acetic anhydride for 4 hours at 140 C. Then it is allowed to cool, poured onto ice water and the precipitate is suction filtered. The product is again washed with water, then taken up in methylene chloride, dried over sodium sulphate and concentrated by evaporation.
Yield: 11 g (86 % of theory), Rf value: 0.63 (silica gel; methylene chloride/methanol =
50:1) Example II
Methyl 1-acetyl-3-(1-ethoxy-l-phenyl-methylene)-2-indolinone-5-carboxylate 11 g of methyl 1-acetyl-2-indolinone-5-carboxylate are stirred into 110 ml of acetic anhydride and 30 ml of triethyl orthobenzoate for 2 hours at 100 C. Then the mixture is concentrated by rotary evaporation, the residue is washed with ether and suction filtered.
Yield: 11.5 g (67 % of theory), Rf value: 0.55 (silica gel, methylene chloride/petroleum ether/ethyl acetate = 4:5:1) Example III
28.0 g of Rink resin (MBHA resin, Messrs Novobiochem) are allowed to swell in 330 ml of dimethylformamide. Then 330 ml of 30 % piperidine in dimethylformamide are added and the mixture is shaken for 7 minutes in order to cleave the FMOC protecting group. The resin is then washed several times with dimethylformamide. Finally, 7.3 g of 2-indolinone-5-carboxylic acid, 5.6 g of hydroxybenzotriazole, 13.3 g of 0-(benzotriazol-1-yl)-N,N,N',N'-tetramethyl-uronium-tetrafluoroborate and 5.7 ml of N-ethyl-diisopropylamine in 300 ml of dimethylformamide are added and the mixture is shaken for 1 hour. The solution is then suction filtered and the resin is washed five times with 300 ml of dimethylformamide and three times with 300 ml of methylene chloride. To dry the resin, nitrogen is blown through it.
Yield: 28 g of charged resin Example IV
5 g of the charged resin prepared according to Example III are stirred with 15 ml of acetic anhydride at 80 C
for 1 hour. Then 15 ml of triethyl orthobenzoate are added and the resulting mixture is shaken for a further 3 hours at 110 C. The resin is then suction filtered and washed with dimethylformamide, methanol and finally with methylene chloride.
Yield: 7 g of moist resin Exam lp e V
4-(Ethylamino-methyl)-nitrobenzene 6 g of 4-nitrobenzylbromide are dissolved in 25 ml of ethanol, mixed with 25 ml of 10% ethanolic ethylamine solution and refluxed for 2 hours. Then the solution is evaporated down, the residue is taken up in methylene chloride and washed with dilute sodium hydroxide solution. Finally, the organic phase is evaporated down.
Yield: 2.3 g (46 % of theory), Rf value: 0.2 (silica gel; methylene chloride/methanol =
9:1) The following are prepared analogously:
4- [N- (4-chlorophenyl-methyl) -amino-methyl] -nitrobenzene 4-(N-cyclohexyl-amino-methyl)-nitrobenzene 4-(N-isopropyl-amino-methyl)-nitrobenzene 4-(N-butyl-amino-methyl)-nitrobenzene 4- (N-methoxycarbonyl-methyl-amino-methyl) -nitrobenzene 4- (N- (phenyl-methyl) -amino-methyl) -nitrobenzene 4-(pyrrolidino-methyl)-nitrobenzene 4-(morpholino-methyl)-nitrobenzene 4-(piperidino-methyl)-nitrobenzene 4-(hexamethyleneimino)-nitrobenzene 4-(4-hydroxy-piperidino-methyl)-nitrobenzene 4-(4-methyl-piperidino-methyl)-nitrobenzene 4-(4-ethyl-piperidino-methyl)-nitrobenzene 4-(4-isopropyl-piperidino-methyl)-nitrobenzene 4-(4-phenyl-piperidino-methyl)-nitrobenzene 4-(4-benzyl-piperidino-methyl)-nitrobenzene 4- (4-ethoxycarbonyl-piperidino-methyl) -nitrobenzene 4-(dimethylamino-methyl)-nitrobenzene 4-(dipropylamino-methyl)-nitrobenzene 4-(4-tert.butyloxycarbonyl-piperazino-methyl)-nitrobenzene 3-(dimethylamino-methyl)-nitrobenzene 4-(2-diethylamino-ethyl)-nitrobenzene 4-(2-morpholinyl-ethyl)-nitrobenzene 4-(2-pyrrolidinyl-ethyl)-nitrobenzene 4-(2-piperidinyl-ethyl)-nitrobenzene 4-(N-ethyl-N-benzyl-amino-methyl)-nitrobenzene 4-(N-propyl-N-benzyl-amino-methyl)-nitrobenzene 4-[N-methyl-N-(4-chlorophenylmethyl)-amino-methyl])-nitrobenzene 4-[N-methyl-N-(4-bromophenylmethyl)-amino-methyl]-nitrobenzene 4-[N-methyl-N-(3-chlorophenylmethyl)-amino-methyl]-nitrobenzene 4-[N-methyl-N-(3,4-dimethoxyphenylmethyl)-amino-methyl]-nitrobenzene 4-[N-methyl-N-(4-methoxyphenylmethyl)-amino-methyl]-nitrobenzene 4-[N-2,2,2-trifluoroethyl-N-(phenylmethyl)-amino-methyl]-nitrobenzene 4-[N-2,2,2-trifluoroethyl-N-(4-chlorophenylmethyl)-amino-methyl]-nitrobenzene Example VI
4-(N-ethyl-N-tert.butor>ycarbonyl-amino-methyl)-nitrobenzene 2.2 g of 4-(ethylamino-methyl)-nitrobenzene are dissolved in 50 ml of ethyl acetate and stirred with 2.6 g of di-tert-butyl-dicarbonate for 30 minutes at ambient temperature. Then the solution is washed with water and concentrated by evaporation.
Yield: 3.4 g, Rf value: 0.9 (silica gel, methylene chloride/methanol =
9:1) The following are prepared analogously:
4-[N-(4-chlorophenyl-methyl)-N-tert.butoxycarbonyl-amino-methyl)-nitrobenzene 4-(N-cyclohexyl-N-tert.butoxycarbonyl-amino-methyl)-nitrobenzene 4-(N-isopropyl-N-tert.butoxycarbonyl-amino-methyl)-nitrobenzene 4-(N-butyl-N-tert.butoxycarbonyl-amino-methyl)-nitrobenzene 4-(N-methoxycarbonyl-methyl-N-tert.butoxycarbonyl-amino-methyl)-nitrobenzene 4-(N-(phenyl-methyl)-N-tert.butoxycarbonyl-amino-methyl)-nitrobenzene Example VII
4-(N-ethyl-N-tert.butoxycarbonyl-amino-methyl)-aniline 6.4 g of 4-(N-ethyl-N-tert.butoxycarbonyl-amino-methyl)-nitrobenzene are dissolved in 60 ml of methanol and hydrogenated with 1.5 g of Raney nickel at ambient temperature and hydrogenated under 3 bars of pressure.
Then the catalyst is filtered off and the solution is evaporated down.
Yield: 4.78 g, Rf value: 0.7 (silica gel, methylene chloride/methanol 50:1) The following are prepared analogously:
4-[N-(4-chlorophenyl-methyl)-N-tert.butoxycarbonyl-amino-methyl]-aniline 4-(N-cyclohexyl-N-tert.butoxycarbonyl-amino-methyl)-aniline 4-(N-isopropyl-N-tert.butoxycarbonyl-amino-methyl)-aniline 4-(N-butyl-N-tert.butoxycarbonyl-amino-methyl)-aniline 4-(N-methoxycarbonyl-methyl-N-tert.butoxycarbonyl-amino-methyl)-aniline 4-(N-(phenyl-methyl)-N-tert.butoxycarbonyl-amino-methyl)-aniline 4-(pyrrolidino-methyl)-aniline 4-(morpholino-methyl)-aniline 4-(piperidino-methyl)-aniline 4-(hexamethyleneimino-methyl)-aniline 4-(4-hydroxy-piperidino-methyl)-aniline 4-(4-methyl-piperidino-methyl)-aniline 4-(4-ethyl-piperidino-methyl)-aniline 4-(4-isopropyl-piperidino-methyl)-aniline 4-(4-phenyl-piperidino-methyl)-aniline 4-(4-benzyl-piperidino-methyl)-aniline 4-(4-ethoxycarbonyl-piperidino-methyl)-aniline 4-(dimethylamino-methyl)-aniline 4-(dipropylamino-methyl)-aniline 4-(4-tert.butoxycarbonyl-piperazinyl-methyl)-aniline 3-(dimethylamino-methyl)-aniline 4-(2-diethylamino-ethyl)-aniline 4-(2-morpholinyl-ethyl)-aniline 4-(2-pyrrolidinyl-ethyl)-aniline 4-(2-piperidinyl-ethyl)-aniline 4-(N-ethyl-N-benzyl-amino-methyl)-aniline 4-(N-propyl-N-benzyl-amino-methyl)-aniline 4-[N-methyl-N-(4-chlorophenylmethyl)-amino-methyl]-aniline 4- [N-methyl-N- (4-bromophenylmethyl) -amino-methyl] -aniline 4-[N-methyl-N-(3-chlorophenylmethyl)-amino-methyl]-aniline 4-[N-methyl-N-(3,4-dimethoxyphenylmethyl)-amino-methyl]-aniline 4-[N-methyl-N-(4-methoxyphenylmethyl)-amino-methyl]-aniline 4- [N-2, 2, 2-trifluoroethyl-N- (phenylmethyl) -amino-methyl] -aniline 4- [N-2, 2, 2-trifluoroethyl-N- (4-chlorophenylmethyl) -amino-methyl]-aniline Preparation of the end products:
Example 1 methyl 3-Z-[1-(1-methyl-piperidin-4-yl-amino)-1-phenyl-methylenel-2-indolinone-5-carboxylate 11.5 g of methyl 1-acetyl-3-(1-ethoxy-l-phenyl-methylene)-2-indolinone-5-carboxylate are dissolved in 115 ml of methylene chloride and stirred with 10.8 g of 4-amino-N-methylpiperidine for 5 hours at ambient temperature. Then 20 ml of methanolic ammonia are added and the mixture is left to stand overnight. The solution is evaporated down and the residue is washed with ether.
Yield: 11.9 g (97 % of theory), Rf value: 0.20 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 391 (M') The.following are prepared analogously:
(1) methyl 3-Z-[l-(4-(piperidino-methyl)-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylate Rf value:
0.4 (silica gel, methylene chloride/methanol = 9:1) mass spectrum: m/z = 467 (M+) (2) methyl 3-Z-[1-(4-(N-phenylmethyl-N-methylamino-methyl)-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylate C32H29N303 mass spectrum: m/z = 503 (M+) (3) methyl 3-Z-[1-(4-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylate C26H25N-303 mass spectrum: m/z = 427 (M') (4) methyl 3-Z-[1-(3-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylate C26H25N303 mass spectrum: m/z = 427 (M') (5) methyl 3-Z-[1-(4-chlorophenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylate (6) methyl 3-Z-(1-phenylamino-l-phenyl-methylene)-2-indolinone-5-carboxylate Example 2 3-Z-[1-(l-methyl-piperidine-4-yl-amino)-1-phenyl-methvlenel-2-indolinone-5- arboxylic acid 11.9 g of methyl 3-Z-[1-(1-methyl-piperidin-4-yl-amino)-1-phenyl-methylene]-2-indolinone-5-carboxylate are refluxed in 300 ml of methanol and 150 ml of 1N sodium hydroxide solution for 4 hours. Then the mixture is neutralised with 150 ml of 1N hydrochloric acid and evaporated to dryness. The residue is washed with water several times and dried.
Yield: 86 % of theory, Rf value: 0.17 (silica gel; methylene chloride/methanol =
4:1) Mass spectrum: m/z = 377 (M+) The following are prepared analogously:
(1) 3-Z-[1-(4-(piperidino-methyl)-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acidRf value: 0.15 (silica gel, methylene chloride/methanol = 9:1) mass spectrum: m/z = 453 (M+) (2) 3-Z-[1-(4-(N-phenylmethyl-N-methylamino-methyl)-phenylamino)-1-phenyl-methylene)-2-indolinone-5-carboxylic acid mass spectrum: m/z = 489 (M+) (3) 3-Z-[1-(4-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acidC25H23N30, mass spectrum: m/z = 413 (M+) (4) 3-Z-[1-(3-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene) -2-indolinone-5-carboxylic acidC25H23N303 mass spectrum: m/z = 413 (M+) (5) 3-Z-[1-(4-chlorophenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acid (6) 3-Z-[1-phenylamino-l-phenyl-methylene)-2-indolinone-5-carboxylic acid Exam lp e 3 3-Z-[1-(1-methyl-piperidine-4-yl-amino)-1-phenyl-methvlenel-5-dimethylcarbamoyl-2-indolinone 2 g of 3-Z-[1-(1-methyl-piperidin-4-yl-amino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acid are refluxed with 5 ml of thionylchloride for 2 hours. Then the mixture is concentrated by rotary evaporation and the residue is washed with ether. 0.5 g of this acid chloride are taken up in 5 ml of methylene chloride without further purification and mixed with 0.5 ml of dimethylamine in 5 ml of methylene chloride and stirred overnight at ambient temperature. The product is chromatographed over a silica gel column with methylene chloride/methanol/ammonia (4:1:0.1).
Yield: 50 % of theory, Rf value: 0.14 (silica gel: methylene chloride/methanol =
9:1) C2qHzBN402 Mass spectrum: m/z = 404 (M') The following compounds are prepared analogously:
(1) 3-Z-[1-(1-methyl-piperidin-4-yl-amino)-1-phenyl-methylene]-5-methylcarbamoyl-2-indolinone Yield: 49 % of theory, Rf value: 0.19 (silica gel; methylene chloride/methanol =
4:1) Mass spectrum: m/z = 390 (M+) (2) 3-Z-[1-(1-methyl-piperidin-4-yl-amino)-1-phenyl-methylene]-5-carbamoyl-2-indolinone Yield: 58 % of theory, Rf value: 0.15 (silica gel; methylene chloride/methanol =
4:1) C22H2qNq02 Mass spectrum: m/z = 376 (M+) (3) 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-5-dimethylcarbamoyl-2-indolinonePrepared from 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acid and dimethylamine or 0.64 g of Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acid, 0.34 g of dimethylamine hydrochloride, 0.9 g of 0-benzotriazol-1-yl-N,N,N`,N`-tetramethyluro-nium-tetrafluoroborate), 0.4 g of 1-hydroxy-1H-benzotriazole and 2.9 g of diisopropylethylamine are stirred in 20 ml of dimethylformamide for 20 hours at ambient temperature. The mixture is then evaporated down and the residue is suspended in water. The precipitate is suction filtered.
Yield: 600 mg (88% of theory), Rf value: 0.2 (silica gel, methylene chloride/ethanol =
4- [N- (4-chlorophenyl-methyl) -amino-methyl] -nitrobenzene 4-(N-cyclohexyl-amino-methyl)-nitrobenzene 4-(N-isopropyl-amino-methyl)-nitrobenzene 4-(N-butyl-amino-methyl)-nitrobenzene 4- (N-methoxycarbonyl-methyl-amino-methyl) -nitrobenzene 4- (N- (phenyl-methyl) -amino-methyl) -nitrobenzene 4-(pyrrolidino-methyl)-nitrobenzene 4-(morpholino-methyl)-nitrobenzene 4-(piperidino-methyl)-nitrobenzene 4-(hexamethyleneimino)-nitrobenzene 4-(4-hydroxy-piperidino-methyl)-nitrobenzene 4-(4-methyl-piperidino-methyl)-nitrobenzene 4-(4-ethyl-piperidino-methyl)-nitrobenzene 4-(4-isopropyl-piperidino-methyl)-nitrobenzene 4-(4-phenyl-piperidino-methyl)-nitrobenzene 4-(4-benzyl-piperidino-methyl)-nitrobenzene 4- (4-ethoxycarbonyl-piperidino-methyl) -nitrobenzene 4-(dimethylamino-methyl)-nitrobenzene 4-(dipropylamino-methyl)-nitrobenzene 4-(4-tert.butyloxycarbonyl-piperazino-methyl)-nitrobenzene 3-(dimethylamino-methyl)-nitrobenzene 4-(2-diethylamino-ethyl)-nitrobenzene 4-(2-morpholinyl-ethyl)-nitrobenzene 4-(2-pyrrolidinyl-ethyl)-nitrobenzene 4-(2-piperidinyl-ethyl)-nitrobenzene 4-(N-ethyl-N-benzyl-amino-methyl)-nitrobenzene 4-(N-propyl-N-benzyl-amino-methyl)-nitrobenzene 4-[N-methyl-N-(4-chlorophenylmethyl)-amino-methyl])-nitrobenzene 4-[N-methyl-N-(4-bromophenylmethyl)-amino-methyl]-nitrobenzene 4-[N-methyl-N-(3-chlorophenylmethyl)-amino-methyl]-nitrobenzene 4-[N-methyl-N-(3,4-dimethoxyphenylmethyl)-amino-methyl]-nitrobenzene 4-[N-methyl-N-(4-methoxyphenylmethyl)-amino-methyl]-nitrobenzene 4-[N-2,2,2-trifluoroethyl-N-(phenylmethyl)-amino-methyl]-nitrobenzene 4-[N-2,2,2-trifluoroethyl-N-(4-chlorophenylmethyl)-amino-methyl]-nitrobenzene Example VI
4-(N-ethyl-N-tert.butor>ycarbonyl-amino-methyl)-nitrobenzene 2.2 g of 4-(ethylamino-methyl)-nitrobenzene are dissolved in 50 ml of ethyl acetate and stirred with 2.6 g of di-tert-butyl-dicarbonate for 30 minutes at ambient temperature. Then the solution is washed with water and concentrated by evaporation.
Yield: 3.4 g, Rf value: 0.9 (silica gel, methylene chloride/methanol =
9:1) The following are prepared analogously:
4-[N-(4-chlorophenyl-methyl)-N-tert.butoxycarbonyl-amino-methyl)-nitrobenzene 4-(N-cyclohexyl-N-tert.butoxycarbonyl-amino-methyl)-nitrobenzene 4-(N-isopropyl-N-tert.butoxycarbonyl-amino-methyl)-nitrobenzene 4-(N-butyl-N-tert.butoxycarbonyl-amino-methyl)-nitrobenzene 4-(N-methoxycarbonyl-methyl-N-tert.butoxycarbonyl-amino-methyl)-nitrobenzene 4-(N-(phenyl-methyl)-N-tert.butoxycarbonyl-amino-methyl)-nitrobenzene Example VII
4-(N-ethyl-N-tert.butoxycarbonyl-amino-methyl)-aniline 6.4 g of 4-(N-ethyl-N-tert.butoxycarbonyl-amino-methyl)-nitrobenzene are dissolved in 60 ml of methanol and hydrogenated with 1.5 g of Raney nickel at ambient temperature and hydrogenated under 3 bars of pressure.
Then the catalyst is filtered off and the solution is evaporated down.
Yield: 4.78 g, Rf value: 0.7 (silica gel, methylene chloride/methanol 50:1) The following are prepared analogously:
4-[N-(4-chlorophenyl-methyl)-N-tert.butoxycarbonyl-amino-methyl]-aniline 4-(N-cyclohexyl-N-tert.butoxycarbonyl-amino-methyl)-aniline 4-(N-isopropyl-N-tert.butoxycarbonyl-amino-methyl)-aniline 4-(N-butyl-N-tert.butoxycarbonyl-amino-methyl)-aniline 4-(N-methoxycarbonyl-methyl-N-tert.butoxycarbonyl-amino-methyl)-aniline 4-(N-(phenyl-methyl)-N-tert.butoxycarbonyl-amino-methyl)-aniline 4-(pyrrolidino-methyl)-aniline 4-(morpholino-methyl)-aniline 4-(piperidino-methyl)-aniline 4-(hexamethyleneimino-methyl)-aniline 4-(4-hydroxy-piperidino-methyl)-aniline 4-(4-methyl-piperidino-methyl)-aniline 4-(4-ethyl-piperidino-methyl)-aniline 4-(4-isopropyl-piperidino-methyl)-aniline 4-(4-phenyl-piperidino-methyl)-aniline 4-(4-benzyl-piperidino-methyl)-aniline 4-(4-ethoxycarbonyl-piperidino-methyl)-aniline 4-(dimethylamino-methyl)-aniline 4-(dipropylamino-methyl)-aniline 4-(4-tert.butoxycarbonyl-piperazinyl-methyl)-aniline 3-(dimethylamino-methyl)-aniline 4-(2-diethylamino-ethyl)-aniline 4-(2-morpholinyl-ethyl)-aniline 4-(2-pyrrolidinyl-ethyl)-aniline 4-(2-piperidinyl-ethyl)-aniline 4-(N-ethyl-N-benzyl-amino-methyl)-aniline 4-(N-propyl-N-benzyl-amino-methyl)-aniline 4-[N-methyl-N-(4-chlorophenylmethyl)-amino-methyl]-aniline 4- [N-methyl-N- (4-bromophenylmethyl) -amino-methyl] -aniline 4-[N-methyl-N-(3-chlorophenylmethyl)-amino-methyl]-aniline 4-[N-methyl-N-(3,4-dimethoxyphenylmethyl)-amino-methyl]-aniline 4-[N-methyl-N-(4-methoxyphenylmethyl)-amino-methyl]-aniline 4- [N-2, 2, 2-trifluoroethyl-N- (phenylmethyl) -amino-methyl] -aniline 4- [N-2, 2, 2-trifluoroethyl-N- (4-chlorophenylmethyl) -amino-methyl]-aniline Preparation of the end products:
Example 1 methyl 3-Z-[1-(1-methyl-piperidin-4-yl-amino)-1-phenyl-methylenel-2-indolinone-5-carboxylate 11.5 g of methyl 1-acetyl-3-(1-ethoxy-l-phenyl-methylene)-2-indolinone-5-carboxylate are dissolved in 115 ml of methylene chloride and stirred with 10.8 g of 4-amino-N-methylpiperidine for 5 hours at ambient temperature. Then 20 ml of methanolic ammonia are added and the mixture is left to stand overnight. The solution is evaporated down and the residue is washed with ether.
Yield: 11.9 g (97 % of theory), Rf value: 0.20 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 391 (M') The.following are prepared analogously:
(1) methyl 3-Z-[l-(4-(piperidino-methyl)-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylate Rf value:
0.4 (silica gel, methylene chloride/methanol = 9:1) mass spectrum: m/z = 467 (M+) (2) methyl 3-Z-[1-(4-(N-phenylmethyl-N-methylamino-methyl)-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylate C32H29N303 mass spectrum: m/z = 503 (M+) (3) methyl 3-Z-[1-(4-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylate C26H25N-303 mass spectrum: m/z = 427 (M') (4) methyl 3-Z-[1-(3-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylate C26H25N303 mass spectrum: m/z = 427 (M') (5) methyl 3-Z-[1-(4-chlorophenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylate (6) methyl 3-Z-(1-phenylamino-l-phenyl-methylene)-2-indolinone-5-carboxylate Example 2 3-Z-[1-(l-methyl-piperidine-4-yl-amino)-1-phenyl-methvlenel-2-indolinone-5- arboxylic acid 11.9 g of methyl 3-Z-[1-(1-methyl-piperidin-4-yl-amino)-1-phenyl-methylene]-2-indolinone-5-carboxylate are refluxed in 300 ml of methanol and 150 ml of 1N sodium hydroxide solution for 4 hours. Then the mixture is neutralised with 150 ml of 1N hydrochloric acid and evaporated to dryness. The residue is washed with water several times and dried.
Yield: 86 % of theory, Rf value: 0.17 (silica gel; methylene chloride/methanol =
4:1) Mass spectrum: m/z = 377 (M+) The following are prepared analogously:
(1) 3-Z-[1-(4-(piperidino-methyl)-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acidRf value: 0.15 (silica gel, methylene chloride/methanol = 9:1) mass spectrum: m/z = 453 (M+) (2) 3-Z-[1-(4-(N-phenylmethyl-N-methylamino-methyl)-phenylamino)-1-phenyl-methylene)-2-indolinone-5-carboxylic acid mass spectrum: m/z = 489 (M+) (3) 3-Z-[1-(4-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acidC25H23N30, mass spectrum: m/z = 413 (M+) (4) 3-Z-[1-(3-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene) -2-indolinone-5-carboxylic acidC25H23N303 mass spectrum: m/z = 413 (M+) (5) 3-Z-[1-(4-chlorophenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acid (6) 3-Z-[1-phenylamino-l-phenyl-methylene)-2-indolinone-5-carboxylic acid Exam lp e 3 3-Z-[1-(1-methyl-piperidine-4-yl-amino)-1-phenyl-methvlenel-5-dimethylcarbamoyl-2-indolinone 2 g of 3-Z-[1-(1-methyl-piperidin-4-yl-amino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acid are refluxed with 5 ml of thionylchloride for 2 hours. Then the mixture is concentrated by rotary evaporation and the residue is washed with ether. 0.5 g of this acid chloride are taken up in 5 ml of methylene chloride without further purification and mixed with 0.5 ml of dimethylamine in 5 ml of methylene chloride and stirred overnight at ambient temperature. The product is chromatographed over a silica gel column with methylene chloride/methanol/ammonia (4:1:0.1).
Yield: 50 % of theory, Rf value: 0.14 (silica gel: methylene chloride/methanol =
9:1) C2qHzBN402 Mass spectrum: m/z = 404 (M') The following compounds are prepared analogously:
(1) 3-Z-[1-(1-methyl-piperidin-4-yl-amino)-1-phenyl-methylene]-5-methylcarbamoyl-2-indolinone Yield: 49 % of theory, Rf value: 0.19 (silica gel; methylene chloride/methanol =
4:1) Mass spectrum: m/z = 390 (M+) (2) 3-Z-[1-(1-methyl-piperidin-4-yl-amino)-1-phenyl-methylene]-5-carbamoyl-2-indolinone Yield: 58 % of theory, Rf value: 0.15 (silica gel; methylene chloride/methanol =
4:1) C22H2qNq02 Mass spectrum: m/z = 376 (M+) (3) 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-5-dimethylcarbamoyl-2-indolinonePrepared from 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acid and dimethylamine or 0.64 g of Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acid, 0.34 g of dimethylamine hydrochloride, 0.9 g of 0-benzotriazol-1-yl-N,N,N`,N`-tetramethyluro-nium-tetrafluoroborate), 0.4 g of 1-hydroxy-1H-benzotriazole and 2.9 g of diisopropylethylamine are stirred in 20 ml of dimethylformamide for 20 hours at ambient temperature. The mixture is then evaporated down and the residue is suspended in water. The precipitate is suction filtered.
Yield: 600 mg (88% of theory), Rf value: 0.2 (silica gel, methylene chloride/ethanol =
9:1) mass spectrum: m/z = 481 (M+H)+
(4) 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-5-methylcarbamoyl-2-indolinone Prepared from 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acid and methylamine analogously to Example 3(3).
Rf value: 0.2 (silica gel, methylene chloride/ethanol =
9:1) ~- C29H30N402 mass spectrum: m/z = 467 (M+H)+
(5) 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-5-methylethylcarbamoyl-2-indolinonePrepared from 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acid and methyl-ethylamine analogously to Example 3(3).
Rf value: 0.55 (silica gel, methylene chloride/ethanol =
9:1) mass spectrum: m/z = 495 (M+H)' (6) 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-5-propylcarbamoyl-2-indolinonePrepared from 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-2-indol=inone-5-carboxylic acid and propylamine analogously to Example 3(3).
Rf value: 0.31 (silica gel, methylene chloride/ethanol =
9:1) mass spectrum: m/z = 495 (M+H)+
(7) 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-5-diethylcarbamoyl-2-indolinonePrepared from 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acid and diethylamine analogously to Example 3(3).-Rf value: 0.55 (silica gel, methylene chloride/ethanol =
9:1) mass spectrum: m/z = 509 (M+H)+
(8) 3-Z-[l-(4-(N-phen_ylmethyl-N-methyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-methylcarbamoyl-2-indolinone (9) 3-Z-[1-(4-(N-phenylmethyl-N-methyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-dimethylcarbamoyl-2-indolinone (10) 3-Z-[1-(4-(N-phenylmethyl-N-methyl-aminomethyl)-phenylamino)-l-phenyl-methylene]-5-diethylcarbamoyl-2-indolinone (11) 3-Z-[l-(4-(N-phenylmethyl-N-methyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-propylcarbamoyl-2-indolinone (12) 3-Z-[l-(4-(N-phenylmethyl-N-methyl-aminomethyl)-~ 25 phenylamino)-1-phenyl-methylene]-5-dipropylcarbamoyl-2-indolinone (13) 3-Z-[l-(4-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-methylcarbamoyl-2-indolinone (14) 3-Z-[l-(4-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-dimethylcarbamoyl-2-indolinone (15) 3-Z-[1-(4-(dimethylamino-methyl)-phenylamino-l-phenyl-methylene]-5-diethylcarbamoyl-2-indolinone (16) 3-Z-[1-(4-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-propylcarbamoyl-2-indolinone (17) 3-Z-[1-(4-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-dipropylcarbamoyl-2-indolinone (18) 3-Z-[1-(3-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-methylcarbamoyl-2-indolinone (19) 3-Z-[1-(3-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-dimethylcarbamoyl-2-indolinone (20) 3-Z-[1-(3-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-diethylcarbamoyl-2-indolinone (21) 3-Z-[1-(3-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-propylcarbamoyl-2-indolinone (22) 3-Z-[1-(3-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-dipropylcarbamoyl-2-indolinone (23) 3-Z-[1-(4-chlorophenylamino)-1-phenyl-methylene]-5-methylcarbamoyl-2-indolinone (24) 3-Z-[1-(4-chlorophenylamino)-1-phenyl-methylene]-5-dimethylcarbamoyl-2-indolinone (25) 3-Z-[1-(4-chlorophenylamino-l-phenyl-methylene]-5-diethylcarbamoyl-2-indolinone (26) 3-Z-[1-(4-chlorophenylamino)-1-phenyl-methylene]-5-propylcarbamoyl-2-indolinone (27) 3-Z-[1-(4-chlorophenylamino)-1-phenyl-methylene]-5-dipropylcarbamoyl-2-indolinone (28) 3-Z-(1-phenylamino-l-phenyl-methylene)-5-methylcarbamoyl-2-indolinone (29) 3-Z-(1-phenylamino-l-phenyl-methylene)-5-dimethylcarbamoyl-2-indolinone (30) 3-Z-(1-phenylamino-l-phenyl-methylene)-5-diethylcarbamoyl-2-indolinone (31) 3-Z-(1-phenylamino-l-phenyl-methylene)-5-propylcarbamoyl-2-indolinone (32) 3-Z-(1-phenylamino-l-phenyl-methylene)-5-dipropylcarbamoyl-2-indolinone Example 4 3-Z-[1-(4-amino-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone 800 mg of resin prepared according to Example IV are suspended in 4 ml of methylene chloride and shaken with 0.8 g of 1,4-phenylenediamine for 16 hours at ambient temperature. The mixture is filtered and the resin is washed several times with methylene chloride, methanol and dimethylformamide. Then 3 ml of methanolic ammonia is added for 2 hours in order to eliminate the acetyl group.
Finally, after further washing, 4 ml of 10%
trifluoroacetic acid in methylene chloride is added over a period of 90 minutes, the resin is separated off and the solution is evaporated down. The residue is taken up in a little 1N sodium hydroxide solution and extracted with methylene chloride. The organic phase is dried over sodium sulphate and concentrated by rotary evaporation.
Yield: 45 mg (30 % of theory over all the steps), Rf value: 0.26 (silica gel; methylene chloride/methanol =
9:1) CZZH18Nq02 Mass spectrum: m/z = 370 (M`) The following compounds are prepared analogously:
(1) 3-Z-[1-(3-amino-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 24 % of theory, Rf value: 0.44 (silica gel; methylene chloride/methanol =
9:1) CzzHieNa02 Mass spectrum: m/z = 370 (M+) (2) 3-Z-(1-phenylamino)-l-phenyl-methylene)-5-amido-2-indolinone Yield: 27 % of theory, Rf value: 0.53 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 355 (M+) (3) 3-Z-[1-(4-acetylamino-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 28 % of theory, Rf value: 0.35 (silica gel; methylene chloride/methanol =
9:1) C2aH2oNa03 Mass spectrum: m/z = 412 (M+) (4) 3-Z-[l-(4-acetyl-N-methyl-amino-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 15 % of theory, Rf value: 0.36 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 426 (M+) ~e (5) 3-Z-[l-(4-(2-amino-ethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 30 % of theory, Rf value: 0.04 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 398 (M+) (6) 3-Z-[l-(4-methoxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 32 % of theory, Rf value: 0.48 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 385 (M+) (7) 3-Z-[l-(4-biphenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 22 % of theory, Rf value: 0.51 (silica gel; methylene chloride/methanol =
9:1) C2eH2iN302 Mass spectrum: m/z = 431 (M') (8) 3-Z-[1-(3-pyridylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 35 % of theory, Rf value: 0.41 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 356 (M+) (9) 3-Z-[1-(4-dimethylamineo-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 19 % of theory, Rf value: 0.49 (silica gel; methylene chloride/methanol =
9:1) C24H22N40, Mass spectrum: m/z = 398 (M') (10) 3-Z-[l-(4-morpholino-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 42 % of theory, Rf value: 0.48 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 440 (M+) (11) 3-Z-[1-(4-tert.butyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 32 % of theory, Rf value: 0.48 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 411 (M+) (12) 3-Z-[1-(2-amino-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 28 % of theory, Rf value: 0.52 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 370 (M+) (13) 3-Z-[1-(4-benzyloxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 40 % of theory, Rf value: 0.4 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 461 (M+) (14) 3-Z-[l-(4-bromophenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 35 % of theory, Rf value: 0.46 (silica gel; methylene chloride/methanol =
9:1) C22H16BrN3O2 Mass spectrum: m/z = 433/435 (M+) (15) 3-Z-[1-(4-methoxycarbonyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 34 % of theory, Rf value: 0.36 (silica gel; methylene chloride/methanol =
9:1) C2qH19N304 Mass spectrum: m/z = 413 (M+) (16) 3-Z-[1-(3-amido-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 32 % of theory, Rf value: 0.32 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 398 (M+) (17) 3-Z-[1-(3-methyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 12 % of theory, Rf value: 0.5 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 369 (M+) (18) 3-Z-[1-(2-methyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 21 % of theory, Rf value: 0.5 (silica gel; methylene chloride/methanol =
9:1) C23Hi9N302 Mass spectrum: m/z = 369 (M+) (19) 3-Z-[1-(3-methoxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.49 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 385 (M+) (20) 3-Z-[1-(3-ethoxycarbonyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.48 (silica gel; methylene chloride/methanol =
9:1) C2sH2iN3Ca Mass spectrum: m/z = 427 (M+) (21) 3-Z-[1-(3-nitro-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 32 % of theory, Rf value: 0.56 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 400 (M+) (22) 3-Z-[1-(4-amido-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinone Yield: 26 % of theory, Rf value: 0.47 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 398 (M+) (23) 3-Z-[1-(4-pyridylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 15 % of theory, Rf value: 0.42 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 356 (M+) (24) 3-Z-[1-(4-methyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 45 % of theory, Rf value: 0.54 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 369 (M') (25) 3-Z-[1-(4-ethoxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 40 % of theory, Rf value: 0.51 (silica gel; methylene chloride/methanol =
9:1) C2aH2iN303 Mass spectrum: m/z = 399 (M+) (26) 3-Z-[l-(3-bromophenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 41 % of theory, Rf value: 0.53 (silica gel; methylene chloride/methanol =
9:1) C22H16BrN3O2 Mass spectrum: m/z = 433/435 (M+) (27) 3-Z-[1-(4-chlorophenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 50 % of theory, Rf value: 0.49 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 389 (M') (28) 3-Z-[1-(4-isopropyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 48 % of theory, Rf value: 0.65 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 397 (M+) (29) 3-Z-[1-(2-fluorenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 43 % of theory, Rf value: 0.58 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 443 (M+) (30) 3-Z-[1-(4-(2-hydroxyethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 22 % of theory, Rf value: 0.37 (silica gel; methylene chloride/methanol =
9:1) C2aH2iN303 Mass spectrum: m/z = 398 (M-H) (31) 3-Z-[1-(4-(4-imidazolyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 23 % of theory, Rf value: 0.5 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 421 (M+) (32) 3-Z-[1-(4-ethoxycarbonylmethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 442 (M+H)+
(33) 3-Z-[1-(4-bromo-3-methyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone C23H18BrN302 Mass spectrum: m/z = 447/449 (M') (34) 3-Z-[1-(4-cyclohexyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 437 (M+) (35) 3-Z-[1-(4-bromo-2-methyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone C23H18BrN3O2 Mass spectrum: m/z = 447/449 (M+) (36) 3-Z-(1-ainino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.3 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 279 (M+) (37) 3-Z-(1-cyclohexylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.55 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 361 (M+) (38) 3-Z-(1-cyclopentylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.53 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 347 (M+) (39) 3-Z-(1-methylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.5 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 293 (M+) (40) 3-Z-(1-ethylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.52 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 307 (M+) (41) 3-Z-(1-isopropylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.44 (silica gel; methylene chloride/methanol =
9:1) C29Hi9N302 Mass spectrum: m/z = 321 (M+) (42) 3-Z-(1-dimethylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.39 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 307 (M+) (43) 3-Z-(1-cyclopropylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.47 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 319 (M+) (44) 3-Z-(1-cycloheptylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.58 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 375 (M+) (45) 3-Z-(1-cyclobutylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.49 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 333 (M+) (46) 3-Z-[1-(4-methylcyclohexylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.67 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 375 (M+) (47) 3-Z-[1-(1-(R,S)-indanylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.59 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 395 (M+) (48) 3-Z-[1-(methoxycarbonylmethylamino)-l-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.46 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 351 (M+) (49) 3-Z-[l-((2-methoxycarbonyl-ethyl)-amino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.45 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 365 (M+) (50) 3-Z-[1-(4-aminomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 32 % of theory, Rf value: 0.46 (silica gel; methylene chloride/methanol =
(4) 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-5-methylcarbamoyl-2-indolinone Prepared from 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acid and methylamine analogously to Example 3(3).
Rf value: 0.2 (silica gel, methylene chloride/ethanol =
9:1) ~- C29H30N402 mass spectrum: m/z = 467 (M+H)+
(5) 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-5-methylethylcarbamoyl-2-indolinonePrepared from 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acid and methyl-ethylamine analogously to Example 3(3).
Rf value: 0.55 (silica gel, methylene chloride/ethanol =
9:1) mass spectrum: m/z = 495 (M+H)' (6) 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-5-propylcarbamoyl-2-indolinonePrepared from 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-2-indol=inone-5-carboxylic acid and propylamine analogously to Example 3(3).
Rf value: 0.31 (silica gel, methylene chloride/ethanol =
9:1) mass spectrum: m/z = 495 (M+H)+
(7) 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-5-diethylcarbamoyl-2-indolinonePrepared from 3-Z-[1-(4-piperidino-methyl-phenylamino)-1-phenyl-methylene]-2-indolinone-5-carboxylic acid and diethylamine analogously to Example 3(3).-Rf value: 0.55 (silica gel, methylene chloride/ethanol =
9:1) mass spectrum: m/z = 509 (M+H)+
(8) 3-Z-[l-(4-(N-phen_ylmethyl-N-methyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-methylcarbamoyl-2-indolinone (9) 3-Z-[1-(4-(N-phenylmethyl-N-methyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-dimethylcarbamoyl-2-indolinone (10) 3-Z-[1-(4-(N-phenylmethyl-N-methyl-aminomethyl)-phenylamino)-l-phenyl-methylene]-5-diethylcarbamoyl-2-indolinone (11) 3-Z-[l-(4-(N-phenylmethyl-N-methyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-propylcarbamoyl-2-indolinone (12) 3-Z-[l-(4-(N-phenylmethyl-N-methyl-aminomethyl)-~ 25 phenylamino)-1-phenyl-methylene]-5-dipropylcarbamoyl-2-indolinone (13) 3-Z-[l-(4-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-methylcarbamoyl-2-indolinone (14) 3-Z-[l-(4-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-dimethylcarbamoyl-2-indolinone (15) 3-Z-[1-(4-(dimethylamino-methyl)-phenylamino-l-phenyl-methylene]-5-diethylcarbamoyl-2-indolinone (16) 3-Z-[1-(4-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-propylcarbamoyl-2-indolinone (17) 3-Z-[1-(4-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-dipropylcarbamoyl-2-indolinone (18) 3-Z-[1-(3-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-methylcarbamoyl-2-indolinone (19) 3-Z-[1-(3-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-dimethylcarbamoyl-2-indolinone (20) 3-Z-[1-(3-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-diethylcarbamoyl-2-indolinone (21) 3-Z-[1-(3-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-propylcarbamoyl-2-indolinone (22) 3-Z-[1-(3-(dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-dipropylcarbamoyl-2-indolinone (23) 3-Z-[1-(4-chlorophenylamino)-1-phenyl-methylene]-5-methylcarbamoyl-2-indolinone (24) 3-Z-[1-(4-chlorophenylamino)-1-phenyl-methylene]-5-dimethylcarbamoyl-2-indolinone (25) 3-Z-[1-(4-chlorophenylamino-l-phenyl-methylene]-5-diethylcarbamoyl-2-indolinone (26) 3-Z-[1-(4-chlorophenylamino)-1-phenyl-methylene]-5-propylcarbamoyl-2-indolinone (27) 3-Z-[1-(4-chlorophenylamino)-1-phenyl-methylene]-5-dipropylcarbamoyl-2-indolinone (28) 3-Z-(1-phenylamino-l-phenyl-methylene)-5-methylcarbamoyl-2-indolinone (29) 3-Z-(1-phenylamino-l-phenyl-methylene)-5-dimethylcarbamoyl-2-indolinone (30) 3-Z-(1-phenylamino-l-phenyl-methylene)-5-diethylcarbamoyl-2-indolinone (31) 3-Z-(1-phenylamino-l-phenyl-methylene)-5-propylcarbamoyl-2-indolinone (32) 3-Z-(1-phenylamino-l-phenyl-methylene)-5-dipropylcarbamoyl-2-indolinone Example 4 3-Z-[1-(4-amino-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone 800 mg of resin prepared according to Example IV are suspended in 4 ml of methylene chloride and shaken with 0.8 g of 1,4-phenylenediamine for 16 hours at ambient temperature. The mixture is filtered and the resin is washed several times with methylene chloride, methanol and dimethylformamide. Then 3 ml of methanolic ammonia is added for 2 hours in order to eliminate the acetyl group.
Finally, after further washing, 4 ml of 10%
trifluoroacetic acid in methylene chloride is added over a period of 90 minutes, the resin is separated off and the solution is evaporated down. The residue is taken up in a little 1N sodium hydroxide solution and extracted with methylene chloride. The organic phase is dried over sodium sulphate and concentrated by rotary evaporation.
Yield: 45 mg (30 % of theory over all the steps), Rf value: 0.26 (silica gel; methylene chloride/methanol =
9:1) CZZH18Nq02 Mass spectrum: m/z = 370 (M`) The following compounds are prepared analogously:
(1) 3-Z-[1-(3-amino-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 24 % of theory, Rf value: 0.44 (silica gel; methylene chloride/methanol =
9:1) CzzHieNa02 Mass spectrum: m/z = 370 (M+) (2) 3-Z-(1-phenylamino)-l-phenyl-methylene)-5-amido-2-indolinone Yield: 27 % of theory, Rf value: 0.53 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 355 (M+) (3) 3-Z-[1-(4-acetylamino-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 28 % of theory, Rf value: 0.35 (silica gel; methylene chloride/methanol =
9:1) C2aH2oNa03 Mass spectrum: m/z = 412 (M+) (4) 3-Z-[l-(4-acetyl-N-methyl-amino-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 15 % of theory, Rf value: 0.36 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 426 (M+) ~e (5) 3-Z-[l-(4-(2-amino-ethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 30 % of theory, Rf value: 0.04 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 398 (M+) (6) 3-Z-[l-(4-methoxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 32 % of theory, Rf value: 0.48 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 385 (M+) (7) 3-Z-[l-(4-biphenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 22 % of theory, Rf value: 0.51 (silica gel; methylene chloride/methanol =
9:1) C2eH2iN302 Mass spectrum: m/z = 431 (M') (8) 3-Z-[1-(3-pyridylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 35 % of theory, Rf value: 0.41 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 356 (M+) (9) 3-Z-[1-(4-dimethylamineo-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 19 % of theory, Rf value: 0.49 (silica gel; methylene chloride/methanol =
9:1) C24H22N40, Mass spectrum: m/z = 398 (M') (10) 3-Z-[l-(4-morpholino-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 42 % of theory, Rf value: 0.48 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 440 (M+) (11) 3-Z-[1-(4-tert.butyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 32 % of theory, Rf value: 0.48 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 411 (M+) (12) 3-Z-[1-(2-amino-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 28 % of theory, Rf value: 0.52 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 370 (M+) (13) 3-Z-[1-(4-benzyloxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 40 % of theory, Rf value: 0.4 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 461 (M+) (14) 3-Z-[l-(4-bromophenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 35 % of theory, Rf value: 0.46 (silica gel; methylene chloride/methanol =
9:1) C22H16BrN3O2 Mass spectrum: m/z = 433/435 (M+) (15) 3-Z-[1-(4-methoxycarbonyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 34 % of theory, Rf value: 0.36 (silica gel; methylene chloride/methanol =
9:1) C2qH19N304 Mass spectrum: m/z = 413 (M+) (16) 3-Z-[1-(3-amido-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 32 % of theory, Rf value: 0.32 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 398 (M+) (17) 3-Z-[1-(3-methyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 12 % of theory, Rf value: 0.5 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 369 (M+) (18) 3-Z-[1-(2-methyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 21 % of theory, Rf value: 0.5 (silica gel; methylene chloride/methanol =
9:1) C23Hi9N302 Mass spectrum: m/z = 369 (M+) (19) 3-Z-[1-(3-methoxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.49 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 385 (M+) (20) 3-Z-[1-(3-ethoxycarbonyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.48 (silica gel; methylene chloride/methanol =
9:1) C2sH2iN3Ca Mass spectrum: m/z = 427 (M+) (21) 3-Z-[1-(3-nitro-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 32 % of theory, Rf value: 0.56 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 400 (M+) (22) 3-Z-[1-(4-amido-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinone Yield: 26 % of theory, Rf value: 0.47 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 398 (M+) (23) 3-Z-[1-(4-pyridylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 15 % of theory, Rf value: 0.42 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 356 (M+) (24) 3-Z-[1-(4-methyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 45 % of theory, Rf value: 0.54 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 369 (M') (25) 3-Z-[1-(4-ethoxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 40 % of theory, Rf value: 0.51 (silica gel; methylene chloride/methanol =
9:1) C2aH2iN303 Mass spectrum: m/z = 399 (M+) (26) 3-Z-[l-(3-bromophenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 41 % of theory, Rf value: 0.53 (silica gel; methylene chloride/methanol =
9:1) C22H16BrN3O2 Mass spectrum: m/z = 433/435 (M+) (27) 3-Z-[1-(4-chlorophenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 50 % of theory, Rf value: 0.49 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 389 (M') (28) 3-Z-[1-(4-isopropyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 48 % of theory, Rf value: 0.65 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 397 (M+) (29) 3-Z-[1-(2-fluorenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 43 % of theory, Rf value: 0.58 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 443 (M+) (30) 3-Z-[1-(4-(2-hydroxyethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 22 % of theory, Rf value: 0.37 (silica gel; methylene chloride/methanol =
9:1) C2aH2iN303 Mass spectrum: m/z = 398 (M-H) (31) 3-Z-[1-(4-(4-imidazolyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 23 % of theory, Rf value: 0.5 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 421 (M+) (32) 3-Z-[1-(4-ethoxycarbonylmethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 442 (M+H)+
(33) 3-Z-[1-(4-bromo-3-methyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone C23H18BrN302 Mass spectrum: m/z = 447/449 (M') (34) 3-Z-[1-(4-cyclohexyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 437 (M+) (35) 3-Z-[1-(4-bromo-2-methyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone C23H18BrN3O2 Mass spectrum: m/z = 447/449 (M+) (36) 3-Z-(1-ainino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.3 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 279 (M+) (37) 3-Z-(1-cyclohexylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.55 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 361 (M+) (38) 3-Z-(1-cyclopentylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.53 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 347 (M+) (39) 3-Z-(1-methylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.5 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 293 (M+) (40) 3-Z-(1-ethylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.52 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 307 (M+) (41) 3-Z-(1-isopropylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.44 (silica gel; methylene chloride/methanol =
9:1) C29Hi9N302 Mass spectrum: m/z = 321 (M+) (42) 3-Z-(1-dimethylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.39 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 307 (M+) (43) 3-Z-(1-cyclopropylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.47 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 319 (M+) (44) 3-Z-(1-cycloheptylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.58 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 375 (M+) (45) 3-Z-(1-cyclobutylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.49 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 333 (M+) (46) 3-Z-[1-(4-methylcyclohexylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.67 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 375 (M+) (47) 3-Z-[1-(1-(R,S)-indanylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.59 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 395 (M+) (48) 3-Z-[1-(methoxycarbonylmethylamino)-l-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.46 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 351 (M+) (49) 3-Z-[l-((2-methoxycarbonyl-ethyl)-amino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.45 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 365 (M+) (50) 3-Z-[1-(4-aminomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 32 % of theory, Rf value: 0.46 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 384 (M+) (51) 3-Z-[1-(4-pyrrolidinomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate Yield: 60 % of theory, Rf value: 0.07 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 438 (M+) (52) 3-Z-[1-(4-morpholinomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 65 % of theory, Rf value: 0.46 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 454 (M+) (53) 3-Z-[l-(4-piperidinomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate Yield: 60 % of theory, Rf value: 0.08 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 452 (M+) (54) 3-Z-[1-(4-hexamethyleneiminomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate Mass spectrum: m/z = 466 (M+) (55) 3-Z-[1-(4-(4-hydroxy-piperidinomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 468 (M+) (56) 3-Z-[1-(4-(4-methyl-piperidinomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 466 (M+) (57) 3-Z-[1-(4-(4-ethyl-piperidinomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 480 (M+) (58) 3-Z-[1-(4-(4-isopropyl-piperidinomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 494 (M') (59) 3-Z-[1-(4-(4-phenyl-piperidinomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 528 (M+) (60) 3-Z-[1-(4-(4-benzyl-piperidinomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z 0 542 (M+) (61) 3-Z-[1-(4-(4-ethoxycarbonyl-piperidinomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 524 (M+) (62) 3-Z-[1-(4-dimethylaminomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 412 (M+) (63) 3-Z-[1-(4-dipropylaminomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 468 (M+) (64) 3-Z-[1-(4-piperazinylmethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 453 (M+) (65) 3-Z-[l-(3-dimethylaminomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 412 (M+) (66) 3-Z-[l-(4-(2-diethylamino-ethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 454 (M+) (67) 3-Z-[l-(4-(2-morpholino-ethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 468 (M+) (68) 3-Z-[l-(4-(2-pyrrolidinyl-ethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 452 (M+) (69) 3-Z-[1-(4-(2-piperidinyl-ethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 466 (M+) (70) 3-Z-[1-(2-thiazolylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 30 % of theory, Rf value: 0.48 (silica gel; methylene chloride/methanol =
9:1) C19H14Nq02S
Mass spectrum: m/z = 362 (M) (71) 3-Z-[1-(2-benzimidazolylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 29 % of theory, Rf value: 0.44 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum.: m/z = 395 (MT) (72) 3-Z-[1-(5-methyl-isoxazol-3-yl-amino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 39 % of theory, Rf value: 0.43 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 374 (M+) (73) 3-Z-(1-benzylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.63 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 369 (M+) (74) 3-Z-[1-(4-(1-imidazolyl-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.45 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 436 (M+H)+
9:1) Mass spectrum: m/z = 438 (M+) (52) 3-Z-[1-(4-morpholinomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 65 % of theory, Rf value: 0.46 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 454 (M+) (53) 3-Z-[l-(4-piperidinomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate Yield: 60 % of theory, Rf value: 0.08 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 452 (M+) (54) 3-Z-[1-(4-hexamethyleneiminomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate Mass spectrum: m/z = 466 (M+) (55) 3-Z-[1-(4-(4-hydroxy-piperidinomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 468 (M+) (56) 3-Z-[1-(4-(4-methyl-piperidinomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 466 (M+) (57) 3-Z-[1-(4-(4-ethyl-piperidinomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 480 (M+) (58) 3-Z-[1-(4-(4-isopropyl-piperidinomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 494 (M') (59) 3-Z-[1-(4-(4-phenyl-piperidinomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 528 (M+) (60) 3-Z-[1-(4-(4-benzyl-piperidinomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z 0 542 (M+) (61) 3-Z-[1-(4-(4-ethoxycarbonyl-piperidinomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 524 (M+) (62) 3-Z-[1-(4-dimethylaminomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 412 (M+) (63) 3-Z-[1-(4-dipropylaminomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 468 (M+) (64) 3-Z-[1-(4-piperazinylmethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 453 (M+) (65) 3-Z-[l-(3-dimethylaminomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 412 (M+) (66) 3-Z-[l-(4-(2-diethylamino-ethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 454 (M+) (67) 3-Z-[l-(4-(2-morpholino-ethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 468 (M+) (68) 3-Z-[l-(4-(2-pyrrolidinyl-ethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 452 (M+) (69) 3-Z-[1-(4-(2-piperidinyl-ethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 466 (M+) (70) 3-Z-[1-(2-thiazolylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 30 % of theory, Rf value: 0.48 (silica gel; methylene chloride/methanol =
9:1) C19H14Nq02S
Mass spectrum: m/z = 362 (M) (71) 3-Z-[1-(2-benzimidazolylamino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 29 % of theory, Rf value: 0.44 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum.: m/z = 395 (MT) (72) 3-Z-[1-(5-methyl-isoxazol-3-yl-amino)-1-phenyl-methylene]-5-amido-2-indolinone Yield: 39 % of theory, Rf value: 0.43 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 374 (M+) (73) 3-Z-(1-benzylamino-l-phenyl-methylene)-5-amido-2-indolinone Rf value: 0.63 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 369 (M+) (74) 3-Z-[1-(4-(1-imidazolyl-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.45 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 436 (M+H)+
(75) 3-Z-[1-(4-((2-diethylamino-ethyl)-aminocarbonyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate Yield: 27 % of theory, Rf value: 0.05 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 497 (M+) (76) 3-Z-[1-(4-acetylaminomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.4 (silica gel; methylene chloride/methanol =
9:1) C2sH22Na03 Mass spectrum: m/z = 426 (M+) (77) 3-Z-[1-(4-((2-dimethylaminoethyl)-N-methanesulphonyl-amino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.1 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 519 (M+) (78) 3-Z- [ 1- ( 4- ( N- ( ethoxycarbonylmethyl )-N-methanesulphonyl-amino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.57 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 534 (M+) (79) 3-Z-[1-(4-(N-(cyanomethyl)-N-methanesulphonyl-amino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.49 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 487 (M+) (80) 3-Z-[1-(4-(N-methyl-N-methanesulphonyl-amino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.46 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 462 (M+) (81) 3-Z-[l-(4-(2-oxo-pyrrolidin-1-yl-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 452 (M+) (82) 3-Z-[1-(4-(2-oxo-piperidin-1-yl-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 466 (M+) (83) 3-Z-[1-(4-(4-cyclohexyl-piperidino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate C34H38N402 mass spectrum: m/z = 534 (M+) (84) 3-Z-[1-(4-(2,6-dimethyl-piperidino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z: 480 (M') (85) 3-Z-[l-(4-(4-phenyl-4-hydroxy-piperidino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 545 (M+) Rf value: 0.66 (silica gel, methylene chloride/methanol =
4:1) (86) 3-Z-[1-(4-(2-methoxycarbonyl-pyrrolidino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 497 (M+H)+
Rf value: 0.65 (silica gel, methylene chloride/methanol =
4:1) (87) 3-Z-[1-(4-(1-oxo-thiomorpholin-4-ylmethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 487 (M+H)+
Rf value: 0.68 (silica gel, methylene chloride/methanol =
4:1) (88) 3-Z-[1-(4-(3,6-dihydro-2H-pyridin-1-ylmethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 451 (M+H)+
9:1) Mass spectrum: m/z = 497 (M+) (76) 3-Z-[1-(4-acetylaminomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.4 (silica gel; methylene chloride/methanol =
9:1) C2sH22Na03 Mass spectrum: m/z = 426 (M+) (77) 3-Z-[1-(4-((2-dimethylaminoethyl)-N-methanesulphonyl-amino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.1 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 519 (M+) (78) 3-Z- [ 1- ( 4- ( N- ( ethoxycarbonylmethyl )-N-methanesulphonyl-amino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.57 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 534 (M+) (79) 3-Z-[1-(4-(N-(cyanomethyl)-N-methanesulphonyl-amino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.49 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 487 (M+) (80) 3-Z-[1-(4-(N-methyl-N-methanesulphonyl-amino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.46 (silica gel; methylene chloride/methanol =
9:1) Mass spectrum: m/z = 462 (M+) (81) 3-Z-[l-(4-(2-oxo-pyrrolidin-1-yl-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Mass spectrum: m/z = 452 (M+) (82) 3-Z-[1-(4-(2-oxo-piperidin-1-yl-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 466 (M+) (83) 3-Z-[1-(4-(4-cyclohexyl-piperidino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate C34H38N402 mass spectrum: m/z = 534 (M+) (84) 3-Z-[1-(4-(2,6-dimethyl-piperidino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z: 480 (M') (85) 3-Z-[l-(4-(4-phenyl-4-hydroxy-piperidino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 545 (M+) Rf value: 0.66 (silica gel, methylene chloride/methanol =
4:1) (86) 3-Z-[1-(4-(2-methoxycarbonyl-pyrrolidino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 497 (M+H)+
Rf value: 0.65 (silica gel, methylene chloride/methanol =
4:1) (87) 3-Z-[1-(4-(1-oxo-thiomorpholin-4-ylmethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 487 (M+H)+
Rf value: 0.68 (silica gel, methylene chloride/methanol =
4:1) (88) 3-Z-[1-(4-(3,6-dihydro-2H-pyridin-1-ylmethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 451 (M+H)+
(89) 3-Z-[l-(4-(2,5-dihydro-pyrrol-1-ylmethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 437 (M+H)+
Rf value: 0.49 (silica gel, methylene chloride/methanol =
4:1) (90) 3-Z-[1-(4-(thiomorpholin-4-ylmethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate Cz,H26Nq02S
mass spectrum: m/z = 471 (M+H)+
Rf value: 0.78 (silica gel, methylene chloride/methanol =
4:1) (91) 3-Z-[1-(4-(6,7-dimethoxy-tetrahydroisoquinolin-2-ylmethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 561 (M+H)+
Rf value: 0.8 (silica gel, methylene chloride/methanol =
4:1) (92) 3-Z-[1-(4-(4-phenyl-piperazin-1-ylmethyl))-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 530 (M+H)+
Rf value: 0.78 (silica gel, methylene chloride/methanol =
4:1) (93) 3-Z-[1-(4-(3,5-dimethyl-piperidino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 480 (M+) Rf value: 0.54 (silica gel, methylene chloride/methanol =
4:1) (94) 3-Z-[1-(4-(N-methyl-N-benzyl-amino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 488 (M+) (95) 3-Z-[1-(3,4-dimethoxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 415 (M+) Rf value: 0.5 (silica gel, methylene chloride/methanol =
9:1) (96) 3-Z-[1-(4-trifluoromethoxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 439 (M+) Rf value: 0.5 (silica gel, methylene chloride/methanol =
9:1) (97) 3-Z-[1-(3-ethoxycarbonyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 427 (M+) Rf value: 0.52 (silica gel, methylene chloride/methanol =
9:1) (98) 3-Z-[1-(3-carboxy-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 399 (M+) Rf value: 0.14 (silica gel, methylene chloride/methanol =
9:1) (99) 3-Z-[1-(3-diethylcarbamoyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone C2.7H26N403 mass spectrum: m/z = 454 (M+) Rf value: 0.48 (silica gel, methylene chloride/methanol =
9:1) (100) 3-Z-[1-(3-ethylcarbamoyl-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 426 (M+) Rf value: 0.42 (silica gel, methylene chloride/methanol =
9:1) (101) 3-Z-[1-(3-trifluoromethoxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 439 (M') Rf value: 0.5 (silica gel, methylene chloride/methanol =
9:1) (102) 3-Z-[l-(3-ethoxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 399 (M+) Rf value: 0.49 (silica gel, methylene chloride/methanol =
9:1) (103) 3-Z-[1-(4-methoxymethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 399 (M+) Rf value: 0.4 (silica gel, methylene chloride/methanol =
4:1) (104) 3-Z-[1-(4-ethyl-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinone C2aH21N302 mass spectrum: m/z = 383 (M+) Rf value: 0.52 (silica gel, methylene chloride/methanol =
4:1) (105) 3-Z-[1-(4-methyl-3-nitro-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone C23H1eNaDa mass spectrum: m/z = 414 (M') (106) 3-Z-[1-(4-methyl-3-methoxy-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 399 (M+) (107) 3-Z-[1-(4-(4-aminophenyl-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate C29H24N40z mass spectrum: m/z = 460 (M+) (108) 3-Z-[1-(4-methoxycarbonyl-3-methyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 427 (M+) Rf value: 0.56 (silica gel, methylene chloride/methanol =
4:1) (109) 3-Z-[1-(4-cyanophenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 380 (M+) Rf value: 0.65 (silica gel, methylene chloride/methanol =
9:1) (110) 3-Z-[1-(S-methyl-pyridin-2-yl-amino)-1-phenyl-methylene]-S-amido-2-indolinone Rf value: 0.6 (silica gel, methylene chloride/methanol =
9:1) C2zHieNa02 mass spectrum: m/z = 370 (M+) (111) 3-Z-[1-(5-bromo-pyridin-2-yl-amino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.65 (silica gel, methylene chloride/methanol =
9:1) C21H15BrN402 mass spectrum: m/z = 434/436 (M+) (112) 3-Z-[1-(2-chloropyridin-5-yl-amino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.49 (silica gel, methylene chloride/methanol =
9:1) C21H15C1Nq02 mass spectrum: m/z = 390/392 (M+) (113) 3-Z-[1-(3-cyanophenylamino)-1-phenyl-methylene]-5-amido-2-indolinone C23Hi6Na02 mass spectrum: m/z = 380 (M') Rf value: 0.57 (silica gel, methylene chloride/methanol =
9:1) (114) 3-Z-[1-(4-(N-phenyl-amino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone C29H2qNq02 mass spectrum: m/z = 460 (M+) Rf value: 0.74 (silica gel, methylene chloride/methanol =
9:1) (115) 3-Z-[1-(4-(N-methyl-N-phenyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 474 (M+) Rf value: 0.75 (silica gel, methylene chloride/methanol =
9:1) (116) 3-Z-[1-(4-(N-ethyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 412 (M+) (117) 3-Z-[1-(4-(N-(4-chlorophenyl-methyl)-aminomethyl)-phenyl-amino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 508/510 (M') (118) 3-Z-[1-(4-(N-cyclohexyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate C2vH3oNaO2 mass spectrum: m/z = 466 (M') (119) 3-Z-[l-(4-(N-isopropyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 426 (M') (120) 3-Z-[1-(4-(N-butyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 440 (M') (121) 3-Z-[1-(4-(N-methoxycarbonyl-methylamino-methyl)-phenyl-amino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 456 (M+) (122) 3-Z-[1-(4-(N-(phenyl-methyl)-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 464 (M+) (123) 3-Z-[1-(4-(N-acetyl-N-ethoxycarbonylmethyl-amino)-phenyl-amino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 498 (M+) (124) 3-Z-[1-(4-methyl-3-sulphamoyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 448 (M+) (125) 3-Z-[1-(4-(N-methanesulphonyl-N-(methylcarbamoylmethyl)-amino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 519 (M') (126) 3-Z-[1-(4-(N-methanesulphonyl-N-(piperidine-carbonyl-methyl)amino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 573 (M+) (127) 3-Z-[1-(4-carboxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 398 (M-H+) (128) 3-Z-[1-(4-carboxy-3-methyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 412 (M-H+) (129) 3-Z-[1-(4-(3-diethylamino-propoxy)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 484 (M') (130) 3-Z-[1-(4-(2-piperidino-ethoxy)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 483 (M+H)+
Rf value: 0.49 (silica gel, methylene chloride/methanol =
4:1) (90) 3-Z-[1-(4-(thiomorpholin-4-ylmethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate Cz,H26Nq02S
mass spectrum: m/z = 471 (M+H)+
Rf value: 0.78 (silica gel, methylene chloride/methanol =
4:1) (91) 3-Z-[1-(4-(6,7-dimethoxy-tetrahydroisoquinolin-2-ylmethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 561 (M+H)+
Rf value: 0.8 (silica gel, methylene chloride/methanol =
4:1) (92) 3-Z-[1-(4-(4-phenyl-piperazin-1-ylmethyl))-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 530 (M+H)+
Rf value: 0.78 (silica gel, methylene chloride/methanol =
4:1) (93) 3-Z-[1-(4-(3,5-dimethyl-piperidino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 480 (M+) Rf value: 0.54 (silica gel, methylene chloride/methanol =
4:1) (94) 3-Z-[1-(4-(N-methyl-N-benzyl-amino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 488 (M+) (95) 3-Z-[1-(3,4-dimethoxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 415 (M+) Rf value: 0.5 (silica gel, methylene chloride/methanol =
9:1) (96) 3-Z-[1-(4-trifluoromethoxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 439 (M+) Rf value: 0.5 (silica gel, methylene chloride/methanol =
9:1) (97) 3-Z-[1-(3-ethoxycarbonyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 427 (M+) Rf value: 0.52 (silica gel, methylene chloride/methanol =
9:1) (98) 3-Z-[1-(3-carboxy-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 399 (M+) Rf value: 0.14 (silica gel, methylene chloride/methanol =
9:1) (99) 3-Z-[1-(3-diethylcarbamoyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone C2.7H26N403 mass spectrum: m/z = 454 (M+) Rf value: 0.48 (silica gel, methylene chloride/methanol =
9:1) (100) 3-Z-[1-(3-ethylcarbamoyl-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 426 (M+) Rf value: 0.42 (silica gel, methylene chloride/methanol =
9:1) (101) 3-Z-[1-(3-trifluoromethoxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 439 (M') Rf value: 0.5 (silica gel, methylene chloride/methanol =
9:1) (102) 3-Z-[l-(3-ethoxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 399 (M+) Rf value: 0.49 (silica gel, methylene chloride/methanol =
9:1) (103) 3-Z-[1-(4-methoxymethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 399 (M+) Rf value: 0.4 (silica gel, methylene chloride/methanol =
4:1) (104) 3-Z-[1-(4-ethyl-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinone C2aH21N302 mass spectrum: m/z = 383 (M+) Rf value: 0.52 (silica gel, methylene chloride/methanol =
4:1) (105) 3-Z-[1-(4-methyl-3-nitro-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone C23H1eNaDa mass spectrum: m/z = 414 (M') (106) 3-Z-[1-(4-methyl-3-methoxy-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 399 (M+) (107) 3-Z-[1-(4-(4-aminophenyl-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate C29H24N40z mass spectrum: m/z = 460 (M+) (108) 3-Z-[1-(4-methoxycarbonyl-3-methyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 427 (M+) Rf value: 0.56 (silica gel, methylene chloride/methanol =
4:1) (109) 3-Z-[1-(4-cyanophenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 380 (M+) Rf value: 0.65 (silica gel, methylene chloride/methanol =
9:1) (110) 3-Z-[1-(S-methyl-pyridin-2-yl-amino)-1-phenyl-methylene]-S-amido-2-indolinone Rf value: 0.6 (silica gel, methylene chloride/methanol =
9:1) C2zHieNa02 mass spectrum: m/z = 370 (M+) (111) 3-Z-[1-(5-bromo-pyridin-2-yl-amino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.65 (silica gel, methylene chloride/methanol =
9:1) C21H15BrN402 mass spectrum: m/z = 434/436 (M+) (112) 3-Z-[1-(2-chloropyridin-5-yl-amino)-1-phenyl-methylene]-5-amido-2-indolinone Rf value: 0.49 (silica gel, methylene chloride/methanol =
9:1) C21H15C1Nq02 mass spectrum: m/z = 390/392 (M+) (113) 3-Z-[1-(3-cyanophenylamino)-1-phenyl-methylene]-5-amido-2-indolinone C23Hi6Na02 mass spectrum: m/z = 380 (M') Rf value: 0.57 (silica gel, methylene chloride/methanol =
9:1) (114) 3-Z-[1-(4-(N-phenyl-amino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone C29H2qNq02 mass spectrum: m/z = 460 (M+) Rf value: 0.74 (silica gel, methylene chloride/methanol =
9:1) (115) 3-Z-[1-(4-(N-methyl-N-phenyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 474 (M+) Rf value: 0.75 (silica gel, methylene chloride/methanol =
9:1) (116) 3-Z-[1-(4-(N-ethyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 412 (M+) (117) 3-Z-[1-(4-(N-(4-chlorophenyl-methyl)-aminomethyl)-phenyl-amino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 508/510 (M') (118) 3-Z-[1-(4-(N-cyclohexyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate C2vH3oNaO2 mass spectrum: m/z = 466 (M') (119) 3-Z-[l-(4-(N-isopropyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 426 (M') (120) 3-Z-[1-(4-(N-butyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 440 (M') (121) 3-Z-[1-(4-(N-methoxycarbonyl-methylamino-methyl)-phenyl-amino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 456 (M+) (122) 3-Z-[1-(4-(N-(phenyl-methyl)-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 464 (M+) (123) 3-Z-[1-(4-(N-acetyl-N-ethoxycarbonylmethyl-amino)-phenyl-amino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 498 (M+) (124) 3-Z-[1-(4-methyl-3-sulphamoyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 448 (M+) (125) 3-Z-[1-(4-(N-methanesulphonyl-N-(methylcarbamoylmethyl)-amino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 519 (M') (126) 3-Z-[1-(4-(N-methanesulphonyl-N-(piperidine-carbonyl-methyl)amino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 573 (M+) (127) 3-Z-[1-(4-carboxy-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 398 (M-H+) (128) 3-Z-[1-(4-carboxy-3-methyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone mass spectrum: m/z = 412 (M-H+) (129) 3-Z-[1-(4-(3-diethylamino-propoxy)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 484 (M') (130) 3-Z-[1-(4-(2-piperidino-ethoxy)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 483 (M+H)+
(131) 3-Z-[1-(4-(3-piperidino-propoxy)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 496 (M+) (132) 3-Z-[1-(4-(3-dimethylamino-propoxy)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 457 (M+H)+
(133) 3-Z-[1-(4-(3-N-methyl-N-benzylamino-propoxy)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 533 (M+H)+
(134) 3-Z-[1-(4-(2-dimethylamino-ethoxy)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetate mass spectrum: m/z = 443 (M+H)' (135) 3-Z-[1-(4-(N-ethyl-N-benzyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone (136) 3-Z-[1-(4-(N-propyl-N-benzyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone (137) 3-Z-[1-(4-(N-methyl-N-(4-chlorophenyl-methyl)-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone (138) 3-Z-[1-(4-(N-methyl-N-(4-bromophenyl-methyl)-amino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone (139) 3-Z-[1-(4-(N-methyl-N-(3-chlorophenyl-methyl)-amino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone (140) 3-Z-[1-(4-(N-methyl-N-(3,4-dimethoxyphenyl-methyl)-amino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone (141) 3-Z-[1-(4-(N-methyl-N-(4-methoxyphenyl-methyl)-amino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone (142) 3-Z-[1-(4-(N-trifluoroethyl-N-(phenyl-methyl)-amino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone (143) 3-Z-[1-(4-(N-trifluoroethyl-N-(4-chlorophenyl-methyl)-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Examiple 5 3-Z-[1-(4-(4-acetyl-piperazinylmethyl)-phenylamino)-1-phenvl-methXlenel-5-amido-2-indolinone mg of 3-Z-[1-(4-(4-piperazinylmethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone and 0.02 g of 20 triethylamine are dissolved in 10 ml of methylene chloride and mixed with 5 mg of acetylchloride and the solution is stirred for 16 hours at ambient temperature.
Then it is washed with water and the organic phase is then evaporated down.
25 Yield: 15 mg (68 % of theory), C29H29Ns03 Mass spectrum: m/z = 495 (M+) The following compound is prepared analogously:
(1) 3-Z-[1-(4-(4-benzoyl-piperazinylmethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Prepared from 3-Z-[1-(4-(4-piperazinyl-methyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone and benzoylchloride.
Yield: 91 % of theory, C34H31N~,O3 Mass spectrum: m/z = 557 (M+) Example 6 3-Z-[1-(4-diethylcarbamoyl-phenylamino-l-phenyl-methylenel-5-amido-2-indolinone 7 g of resin from step IV are reacted analogously to Example 4 with ethyl 4-aminobenzoate. The moist charged resin is suspended in 30 ml of dioxane and 30 ml of methanol and stirred with 25 ml of 1 N sodium hydroxide solution for 40 hours. Then it is neutralised with dilute hydrochloric acid and washed with methylene chloride, methanol and dimethylformamide. 300 mg of the resin are then suspended in 3 ml of dimethylformamide, and left to stand for 60 hours at ambient temperature with 0.2 ml of diethylamine, 0.5 g of 0-(benzotriazol-1-yl)-N,N,N',N'-tetramethyl-uronium-tetrafluoroborate and 0.8 ml of ethyldiisopropylamine. Finally, the product is cleaved from the resin as described in Example 4.
Yield: 29 mg, Rf value: 0.46 (silica gel, methylene chloride/methanol =
9:1) mass spectrum: m/z = 454 (M') The following are prepared analogously:
(1) 3-Z-[l-(4-(piperidinocarbonyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinoneRf value: 0.43 (silica gel, methylene chloride/methanol = 9:1) mass spectrum: m/z = 466 (M+) (2) 3-Z-[l-(4-(4-methylpiperazinocarbonyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetateRf value: 0.84 (silica gel, methylene chloride/methanol = 4:1) C2eH2iN503 mass spectrum: m/z = 481 (M') (3) 3-Z-[l-(4-(N-(2-dimethylamino-ethyl)-N-methyl-carbamoyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetateRf value: 0.25 (silica gel, methylene chloride/methanol = 9:1) mass spectrum: m/z = 484 (M+H)+
(4) 3-Z-[1-(4-(N-methoxycarbonylmethyl-carbamoyl)-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinoneRf value: 0.4 (silica gel, methylene chloride/methanol =
9:1) mass spectrum: m/z = 470 (M+) (5) 3-Z-[1-(4-benzylcarbamoyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinoneRf value: 0.48 (silica gel, methylene chloride/methanol = 9:1) mass spectrum: m/z = 488 (M+) Example 7 3-Z-[1-(4-(N-methyl-benzoylamino)-phenylamino)-1-phenyl-methylenel-5-amido-2-indolinone 4.5 g of resin from step IV are reacted analogously to Example 4 with 3.4 g of 4-(9H-fluoren-9-ylmethoxycarbonyl)-methyl-amino)-aniline in dimethylformamide. Then the 9H-fluorene protecting group is cleaved with 4 ml of 30% piperidine in dimethylformamide and the resin is washed several times.
400 mg of the resin are then suspended in 4 ml of dimethylformamide and 0.3 ml of triethylamine and reacted with 0.3 ml of benzoylchloride for one hour at ambient temperature. Finally the product is cleaved from the resin as described in Example 4.
Yield: 33 mg.
Rf value: 0.45 (silica gel, methylene chloride/methanol =
9:1) C3oH24N403 mass spectrum: m/z = 488 (M') The following are prepared analogously:
(1) 3-Z-[l-(4-(N-methyl-propionylamino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinoneRf value: 0.42 (silica gel, methylene chloride/methanol = 9:1) mass spectrum: m/z = 440 (M+) (2) 3-Z-[l-(4-(N-methyl-butyrylamino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinoneRf value: 0.44 (silica gel, methylene chloride/methanol = 9:1) mass spectrum: m/z = 453 (M-H') (3) 3-Z-[1-(4-(N-methyl-ethylsulphonylamino)-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinoneRf value: 0.42 (silica gel, methylene chloride/methanol =
9:1) mass spectrum: m/z = 475 (M-H+) (4) 3-Z-[1-(4-(N-methyl-propylsulphonylamino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinoneRf value: 0.44 (silica gel, methylene chloride/methanol =
9:1) C25H26N90qS
mass spectrum: m/z = 491 (M+H)+
(5) 3-Z-[1-(4-(N-methyl-phenylsulphonylamino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinoneRf value: 0.53 (silica gel, methylene chloride/methanol =
9:1) mass spectrum: m/z = 524 (M+) Example 8 Dry ampoule containing 75 mg of active substance per 10 ml Composition:
Active substance 75.0 mg Mannitol 50.0 mg water for injections ad 10.0 ml Preparation:
Active substance and mannitol are dissolved in water.
After packaging the solution is freeze-dried. To produce the solution ready for use, the product is dissolved in water for injections.
Example 9 Dry ampoule containing 35 mg of active substance per 2 ml Composition:
Active substance 35.0 mg Mannitol 100.0 mg water for injections ad 2.0 ml Preparation:
Active substance and mannitol are dissolved in water.
After packaging, the solution is freeze-dried.
To produce the solution ready for use, the product is dissolved in water for injections.
Example 10 Tablet containing 50 mg of active substance Composition:
(1) Active substance 50.0 mg (2) Lactose 98.0 mg (3) Maize starch 50.0 mg (4) Polyvinylpyrrolidone 15.0 mg (5) Magnesium stearate 2.0 mg 215.0 mg Preparation:
(1), (2) and (3) are mixed together and granulated with an aqueous solution of (4). (5) is added to the dried granulated material. From this mixture tablets are pressed, biplanar, faceted on both sides and with a dividing notch on one side.
Diameter of the tablets: 9 mm.
Example 11 Tablet containing 350 mg of active substance Preparation:
(1) Active substance 350.0 mg (2) Lactose 136.0 mg (3) Maize starch 80.0 mg (4) Polyvinylpyrrolidone 30.0 mg (5) Magnesium stearate 4.0 mg 600.0 mg (1), (2) and (3) are mixed together and granulated with an aqueous solution of (4). (5) is added to the dried granulated material. From this mixture tablets are pressed, biplanar, faceted on both sides and with a dividing notch on one side.
Diameter of the tablets: 12 mm.
Example 12 Capsules containing 50 mg of active substance Composition:
(1) Active substance 50.0 mg (2) Dried maize starch 58.0 mg (3) Powdered lactose 50.0 mg (4) Magnesium stearate 2.0 mg 160.0 mg Preparation:
(1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with vigorous mixing.
This powder mixture is packed into size 3 hard gelatin capsules in a capsule filling machine.
Example 13 Capsules containing 350 mg of active substance Composition:
(1) Active substance 350.0 mg (2) Dried maize starch 46.0 mg (3) Powdered lactose 30.0 mg (4) Magnesium stearate 4.0 mg 430.0 mg Preparation:
(1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with vigorous mixing.
This powder mixture is packed into size 0 hard gelatin capsules in a capsule filling machine.
Example 14 Suppositories containing 100 mg of active substance 1 suppository contains:
Active substance 100.0 mg Polyethyleneglycol (M.W. 1500) 600.0 mg Polyethyleneglycol (M.W. 6000) 460.0 mg Polyethylenesorbitan monostearate 840.0 mg 2,000.0 mg Preparation:
The polyethyleneglycol is melted together with polyethylene sorbitanmonostearate. At 40 C the ground active substance is homogeneously dispersed in the melt.
It is cooled to 38 C and poured into slightly chilled suppository moulds.
Then it is washed with water and the organic phase is then evaporated down.
25 Yield: 15 mg (68 % of theory), C29H29Ns03 Mass spectrum: m/z = 495 (M+) The following compound is prepared analogously:
(1) 3-Z-[1-(4-(4-benzoyl-piperazinylmethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone Prepared from 3-Z-[1-(4-(4-piperazinyl-methyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone and benzoylchloride.
Yield: 91 % of theory, C34H31N~,O3 Mass spectrum: m/z = 557 (M+) Example 6 3-Z-[1-(4-diethylcarbamoyl-phenylamino-l-phenyl-methylenel-5-amido-2-indolinone 7 g of resin from step IV are reacted analogously to Example 4 with ethyl 4-aminobenzoate. The moist charged resin is suspended in 30 ml of dioxane and 30 ml of methanol and stirred with 25 ml of 1 N sodium hydroxide solution for 40 hours. Then it is neutralised with dilute hydrochloric acid and washed with methylene chloride, methanol and dimethylformamide. 300 mg of the resin are then suspended in 3 ml of dimethylformamide, and left to stand for 60 hours at ambient temperature with 0.2 ml of diethylamine, 0.5 g of 0-(benzotriazol-1-yl)-N,N,N',N'-tetramethyl-uronium-tetrafluoroborate and 0.8 ml of ethyldiisopropylamine. Finally, the product is cleaved from the resin as described in Example 4.
Yield: 29 mg, Rf value: 0.46 (silica gel, methylene chloride/methanol =
9:1) mass spectrum: m/z = 454 (M') The following are prepared analogously:
(1) 3-Z-[l-(4-(piperidinocarbonyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinoneRf value: 0.43 (silica gel, methylene chloride/methanol = 9:1) mass spectrum: m/z = 466 (M+) (2) 3-Z-[l-(4-(4-methylpiperazinocarbonyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetateRf value: 0.84 (silica gel, methylene chloride/methanol = 4:1) C2eH2iN503 mass spectrum: m/z = 481 (M') (3) 3-Z-[l-(4-(N-(2-dimethylamino-ethyl)-N-methyl-carbamoyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone-trifluoroacetateRf value: 0.25 (silica gel, methylene chloride/methanol = 9:1) mass spectrum: m/z = 484 (M+H)+
(4) 3-Z-[1-(4-(N-methoxycarbonylmethyl-carbamoyl)-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinoneRf value: 0.4 (silica gel, methylene chloride/methanol =
9:1) mass spectrum: m/z = 470 (M+) (5) 3-Z-[1-(4-benzylcarbamoyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinoneRf value: 0.48 (silica gel, methylene chloride/methanol = 9:1) mass spectrum: m/z = 488 (M+) Example 7 3-Z-[1-(4-(N-methyl-benzoylamino)-phenylamino)-1-phenyl-methylenel-5-amido-2-indolinone 4.5 g of resin from step IV are reacted analogously to Example 4 with 3.4 g of 4-(9H-fluoren-9-ylmethoxycarbonyl)-methyl-amino)-aniline in dimethylformamide. Then the 9H-fluorene protecting group is cleaved with 4 ml of 30% piperidine in dimethylformamide and the resin is washed several times.
400 mg of the resin are then suspended in 4 ml of dimethylformamide and 0.3 ml of triethylamine and reacted with 0.3 ml of benzoylchloride for one hour at ambient temperature. Finally the product is cleaved from the resin as described in Example 4.
Yield: 33 mg.
Rf value: 0.45 (silica gel, methylene chloride/methanol =
9:1) C3oH24N403 mass spectrum: m/z = 488 (M') The following are prepared analogously:
(1) 3-Z-[l-(4-(N-methyl-propionylamino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinoneRf value: 0.42 (silica gel, methylene chloride/methanol = 9:1) mass spectrum: m/z = 440 (M+) (2) 3-Z-[l-(4-(N-methyl-butyrylamino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinoneRf value: 0.44 (silica gel, methylene chloride/methanol = 9:1) mass spectrum: m/z = 453 (M-H') (3) 3-Z-[1-(4-(N-methyl-ethylsulphonylamino)-phenylamino)-l-phenyl-methylene]-5-amido-2-indolinoneRf value: 0.42 (silica gel, methylene chloride/methanol =
9:1) mass spectrum: m/z = 475 (M-H+) (4) 3-Z-[1-(4-(N-methyl-propylsulphonylamino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinoneRf value: 0.44 (silica gel, methylene chloride/methanol =
9:1) C25H26N90qS
mass spectrum: m/z = 491 (M+H)+
(5) 3-Z-[1-(4-(N-methyl-phenylsulphonylamino)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinoneRf value: 0.53 (silica gel, methylene chloride/methanol =
9:1) mass spectrum: m/z = 524 (M+) Example 8 Dry ampoule containing 75 mg of active substance per 10 ml Composition:
Active substance 75.0 mg Mannitol 50.0 mg water for injections ad 10.0 ml Preparation:
Active substance and mannitol are dissolved in water.
After packaging the solution is freeze-dried. To produce the solution ready for use, the product is dissolved in water for injections.
Example 9 Dry ampoule containing 35 mg of active substance per 2 ml Composition:
Active substance 35.0 mg Mannitol 100.0 mg water for injections ad 2.0 ml Preparation:
Active substance and mannitol are dissolved in water.
After packaging, the solution is freeze-dried.
To produce the solution ready for use, the product is dissolved in water for injections.
Example 10 Tablet containing 50 mg of active substance Composition:
(1) Active substance 50.0 mg (2) Lactose 98.0 mg (3) Maize starch 50.0 mg (4) Polyvinylpyrrolidone 15.0 mg (5) Magnesium stearate 2.0 mg 215.0 mg Preparation:
(1), (2) and (3) are mixed together and granulated with an aqueous solution of (4). (5) is added to the dried granulated material. From this mixture tablets are pressed, biplanar, faceted on both sides and with a dividing notch on one side.
Diameter of the tablets: 9 mm.
Example 11 Tablet containing 350 mg of active substance Preparation:
(1) Active substance 350.0 mg (2) Lactose 136.0 mg (3) Maize starch 80.0 mg (4) Polyvinylpyrrolidone 30.0 mg (5) Magnesium stearate 4.0 mg 600.0 mg (1), (2) and (3) are mixed together and granulated with an aqueous solution of (4). (5) is added to the dried granulated material. From this mixture tablets are pressed, biplanar, faceted on both sides and with a dividing notch on one side.
Diameter of the tablets: 12 mm.
Example 12 Capsules containing 50 mg of active substance Composition:
(1) Active substance 50.0 mg (2) Dried maize starch 58.0 mg (3) Powdered lactose 50.0 mg (4) Magnesium stearate 2.0 mg 160.0 mg Preparation:
(1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with vigorous mixing.
This powder mixture is packed into size 3 hard gelatin capsules in a capsule filling machine.
Example 13 Capsules containing 350 mg of active substance Composition:
(1) Active substance 350.0 mg (2) Dried maize starch 46.0 mg (3) Powdered lactose 30.0 mg (4) Magnesium stearate 4.0 mg 430.0 mg Preparation:
(1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with vigorous mixing.
This powder mixture is packed into size 0 hard gelatin capsules in a capsule filling machine.
Example 14 Suppositories containing 100 mg of active substance 1 suppository contains:
Active substance 100.0 mg Polyethyleneglycol (M.W. 1500) 600.0 mg Polyethyleneglycol (M.W. 6000) 460.0 mg Polyethylenesorbitan monostearate 840.0 mg 2,000.0 mg Preparation:
The polyethyleneglycol is melted together with polyethylene sorbitanmonostearate. At 40 C the ground active substance is homogeneously dispersed in the melt.
It is cooled to 38 C and poured into slightly chilled suppository moulds.
Claims (24)
1. A compound of the formula I
wherein:
X is an oxygen atom, R1 is a hydrogen atom or a C1-4-alkoxycarbonyl group;
R2 is a carboxy, C1-4-alkoxycarbonyl, or aminocarbonyl group wherein the amino moiety may be substituted by one or two C1-3-alkyl groups and the substituents may be identical or different;
R3 is a phenyl group unsubstituted or substituted by a fluorine, chlorine, or bromine atom, or by a methyl, cyano, or aminomethyl group;
R4 is a hydrogen atom or a C1-3-alkyl group; and R5 is a hydrogen atom, a C1-5-alkyl group unsubstituted or substituted by a carboxy or C1-3-alkoxycarbonyl group, or a benzyl group, a C3-7-cycloalkyl group unsubstituted or substituted by a methyl group, an indanyl, pyridyl, oxazolyl, thiazolyl, or imidazolyl group unsubstituted or substituted by a methyl group, to which a phenyl ring may additionally be fused via two adjacent carbon atoms, a methylphenyl group unsubstituted or substituted by a fluorine, chlorine, or bromine atom, or by a methoxy, carboxy, C1-3-alkyloxycarbonyl, nitro, or aminosulphonyl group, or a dimethoxyphenyl group, a pyrrolidinyl or piperidinyl group linked via a carbon atom, which may be substituted at the nitrogen atom by a C1-3-alkyl group, a phenyl group which is substituted by a trifluoromethoxy group, by a fluorine, chlorine, bromine, or iodine atom, by a C1-3-alkoxy group which may be substituted in the 2- or 3-position by an amino, C1-3-alkylamino, di-(C1-3-alkyl)amino, phenyl-C1-3-alkylamino, N-(C1-3-alkyl)-phenyl-C1-3-alkylamino, pyrrolidino, or piperidino group, by a phenyl-C1-3-alkylamino-C1-3-alkyl group which may be substituted in the phenyl nucleus by a fluorine, chlorine, bromine, or iodine atom, by a C1-5-alkyl, C1-3-alkoxy, or trifluoromethyl group and additionally at the amine nitrogen atom by a C1-3-alkyl group wherein the hydrogen atoms from the 2-position may be wholly or partially replaced by fluorine atoms, by a C1-5-alkyl, phenyl, imidazolyl, C3-7-cycloalkyl, C1-3-alkoxy-C1-3-alkoxy, phenyl-C1-3-alkoxy, carboxy-C1-3-alkyl, C1-3-alkoxycarbonyl-C1-3-alkyl, carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl, di-(C1-3-alkyl)-aminocarbonyl, phenyl-C1-3-alkylaminocarbonyl, N-(C1-3-alkyl)-phenyl-C1-3-alkylaminocarbonyl, piperazinocarbonyl, N-(C1-3-alkyl)-piperazinocarbonyl, nitro, amino, C1-3-alkylamino, di-(C1-3-alkyl)-amino, pyrrolidino, piperidino, morpholino, C2-4-alkanoyl-amino, N-(C1-3-alkyl)-C2-4-alkanoylamino, benzoylamino, or N-(C1-3-alkyl)-benzoylamino group, by an N-(C1-3-alkyl)-C2-4-alkanoylamino group which is additionally substituted in the alkyl moiety by a carboxy or C1-3-alkoxycarbonyl group, by a C1-3-alkylaminocarbonyl or di-(C1-3-alkyl)-aminocarbonyl group wherein an alkyl moiety is additionally substituted by a di-(C1-3-alkyl)-amino group, or by an N-(C1-3-alkyl)-C1-3-alkylsulphonylamino or N-(C1-3-alkyl)-phenylsulphonylamino group wherein the alkyl moiety may additionally be substituted by a cyano, carboxy, C1-3-alkoxycarbonyl, C1-3-alkylamino, di-(C1-3-alkyl)-amino group, aminocarbonyl, C1-3-alkylaminocarbonyl, di-(C1-3-alkyl)-aminocarbonyl, piperidinocarbonyl, or 2-ethylaminocarbonyl group, a phenyl group unsubstituted or substituted by a C1-3-alkyl group wherein the alkyl moiety is substituted by a hydroxy, C1-3-alkoxy, carboxy, C1-3-alkoxy-carbonyl, amino, C1-5-alkylamino, di-(C1-5-alkyl)-amino, C2-4-alkanoylamino, N-(C1-3-alkyl)-C2-4-alkanoylamino, pyrrolidino, dehydropyrrolidino, piperidino, dehydropiperidino, 3-hydroxypiperidino, 4-hydroxypiperidino, hexamethyleneimino, morpholino, thiomorpholino, piperazino, 4-(C1-3-alkyl)-piperazino, 4-phenyl-piperazino, 4-(C2-4-alkanoyl)-piperazino, 4-benzoyl-piperazino, or imidazolyl group, wherein the abovementioned saturated cycloalkyleneimino rings, C1-5-alkylamino or di-(C1-5-alkyl)-amino groups may additionally be substituted by one or two C1-5-alkyl groups, by a C3-7-cycloalkyl, hydroxy, C1-3-alkoxy, carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl, or di-(C1-3-alkyl)-aminocarbonyl group, by a phenyl-C1-3-alkyl or phenyl group optionally mono- or disubstituted in the phenyl nucleus by fluorine, chlorine, bromine, or iodine atoms or by C1-3-alkyl or cyano groups, wherein the substituents may be identical or different, or a methylene group adjacent to the nitrogen atom in the abovementioned cycloalkyleneimino rings may be replaced by a carbonyl or sulphonyl group, and the abovementioned monosubstituted phenyl groups may additionally be substituted by a fluorine, chlorine, or bromine atom or by a methyl, amino, C1-3-alkylamino, or di-(C1-3-alkyl)-amino group, or a phenyl ring unsubstituted or substituted by one or two C1-3-alkoxy groups may be fused to one of the abovementioned unsubstituted cycloalkyleneimino rings via two adjacent carbon atoms, or a tautomer, stereoisomer or salt thereof.
wherein:
X is an oxygen atom, R1 is a hydrogen atom or a C1-4-alkoxycarbonyl group;
R2 is a carboxy, C1-4-alkoxycarbonyl, or aminocarbonyl group wherein the amino moiety may be substituted by one or two C1-3-alkyl groups and the substituents may be identical or different;
R3 is a phenyl group unsubstituted or substituted by a fluorine, chlorine, or bromine atom, or by a methyl, cyano, or aminomethyl group;
R4 is a hydrogen atom or a C1-3-alkyl group; and R5 is a hydrogen atom, a C1-5-alkyl group unsubstituted or substituted by a carboxy or C1-3-alkoxycarbonyl group, or a benzyl group, a C3-7-cycloalkyl group unsubstituted or substituted by a methyl group, an indanyl, pyridyl, oxazolyl, thiazolyl, or imidazolyl group unsubstituted or substituted by a methyl group, to which a phenyl ring may additionally be fused via two adjacent carbon atoms, a methylphenyl group unsubstituted or substituted by a fluorine, chlorine, or bromine atom, or by a methoxy, carboxy, C1-3-alkyloxycarbonyl, nitro, or aminosulphonyl group, or a dimethoxyphenyl group, a pyrrolidinyl or piperidinyl group linked via a carbon atom, which may be substituted at the nitrogen atom by a C1-3-alkyl group, a phenyl group which is substituted by a trifluoromethoxy group, by a fluorine, chlorine, bromine, or iodine atom, by a C1-3-alkoxy group which may be substituted in the 2- or 3-position by an amino, C1-3-alkylamino, di-(C1-3-alkyl)amino, phenyl-C1-3-alkylamino, N-(C1-3-alkyl)-phenyl-C1-3-alkylamino, pyrrolidino, or piperidino group, by a phenyl-C1-3-alkylamino-C1-3-alkyl group which may be substituted in the phenyl nucleus by a fluorine, chlorine, bromine, or iodine atom, by a C1-5-alkyl, C1-3-alkoxy, or trifluoromethyl group and additionally at the amine nitrogen atom by a C1-3-alkyl group wherein the hydrogen atoms from the 2-position may be wholly or partially replaced by fluorine atoms, by a C1-5-alkyl, phenyl, imidazolyl, C3-7-cycloalkyl, C1-3-alkoxy-C1-3-alkoxy, phenyl-C1-3-alkoxy, carboxy-C1-3-alkyl, C1-3-alkoxycarbonyl-C1-3-alkyl, carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl, di-(C1-3-alkyl)-aminocarbonyl, phenyl-C1-3-alkylaminocarbonyl, N-(C1-3-alkyl)-phenyl-C1-3-alkylaminocarbonyl, piperazinocarbonyl, N-(C1-3-alkyl)-piperazinocarbonyl, nitro, amino, C1-3-alkylamino, di-(C1-3-alkyl)-amino, pyrrolidino, piperidino, morpholino, C2-4-alkanoyl-amino, N-(C1-3-alkyl)-C2-4-alkanoylamino, benzoylamino, or N-(C1-3-alkyl)-benzoylamino group, by an N-(C1-3-alkyl)-C2-4-alkanoylamino group which is additionally substituted in the alkyl moiety by a carboxy or C1-3-alkoxycarbonyl group, by a C1-3-alkylaminocarbonyl or di-(C1-3-alkyl)-aminocarbonyl group wherein an alkyl moiety is additionally substituted by a di-(C1-3-alkyl)-amino group, or by an N-(C1-3-alkyl)-C1-3-alkylsulphonylamino or N-(C1-3-alkyl)-phenylsulphonylamino group wherein the alkyl moiety may additionally be substituted by a cyano, carboxy, C1-3-alkoxycarbonyl, C1-3-alkylamino, di-(C1-3-alkyl)-amino group, aminocarbonyl, C1-3-alkylaminocarbonyl, di-(C1-3-alkyl)-aminocarbonyl, piperidinocarbonyl, or 2-ethylaminocarbonyl group, a phenyl group unsubstituted or substituted by a C1-3-alkyl group wherein the alkyl moiety is substituted by a hydroxy, C1-3-alkoxy, carboxy, C1-3-alkoxy-carbonyl, amino, C1-5-alkylamino, di-(C1-5-alkyl)-amino, C2-4-alkanoylamino, N-(C1-3-alkyl)-C2-4-alkanoylamino, pyrrolidino, dehydropyrrolidino, piperidino, dehydropiperidino, 3-hydroxypiperidino, 4-hydroxypiperidino, hexamethyleneimino, morpholino, thiomorpholino, piperazino, 4-(C1-3-alkyl)-piperazino, 4-phenyl-piperazino, 4-(C2-4-alkanoyl)-piperazino, 4-benzoyl-piperazino, or imidazolyl group, wherein the abovementioned saturated cycloalkyleneimino rings, C1-5-alkylamino or di-(C1-5-alkyl)-amino groups may additionally be substituted by one or two C1-5-alkyl groups, by a C3-7-cycloalkyl, hydroxy, C1-3-alkoxy, carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl, or di-(C1-3-alkyl)-aminocarbonyl group, by a phenyl-C1-3-alkyl or phenyl group optionally mono- or disubstituted in the phenyl nucleus by fluorine, chlorine, bromine, or iodine atoms or by C1-3-alkyl or cyano groups, wherein the substituents may be identical or different, or a methylene group adjacent to the nitrogen atom in the abovementioned cycloalkyleneimino rings may be replaced by a carbonyl or sulphonyl group, and the abovementioned monosubstituted phenyl groups may additionally be substituted by a fluorine, chlorine, or bromine atom or by a methyl, amino, C1-3-alkylamino, or di-(C1-3-alkyl)-amino group, or a phenyl ring unsubstituted or substituted by one or two C1-3-alkoxy groups may be fused to one of the abovementioned unsubstituted cycloalkyleneimino rings via two adjacent carbon atoms, or a tautomer, stereoisomer or salt thereof.
2. A compound, tautomer, stereoisomer or salt according to claim 1, wherein:
X is an oxygen atom;
R1 is a hydrogen atom;
R2 is a carboxy, C1-4-alkoxycarbonyl or aminocarbonyl group wherein the amino moiety may be substituted by one or two C1-3-alkyl groups and the substituents may be identical or different;
R3 is a phenyl group unsubstituted or substituted by a methyl group;
R4 is a hydrogen atom or a methyl group, and R5 is a hydrogen atom, a C1-3-alkyl group, a benzyl group or a methyl or ethyl group substituted by a carboxy or C1-3-alkoxycarbonyl group, a C3-7-cycloalkyl group unsubstituted or substituted by a methyl group, an indanyl, pyridyl, oxazolyl, thiazolyl, or imidazolyl group unsubstituted or substituted by a methyl group, to which a phenyl ring may additionally be fused via two adjacent carbon atoms, a methylphenyl group unsubstituted or substituted by a fluorine, chlorine, or bromine atom, or by a methoxy, carboxy, C1-3-alkyloxycarbonyl, nitro, or aminosulphonyl group, or a dimethoxyphenyl group, a 3-pyrrolidinyl or 4-piperidinyl group which may be substituted at the nitrogen atom by a C1-3-alkyl group, a phenyl group which is substituted by a trifluoromethoxy or nitro group, by a fluorine, chlorine, bromine, or iodine atom, by a C1-3-alkoxy group, wherein the ethoxy and n-propoxy groups may each be terminally substituted by a dimethylamino, diethylamino, N-ethyl-methylamino, N-benzyl-methylamino, or piperidino group, by a phenyl-C1-3-alkylamino-C1-3-alkyl group which may be substituted in the phenyl nucleus by a fluorine, chlorine, bromine, or iodine atom, by a methyl, methoxy or trifluoromethyl group and additionally at the amine nitrogen atom by a C1-3-alkyl or 2,2,2-trifluoroethyl group, by a C1-4-alkyl, phenyl, imidazolyl, cyclohexyl, carboxymethyl, C1-3-alkoxycarbonyl-methyl, carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl, di-(C1-3-alkyl)-aminocarbonyl, phenyl-C1-3-alkylaminocarbonyl, N-(C1-3-alkyl)-phenyl-C1-3-alkylaminocarbonyl, piperazinocarbonyl, N-(C1-3-alkyl)-piperazinocarbonyl, amino, C1-3-alkylamino, di-(C1-3-alkyl) -amino, pyrrolidino, piperidino, morpholino, C2-4-alkanoyl-amino, N-(C1-3-alkyl)-C2-4-alkanoylamino, benzoylamino, or N-(C1-3-alkyl)-benzoylamino group, by an N-(C1-3-alkyl)-C2-4-alkanoylamino group which is additionally substituted in the alkyl moiety by a carboxy or C1-3-alkoxycarbonyl group, by a C1-3-alkylaminocarbonyl or di-(C1-3-alkyl)-aminocarbonyl group wherein an alkyl moiety is additionally substituted by a di-(C1-3-alkyl)-amino group, or by an N-(C1-3-alkyl)-C1-3-alkylsulphonylamino or N-(C1-3-alkyl)-phenylsulphonylamino group wherein the alkyl moiety may additionally be substituted by a cyano, carboxy, C1-3-alkoxycarbonyl, C1-3-alkylamino, di-(C1-3-alkyl)-amino group, aminocarbonyl, C1-3-alkylaminocarbonyl, di-(C1-3-alkyl)-aminocarbonyl, piperidinocarbonyl, or 2-ethylaminocarbonyl group, a phenyl group unsubstituted or substituted by a C1-3-alkyl group wherein the alkyl moiety is substituted by a hydroxy, C1-3-alkoxy, carboxy, C1-3-alkoxy-carbonyl, amino, C1--5-alkylamino, di-(C1-5-alkyl)-amino, C2-4-alkanoylamino, N-(C1-3-alkyl)-C2-4-alkanoylamino, pyrrolidino, dehydropyrrolidino, piperidino, dehydropiperidino, 4-hydroxypiperidino, hexamethyleneimino, morpholino, thiomorpholino, piperazino, 4-(C1-3-alkyl)-piperazino, 4-phenyl-piperazino, 4-(C2-4-alkanoyl)-piperazino, 4-benzoyl-piperazino, or imidazolyl group, wherein the abovementioned saturated cycloalkyleneimino rings may additionally be substituted by a phenyl group or by one or two methyl groups, the abovementioned C1-5-alkylamino and di-(C1-5-alkyl)-amino groups may additionally be substituted by one or two C1-3-alkyl groups, by a cyclohexyl, hydroxy, C1-3-alkoxy, carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl or di-(C1-3-alkyl)-aminocarbonyl group, by a phenyl-C1-3-alkyl or phenyl group unsubstituted or substituted in the phenyl nucleus by a fluorine, chlorine, bromine, or iodine atom or by a methyl or cyano group, or a methylene group adjacent to the nitrogen atom in the abovementioned cycloalkyleneimino rings may be replaced by a carbonyl or sulphonyl group, and the abovementioned monosubstituted phenyl groups may additionally be substituted by a fluorine, chlorine, or bromine atom or by a methyl, amino, C1-3-alkylamino, or di-(C1-3-alkyl)-amino group, or a phenyl ring unsubstituted or substituted by one or two C1-3-alkoxy groups may be fused to one of the abovementioned unsubstituted cycloalkyleneimino rings via two adjacent carbon atoms.
X is an oxygen atom;
R1 is a hydrogen atom;
R2 is a carboxy, C1-4-alkoxycarbonyl or aminocarbonyl group wherein the amino moiety may be substituted by one or two C1-3-alkyl groups and the substituents may be identical or different;
R3 is a phenyl group unsubstituted or substituted by a methyl group;
R4 is a hydrogen atom or a methyl group, and R5 is a hydrogen atom, a C1-3-alkyl group, a benzyl group or a methyl or ethyl group substituted by a carboxy or C1-3-alkoxycarbonyl group, a C3-7-cycloalkyl group unsubstituted or substituted by a methyl group, an indanyl, pyridyl, oxazolyl, thiazolyl, or imidazolyl group unsubstituted or substituted by a methyl group, to which a phenyl ring may additionally be fused via two adjacent carbon atoms, a methylphenyl group unsubstituted or substituted by a fluorine, chlorine, or bromine atom, or by a methoxy, carboxy, C1-3-alkyloxycarbonyl, nitro, or aminosulphonyl group, or a dimethoxyphenyl group, a 3-pyrrolidinyl or 4-piperidinyl group which may be substituted at the nitrogen atom by a C1-3-alkyl group, a phenyl group which is substituted by a trifluoromethoxy or nitro group, by a fluorine, chlorine, bromine, or iodine atom, by a C1-3-alkoxy group, wherein the ethoxy and n-propoxy groups may each be terminally substituted by a dimethylamino, diethylamino, N-ethyl-methylamino, N-benzyl-methylamino, or piperidino group, by a phenyl-C1-3-alkylamino-C1-3-alkyl group which may be substituted in the phenyl nucleus by a fluorine, chlorine, bromine, or iodine atom, by a methyl, methoxy or trifluoromethyl group and additionally at the amine nitrogen atom by a C1-3-alkyl or 2,2,2-trifluoroethyl group, by a C1-4-alkyl, phenyl, imidazolyl, cyclohexyl, carboxymethyl, C1-3-alkoxycarbonyl-methyl, carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl, di-(C1-3-alkyl)-aminocarbonyl, phenyl-C1-3-alkylaminocarbonyl, N-(C1-3-alkyl)-phenyl-C1-3-alkylaminocarbonyl, piperazinocarbonyl, N-(C1-3-alkyl)-piperazinocarbonyl, amino, C1-3-alkylamino, di-(C1-3-alkyl) -amino, pyrrolidino, piperidino, morpholino, C2-4-alkanoyl-amino, N-(C1-3-alkyl)-C2-4-alkanoylamino, benzoylamino, or N-(C1-3-alkyl)-benzoylamino group, by an N-(C1-3-alkyl)-C2-4-alkanoylamino group which is additionally substituted in the alkyl moiety by a carboxy or C1-3-alkoxycarbonyl group, by a C1-3-alkylaminocarbonyl or di-(C1-3-alkyl)-aminocarbonyl group wherein an alkyl moiety is additionally substituted by a di-(C1-3-alkyl)-amino group, or by an N-(C1-3-alkyl)-C1-3-alkylsulphonylamino or N-(C1-3-alkyl)-phenylsulphonylamino group wherein the alkyl moiety may additionally be substituted by a cyano, carboxy, C1-3-alkoxycarbonyl, C1-3-alkylamino, di-(C1-3-alkyl)-amino group, aminocarbonyl, C1-3-alkylaminocarbonyl, di-(C1-3-alkyl)-aminocarbonyl, piperidinocarbonyl, or 2-ethylaminocarbonyl group, a phenyl group unsubstituted or substituted by a C1-3-alkyl group wherein the alkyl moiety is substituted by a hydroxy, C1-3-alkoxy, carboxy, C1-3-alkoxy-carbonyl, amino, C1--5-alkylamino, di-(C1-5-alkyl)-amino, C2-4-alkanoylamino, N-(C1-3-alkyl)-C2-4-alkanoylamino, pyrrolidino, dehydropyrrolidino, piperidino, dehydropiperidino, 4-hydroxypiperidino, hexamethyleneimino, morpholino, thiomorpholino, piperazino, 4-(C1-3-alkyl)-piperazino, 4-phenyl-piperazino, 4-(C2-4-alkanoyl)-piperazino, 4-benzoyl-piperazino, or imidazolyl group, wherein the abovementioned saturated cycloalkyleneimino rings may additionally be substituted by a phenyl group or by one or two methyl groups, the abovementioned C1-5-alkylamino and di-(C1-5-alkyl)-amino groups may additionally be substituted by one or two C1-3-alkyl groups, by a cyclohexyl, hydroxy, C1-3-alkoxy, carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl or di-(C1-3-alkyl)-aminocarbonyl group, by a phenyl-C1-3-alkyl or phenyl group unsubstituted or substituted in the phenyl nucleus by a fluorine, chlorine, bromine, or iodine atom or by a methyl or cyano group, or a methylene group adjacent to the nitrogen atom in the abovementioned cycloalkyleneimino rings may be replaced by a carbonyl or sulphonyl group, and the abovementioned monosubstituted phenyl groups may additionally be substituted by a fluorine, chlorine, or bromine atom or by a methyl, amino, C1-3-alkylamino, or di-(C1-3-alkyl)-amino group, or a phenyl ring unsubstituted or substituted by one or two C1-3-alkoxy groups may be fused to one of the abovementioned unsubstituted cycloalkyleneimino rings via two adjacent carbon atoms.
3. A compound, tautomer, stereoisomer or salt according to claim 1 wherein:
X is an oxygen atom;
R1 is a hydrogen atom;
R2 is a carboxy or aminocarbonyl group wherein the amino moiety may be substituted by one or two C1-3-alkyl groups and the substituents may be identical or different;
R3 is a phenyl group unsubstituted or substituted by a methyl group;
R4 is a hydrogen atom; and R5 is a hydrogen atom, a 3-pyrrolidinyl or 4-piperidinyl group which may be substituted at the nitrogen atom by a C1-3-alkyl group, a phenyl group which is substituted by a C1-3-alkoxy group, wherein the ethoxy and n-propoxy groups may each be terminally substituted by a dimethylamino, diethylamino, N-ethyl-methylamino, N-benzyl-methylamino, or piperidino group, by a phenyl-C1-3-alkylamino-C1-3-alkyl group which may be substituted in the phenyl nucleus by a fluorine, chlorine, bromine, or iodine atom, by a methyl, methoxy, or trifluoromethyl group and additionally at the amine nitrogen atom by a C1-3-alkyl or 2,2,2-trifluoroethyl group, a phenyl group unsubstituted or substituted by a C1-3-alkyl group wherein the alkyl moiety is substituted by a hydroxy, C1-3-alkoxy, carboxy, C1-3-alkoxy-carbonyl, amino, C1-5-alkylamino, di-(C1-5-alkyl)-amino, C2-4-alkanoylamino, N-(C1-3-alkyl)-C2-4-alkanoylamino, pyrrolidino, dehydropyrrolidino, piperidino, dehydropiperidino, 4-hydroxypiperidino, hexamethyleneimino, morpholino, thiomorpholino, piperazino, 4-(C1-3-alkyl)-piperazino, 4-phenyl-piperazino, 4-(C2-4-alkanoyl)-piperazino, 4-benzoyl-piperazino, or imidazolyl group, wherein the abovementioned saturated cycloalkyleneimino rings may additionally be substituted by a phenyl group or by one or two methyl groups, the abovementioned C1-5-alkylamino and di-(C1-5-alkyl)-amino groups may additionally be substituted by one or two C1-3-alkyl groups, by a cyclohexyl, hydroxy, C1-3-alkoxy, carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl, or di-(C1-3-alkyl)-aminocarbonyl group, by a phenyl-C1-3-alkyl or phenyl group unsubstituted or substituted in the phenyl nucleus by a fluorine, chlorine, bromine, or iodine atom or by a methyl or cyano group, or a methylene group adjacent to the nitrogen atom in the abovementioned cycloalkyleneimino rings may be replaced by a carbonyl or sulphonyl group, and the abovementioned monosubstituted phenyl groups may additionally be substituted by a fluorine, chlorine, or bromine atom or by a methyl, amino, C1-3-alkylamino, or di-(C1-3-alkyl)-amino group, or a phenyl ring unsubstituted or substituted by one or two C1-3-alkoxy groups may be fused to one of the abovementioned unsubstituted cycloalkyleneimino rings via two adjacent carbon atoms.
X is an oxygen atom;
R1 is a hydrogen atom;
R2 is a carboxy or aminocarbonyl group wherein the amino moiety may be substituted by one or two C1-3-alkyl groups and the substituents may be identical or different;
R3 is a phenyl group unsubstituted or substituted by a methyl group;
R4 is a hydrogen atom; and R5 is a hydrogen atom, a 3-pyrrolidinyl or 4-piperidinyl group which may be substituted at the nitrogen atom by a C1-3-alkyl group, a phenyl group which is substituted by a C1-3-alkoxy group, wherein the ethoxy and n-propoxy groups may each be terminally substituted by a dimethylamino, diethylamino, N-ethyl-methylamino, N-benzyl-methylamino, or piperidino group, by a phenyl-C1-3-alkylamino-C1-3-alkyl group which may be substituted in the phenyl nucleus by a fluorine, chlorine, bromine, or iodine atom, by a methyl, methoxy, or trifluoromethyl group and additionally at the amine nitrogen atom by a C1-3-alkyl or 2,2,2-trifluoroethyl group, a phenyl group unsubstituted or substituted by a C1-3-alkyl group wherein the alkyl moiety is substituted by a hydroxy, C1-3-alkoxy, carboxy, C1-3-alkoxy-carbonyl, amino, C1-5-alkylamino, di-(C1-5-alkyl)-amino, C2-4-alkanoylamino, N-(C1-3-alkyl)-C2-4-alkanoylamino, pyrrolidino, dehydropyrrolidino, piperidino, dehydropiperidino, 4-hydroxypiperidino, hexamethyleneimino, morpholino, thiomorpholino, piperazino, 4-(C1-3-alkyl)-piperazino, 4-phenyl-piperazino, 4-(C2-4-alkanoyl)-piperazino, 4-benzoyl-piperazino, or imidazolyl group, wherein the abovementioned saturated cycloalkyleneimino rings may additionally be substituted by a phenyl group or by one or two methyl groups, the abovementioned C1-5-alkylamino and di-(C1-5-alkyl)-amino groups may additionally be substituted by one or two C1-3-alkyl groups, by a cyclohexyl, hydroxy, C1-3-alkoxy, carboxy, C1-3-alkoxycarbonyl, aminocarbonyl, C1-3-alkylaminocarbonyl, or di-(C1-3-alkyl)-aminocarbonyl group, by a phenyl-C1-3-alkyl or phenyl group unsubstituted or substituted in the phenyl nucleus by a fluorine, chlorine, bromine, or iodine atom or by a methyl or cyano group, or a methylene group adjacent to the nitrogen atom in the abovementioned cycloalkyleneimino rings may be replaced by a carbonyl or sulphonyl group, and the abovementioned monosubstituted phenyl groups may additionally be substituted by a fluorine, chlorine, or bromine atom or by a methyl, amino, C1-3-alkylamino, or di-(C1-3-alkyl)-amino group, or a phenyl ring unsubstituted or substituted by one or two C1-3-alkoxy groups may be fused to one of the abovementioned unsubstituted cycloalkyleneimino rings via two adjacent carbon atoms.
4. A compound, tautomer, stereoisomer or salt according to claim 1, wherein the group R2 is in the 5-position.
5. 3-Z-[1-(4-Aminomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone; or a tautomer, stereoisomer or salt thereof.
6. 3-Z-((1-Phenylamino)-1-phenyl-methylene)-5-amido-2-indolinone; or a tautomer, stereoisomer or salt thereof.
7. 3-Z-[1-(4-Bromophenylamino)-1-phenyl-methylene]-5-amido-2-indolinone; or a tautomer, stereoisomer or salt thereof.
8. 3-Z-[1-((4-Dimethylamino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone; or a tautomer, stereoisomer or salt thereof.
9. 3-Z-[1-(4-Pyrrolidinomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone; or a tautomer, stereoisomer or salt thereof.
10. 3-Z-[1-(4-Piperidinomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone; or a tautomer, stereoisomer or salt thereof.
11. 3-Z-[1-(4-Hexamethyleneiminomethyl-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone; or a tautomer, stereoisomer or salt thereof.
12. 3-Z-[1-((4-(4-Benzyl-piperidino)-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone; or a tautomer, stereoisomer or salt thereof.
13. 3-Z-[1-(4-(N-Butyl-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone; or a tautomer, stereoisomer or salt thereof.
14. 3-Z-[1-(4-(N-(Phenyl-methyl)-aminomethyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone; or a tautomer, stereoisomer or salt thereof.
15. 3-Z-[1-(4-(N-Methyl-N-benzyl-amino-methyl)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone; or a tautomer, stereoisomer or salt thereof.
16. 3-Z-[1-(4-Piperidino-methyl-phenylamino)-1-phenyl-methylene]-5-dimethylcarbamoyl-2-indolinone; or a tautomer, stereoisomer or salt thereof.
17. 3-Z-[1-(4-Piperidino-methyl-phenylamino)-1-phenyl-methylene]-5-diethylcarbamoyl-2-indolinone; or a tautomer, stereoisomer or salt thereof.
18. 3-Z-[1-(4-(3-Diethylamino-propoxy)-phenylamino)-1-phenyl-methylene]-5-amido-2-indolinone; or a tautomer, stereoisomer or salt thereof.
19. A pharmaceutical composition comprising a compound, tautomer, stereoisomer or salt according to any one of claims 1 to 18 and a pharmaceutically acceptible carrier or diluent.
20. A pharmaceutical composition according to claim 19 for treating excessive or abnormal cell proliferation.
21. A compound, tautomer, stereoisomer or salt according to any one of claims 1 to 18 for treating excessive or abnormal cell proliferation.
22. A use of a compound, tautomer, stereoisomer or salt according to any one of claims 1 to 18 for treating excessive or abnormal cell proliferation.
23. A use of a compound, tautomer, stereoisomer or salt according to any one of claims 1 to 18 in manufacture of a medicament for treating excessive or abnormal cell proliferation.
24. Process for preparing a compound according to claim 1 wherein:
a. a compound of general formula wherein X, R2 and R3 are as defined in claim 1, R6 denotes a hydrogen atom, a protecting group for the nitrogen atom of the lactam group or a bond to a solid phase and Z1 denotes a halogen atom, a hydroxy, alkoxy or aralkoxy group, is reacted with an amine of general formula wherein R4 and R5 are defined as in claim 1, and subsequently, if necessary, any protecting group used for the nitrogen atom of the lactam group is cleaved or a compound thus obtained is cleaved from a solid phase or b. in order to prepare a compound of general formula I which contains an aminomethyl group and where X
denotes an oxygen atom, a compound of general formula wherein R1 to R4 are defined as in claim 1, and R7 has the meanings given for R5 in claim 1, with the proviso that R5 contains a cyano group, is reduced and subsequently if desired a compound of general formula I thus obtained which contains an alkoxycarbonyl group is converted by hydrolysis into a corresponding carboxy compound or a compound of general formula I thus obtained which contains an amino or alkylamino group is converted by alkylation or reductive alkylation into a corresponding alkylamino or dialkylamino compound or a compound of general formula I thus obtained which contains an amino or alkylamino group is converted by acylation into a corresponding acyl compound or a compound of general formula I thus obtained which contains a carboxy group is converted by esterification or amidation into a corresponding ester or aminocarbonyl compound or if necessary a protecting group used during the reactions to protect reactive groups is cleaved or subsequently if desired a compound of general formula I thus obtained is resolved into the stereoisomers thereof or a compound of general formula I thus obtained is converted into a salt thereof with an inorganic or organic acid or base.
a. a compound of general formula wherein X, R2 and R3 are as defined in claim 1, R6 denotes a hydrogen atom, a protecting group for the nitrogen atom of the lactam group or a bond to a solid phase and Z1 denotes a halogen atom, a hydroxy, alkoxy or aralkoxy group, is reacted with an amine of general formula wherein R4 and R5 are defined as in claim 1, and subsequently, if necessary, any protecting group used for the nitrogen atom of the lactam group is cleaved or a compound thus obtained is cleaved from a solid phase or b. in order to prepare a compound of general formula I which contains an aminomethyl group and where X
denotes an oxygen atom, a compound of general formula wherein R1 to R4 are defined as in claim 1, and R7 has the meanings given for R5 in claim 1, with the proviso that R5 contains a cyano group, is reduced and subsequently if desired a compound of general formula I thus obtained which contains an alkoxycarbonyl group is converted by hydrolysis into a corresponding carboxy compound or a compound of general formula I thus obtained which contains an amino or alkylamino group is converted by alkylation or reductive alkylation into a corresponding alkylamino or dialkylamino compound or a compound of general formula I thus obtained which contains an amino or alkylamino group is converted by acylation into a corresponding acyl compound or a compound of general formula I thus obtained which contains a carboxy group is converted by esterification or amidation into a corresponding ester or aminocarbonyl compound or if necessary a protecting group used during the reactions to protect reactive groups is cleaved or subsequently if desired a compound of general formula I thus obtained is resolved into the stereoisomers thereof or a compound of general formula I thus obtained is converted into a salt thereof with an inorganic or organic acid or base.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19816624.9 | 1998-04-15 | ||
| DE19816624A DE19816624A1 (en) | 1998-04-15 | 1998-04-15 | Novel substituted indolinones, their preparation and their use as pharmaceuticals |
| PCT/EP1999/002436 WO1999052869A1 (en) | 1998-04-15 | 1999-04-10 | Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2323111A1 CA2323111A1 (en) | 1999-10-21 |
| CA2323111C true CA2323111C (en) | 2009-09-15 |
Family
ID=7864562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002323111A Expired - Fee Related CA2323111C (en) | 1998-04-15 | 1999-04-10 | New substituted indolinones, the preparation thereof and their use as pharmaceutical compositions |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1071665B1 (en) |
| JP (1) | JP4015365B2 (en) |
| KR (1) | KR100588250B1 (en) |
| CN (1) | CN100338036C (en) |
| AR (1) | AR015763A1 (en) |
| AT (1) | ATE251138T1 (en) |
| AU (1) | AU749829B2 (en) |
| BG (1) | BG64443B1 (en) |
| BR (1) | BR9909688A (en) |
| CA (1) | CA2323111C (en) |
| CO (1) | CO5011040A1 (en) |
| DE (2) | DE19816624A1 (en) |
| DK (1) | DK1071665T3 (en) |
| EA (1) | EA003532B1 (en) |
| EE (1) | EE04432B1 (en) |
| ES (1) | ES2207209T3 (en) |
| HU (1) | HUP0101568A3 (en) |
| ID (1) | ID26420A (en) |
| IL (1) | IL138036A0 (en) |
| MY (1) | MY122357A (en) |
| NO (1) | NO317298B1 (en) |
| NZ (1) | NZ507967A (en) |
| PL (1) | PL343314A1 (en) |
| PT (1) | PT1071665E (en) |
| SK (1) | SK283824B6 (en) |
| TR (1) | TR200002980T2 (en) |
| TW (1) | TW510897B (en) |
| UA (1) | UA63009C2 (en) |
| WO (1) | WO1999052869A1 (en) |
| YU (1) | YU59800A (en) |
| ZA (1) | ZA200004623B (en) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6569868B2 (en) | 1998-04-16 | 2003-05-27 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| GB9904933D0 (en) | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
| GB9904995D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Substituted aza-oxindole derivatives |
| GB9904932D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Composition and method for preventing/reducing the severity of side effects of chemotherapy and/or radiation therapy |
| US6624171B1 (en) | 1999-03-04 | 2003-09-23 | Smithkline Beecham Corporation | Substituted aza-oxindole derivatives |
| DE19924401A1 (en) * | 1999-05-27 | 2000-11-30 | Boehringer Ingelheim Pharma | Novel substituted indolinones, their preparation and their use as pharmaceuticals |
| JP3952369B2 (en) | 1999-08-27 | 2007-08-01 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | Novel substituted indolinones, their production and their use as pharmaceuticals |
| US6762180B1 (en) | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
| UA75054C2 (en) * | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Substituted in position 6 indolinones, producing and use thereof as medicament |
| US6620818B1 (en) | 2000-03-01 | 2003-09-16 | Smithkline Beecham Corporation | Method for reducing the severity of side effects of chemotherapy and/or radiation therapy |
| TWI270545B (en) | 2000-05-24 | 2007-01-11 | Sugen Inc | Mannich base prodrugs of 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| US6706709B2 (en) | 2000-06-02 | 2004-03-16 | Sugen, Inc. | Indolinone derivatives as protein kinase/phosphatase inhibitors |
| US20040019046A1 (en) * | 2000-11-27 | 2004-01-29 | Paolo Pevarello | Phenylacetamido-pyrazole derivatives and their use as antitumor agents |
| DE10117204A1 (en) | 2001-04-06 | 2002-10-10 | Boehringer Ingelheim Pharma | Indolinones substituted in the 6-position, their preparation and their use as medicaments |
| US6599902B2 (en) | 2001-05-30 | 2003-07-29 | Sugen, Inc. | 5-aralkysufonyl-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
| UA80120C2 (en) | 2002-03-26 | 2007-08-27 | Boehringer Ingelheim Pharma | Glucocorticoid mimetics, pharmaceutical composition based thereon |
| US7169936B2 (en) | 2002-07-23 | 2007-01-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments |
| DE10233500A1 (en) * | 2002-07-24 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-Z- [1- (4- (N - ((4-methyl-piperazin-1-yl) -methylcarbonyl) -N-methyl-amino) -anilino) -1-phenyl-methylene] -6-methoxycarbonyl- 2-indolinone monoethanesulfonate and its use as a medicament |
| DE10237423A1 (en) | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Treating immunological (or related) diseases, e.g. inflammatory bowel disease, rheumatoid arthritis or psoriasis, comprises administration of 3-methylene-2-indolinone derivative or quinazoline compound |
| JP4879492B2 (en) * | 2002-11-27 | 2012-02-22 | アラーガン、インコーポレイテッド | Kinase inhibitors for the treatment of diseases |
| US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| UY28526A1 (en) | 2003-09-24 | 2005-04-29 | Boehringer Ingelheim Pharma | GLUCOCORTICOID MIMETICS, METHODS OF PREPARATION PHARMACEUTICAL COMPOSITIONS AND USES OF THE SAME |
| EP1670789B1 (en) * | 2003-10-03 | 2008-11-19 | Boehringer Ingelheim Pharmaceuticals Inc. | Fluorescent probes for use in protein kinase inhibitor binding assay |
| DE102004012070A1 (en) * | 2004-03-12 | 2005-09-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | New cycloalkyl-containing 5-acylindolinones, their preparation and their use as medicaments |
| US7795272B2 (en) | 2004-03-13 | 2010-09-14 | Boehringer Ingelheim Pharmaceutical, Inc. | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof |
| PE20060777A1 (en) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | INDOLINONE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES |
| ATE433958T1 (en) | 2004-12-27 | 2009-07-15 | Boehringer Ingelheim Pharma | GLUCOCORTICOID MIMETICS, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF |
| CA2611401C (en) * | 2005-06-10 | 2014-02-11 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Oxindoles as kinase inhibitors |
| WO2007057399A2 (en) * | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Treatment of cancer with indole derivatives |
| BRPI0720131A2 (en) | 2006-12-06 | 2014-02-04 | Boehringer Ingelheim Int | MIMETIC GLYCORTICOIDS, METHODS FOR MAKING THEM, PHARMACEUTICAL COMPOSITIONS AND USES OF THE SAME. |
| DK2300472T3 (en) | 2008-06-06 | 2012-04-10 | Boehringer Ingelheim Int | Glucocorticoid mimetics, methods of their preparation, pharmaceutical compositions and uses thereof |
| US20170065529A1 (en) | 2015-09-09 | 2017-03-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical dosage form for immediate release of an indolinone derivative |
| WO2011032320A1 (en) * | 2009-09-21 | 2011-03-24 | F. Hoffmann-La Roche Ag | Novel alkene oxindole derivatives |
| US9492430B2 (en) | 2011-11-14 | 2016-11-15 | Ligand Pharmaceuticals, Incorporated | Methods and compositions associated with the granulocyte colony-stimulating factor receptor |
| WO2014150252A1 (en) * | 2013-03-15 | 2014-09-25 | Ligand Pharmaceuticals Incorporated | Methods of treatment associated with the granulocyte colony-stimulating factor receptor |
| CN107033064B (en) * | 2017-04-28 | 2019-07-09 | 西安医学院 | A kind of 3- (morpholine replaces fragrant imido grpup) Benzazole compounds and its preparation method and application |
| CN111285872B (en) * | 2018-12-06 | 2022-05-17 | 北京志健金瑞生物医药科技有限公司 | Indole-2-ketone derivative and preparation method and application thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9501567D0 (en) * | 1995-01-26 | 1995-03-15 | Pharmacia Spa | Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| DE19824922A1 (en) * | 1998-06-04 | 1999-12-09 | Boehringer Ingelheim Pharma | Novel substituted indolinones, their preparation and their use as pharmaceuticals |
| UA75054C2 (en) * | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Substituted in position 6 indolinones, producing and use thereof as medicament |
-
1998
- 1998-04-15 DE DE19816624A patent/DE19816624A1/en not_active Withdrawn
-
1999
- 1999-04-10 JP JP2000543432A patent/JP4015365B2/en not_active Expired - Lifetime
- 1999-04-10 NZ NZ507967A patent/NZ507967A/en unknown
- 1999-04-10 EP EP99920635A patent/EP1071665B1/en not_active Expired - Lifetime
- 1999-04-10 ES ES99920635T patent/ES2207209T3/en not_active Expired - Lifetime
- 1999-04-10 EA EA200001021A patent/EA003532B1/en not_active IP Right Cessation
- 1999-04-10 CA CA002323111A patent/CA2323111C/en not_active Expired - Fee Related
- 1999-04-10 PL PL99343314A patent/PL343314A1/en not_active Application Discontinuation
- 1999-04-10 HU HU0101568A patent/HUP0101568A3/en unknown
- 1999-04-10 BR BR9909688-9A patent/BR9909688A/en not_active Application Discontinuation
- 1999-04-10 AU AU38149/99A patent/AU749829B2/en not_active Ceased
- 1999-04-10 CN CNB998050296A patent/CN100338036C/en not_active Expired - Fee Related
- 1999-04-10 AT AT99920635T patent/ATE251138T1/en active
- 1999-04-10 EE EEP200000598A patent/EE04432B1/en not_active IP Right Cessation
- 1999-04-10 IL IL13803699A patent/IL138036A0/en not_active IP Right Cessation
- 1999-04-10 YU YU59800A patent/YU59800A/en unknown
- 1999-04-10 ID IDW20002062A patent/ID26420A/en unknown
- 1999-04-10 KR KR1020007011454A patent/KR100588250B1/en not_active IP Right Cessation
- 1999-04-10 WO PCT/EP1999/002436 patent/WO1999052869A1/en active IP Right Grant
- 1999-04-10 DK DK99920635T patent/DK1071665T3/en active
- 1999-04-10 DE DE59907199T patent/DE59907199D1/en not_active Expired - Lifetime
- 1999-04-10 TR TR2000/02980T patent/TR200002980T2/en unknown
- 1999-04-10 PT PT99920635T patent/PT1071665E/en unknown
- 1999-04-10 SK SK1513-2000A patent/SK283824B6/en unknown
- 1999-04-13 MY MYPI99001427A patent/MY122357A/en unknown
- 1999-04-14 TW TW088105963A patent/TW510897B/en active
- 1999-04-14 AR ARP990101700A patent/AR015763A1/en active Pending
- 1999-04-14 CO CO99022218A patent/CO5011040A1/en unknown
- 1999-10-04 UA UA2000116456A patent/UA63009C2/en unknown
-
2000
- 2000-09-04 ZA ZA200004623A patent/ZA200004623B/en unknown
- 2000-09-29 BG BG104813A patent/BG64443B1/en active Active
- 2000-10-13 NO NO20005151A patent/NO317298B1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2323111C (en) | New substituted indolinones, the preparation thereof and their use as pharmaceutical compositions | |
| AU764782B2 (en) | Substituted indolinones, the production thereof and their use as medicaments | |
| US6169106B1 (en) | Indolinones having kinase inhibitory activity | |
| AU763361B2 (en) | Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/CDK complexes | |
| US6638965B2 (en) | Substituted indolinones, preparation thereof and their use as pharmaceutical compositions | |
| US20030092756A1 (en) | Substituted indolinones | |
| EP1224169A2 (en) | Production of 5-substituted indolinones and use thereof as medicaments | |
| US6319918B1 (en) | Substituted indolinones with kinase inhibitory activity | |
| CZ20003788A3 (en) | Substituted indolinones | |
| MXPA00010095A (en) | Substituted indolinones, the production thereof and their use as medicaments | |
| CZ20004520A3 (en) | Substituted indolinones, process of their preparation and their use | |
| MXPA00008541A (en) | Substituted indolinones having an inhibiting effect on kinases and cycline/cdk complexes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20130410 |